Solid forms of an FGFR inhibitor and processes for preparing the same
The development of solid forms of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one addresses the need for improved pharmaceutical compositions, enhancing drug performance and treatment efficacy in FGFR-related diseases.
Patent Information
- Application Number
- UA202007685
- Authority / Receiving Office
- UA · UA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-08
- Filing Date
- 2019-05-03
- Publication Date
- 2026-10-21
- Estimated Expiration
- 2039-05-03
AI Technical Summary
Current FGFR inhibitors for treating cancer and other FGFR-mediated diseases lack suitable solid forms that ensure safe, effective, and high-quality pharmaceutical compositions with desirable properties such as ease of handling, processing, storage stability, and bioavailability.
Development of various solid forms, including crystalline and amorphous forms of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (Compound 1), along with methods for their preparation and pharmaceutical compositions, to enhance drug performance.
The solid forms of Compound 1 provide improved ease of handling, storage stability, and bioavailability, leading to enhanced drug performance in treating FGFR-related diseases like cholangiocarcinoma and myeloid/lymphoid neoplasms, with potential for increased survival and reduced progression.
Smart Images

Figure 00000106_0000 
Figure 00000106_0001 
Figure 00000106_0002
Abstract
Description
TECHNICAL FIELD This application relates to solid forms of a fibroblast growth factor receptor (FGFR) inhibitor, including methods for its preparation, and intermediates in its preparation, which are applicable in the treatment of mediated FGFR diseases such as cancer. PREREQUISITES FOR CREATING THE INVENTION Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes, including tissue development, angiogenesis, wound healing, and regulation of metabolism. Upon ligand binding, receptors undergo dimerization and phosphorylation, which leads to stimulation of protein kinase activity and recruitment of many intracellular docking proteins. These interactions contribute to the activation of a number of intracellular signaling pathways, including Ras-MAPK, AKT-PI3K, and phospholipase C, which are important for cell growth, proliferation, and survival (reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005). Aberrant activation of this pathway either through overexpression of FGF or FGFR ligands, or activating mutations in FGFR can lead to tumor development, progression, and resistance to traditional cancer treatments. Genetic alterations, including gene amplification, chromosomal aberrations, have been described in human cancer. translocations and somatic mutations that lead to ligand-independent receptor activation. Large-scale DNA sequencing of thousands of tumor samples has shown that components of the FGFR pathway are among the most frequently mutated in human cancer. Many of these activating mutations are identical to germline mutations lineages that lead to skeletal dysplasia syndromes. Mechanisms that lead to aberrant ligand-dependent signaling in human disease include FGF overexpression and alterations in FGFR splicing, which lead to receptors with more promiscuous ligand binding abilities (reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010). Therefore, the development of inhibitors, targeting FGFR may be useful in the clinical treatment of diseases that have increased activity FGF or FGFR. Types of cancer in which FGF / FGFR are implicated include, but are not limited to: carcinomas (e.g., urinary tract bladder, breast, cervix, colorectal, endometrium, stomach, head and neck, kidney, liver, lung, ovary, prostate); hematopoietic malignancies (e.g. multiple myeloma, chronic lymphocytic lymphoma, Adult T-cell leukemia, acute myelogenous leukemia, non-Hodgkin lymphoma, myeloproliferative neoplasm and Waldenström macroglobulinemia); and other neoplasms (e.g. glioblastoma, melanoma and rhabdosarcoma). In addition to its role in oncogenic neoplasms, FGFR activation is also involved in diseases skeletal and chondrocyte disorders, including, but not limited to, achondroplasia and craniosynostosis syndromes. The FGFR4-FGF19 signaling axis, in particular, is involved in the pathogenesis of a number of cancers, including hepatocellular carcinoma (Heinzle et al., Cur. Pharm. Des. 2014, 20:2881). Ectopic expression of FGF19 in transgenic mice leads to tumor formation in the liver, and it was found that A neutralizing antibody to FGF19 inhibits tumor growth in mice. In addition, overexpression of FGFR4 was observed in many types of tumors, including hepatocellular carcinoma, colorectal cancer, breast cancer, pancreatic cancer gland, prostate, lung and thyroid. Moreover, activating mutations in FGFR4 have been described in rhabdomyosarcoma (Taylor et al. JCI 2009,119:3395). FGFR inhibitors are currently being developed for the treatment of cancer. For example, the molecule 3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one and other small molecule FGFR inhibitors are described, for example, in U.S. Publication Nos.: 2012 / 0165305; 2014- 0045814; 2013-0338134; 2014 / 0171405; 2014 / 0315902; 2016 / 0115164; 2016 / 0244448; 2016 / 0244449; and 2016-0244450. Accordingly, there is a need for new solid forms of FGFR-inhibiting molecules for pharmaceutically acceptable useful compositions and dosage forms with appropriate properties related, for example, to the relief production of safe, effective and high-quality medicinal products ESSENCE OF THE INVENTION This document provides solid forms of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4- ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ("Compound 1"). This document also provides pharmaceutical compositions that include solid forms described in herein, and one or more pharmaceutically acceptable carriers or excipients. This disclosure also provides methods for inhibiting FGFR enzymes using solid forms, such as described in this document. This description also provides therapeutic methods of using solid forms as described herein. document. This description also provides for the use of the solid forms described herein in the manufacture of of a drug for use in therapy. This description also provides solid forms described herein document, for use in therapy. This document also provides processes for the preparation of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl- 8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one and its solid forms, such as described in this document. This document also provides intermediates useful for the preparation of 3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one and its solid forms, as described herein. This document also provides a method of treating cholangiocarcinoma in a patient in need thereof. a treatment comprising administering to a patient a therapeutically effective amount of Compound 1. Also provided is a method of treating myeloid / lymphoid neoplasms (e.g., 8p11 myeloproliferative syndrome) in a patient in need of this treatment, which includes administering to the patient a therapeutically effective amount of Compounds 1. Furthermore, this document provides a method for increasing survival or survival without progression in a patient with cholangiocarcinoma, where the cholangiocarcinoma is characterized by an FGFR2 fusion that involves administering Compound 1 to a patient. BRIEF DESCRIPTION OF FIGURES Fig. 1 shows an X-ray powder diffraction (XRPD) pattern of Compound 1, Form I. Fig. 2 shows a differential scanning calorimetry (DSC) thermogram of Form I, Compound 1. Fig. 3 shows a thermogravimetric analysis (TGA) thermogram of Compound 1, Form I. Fig. 4 shows the XRD pattern of Compound 1, Form II. Fig. 5 shows a DSC thermogram of Form II of Compound 1. Fig. 6 shows a TGA thermogram of Form II of Compound 1. Fig. 7 shows the XRD pattern of Compound 1, Form IIa. Fig. 8 shows a DSC thermogram of Form IIa of Compound 1. Fig. 9 shows a TGA thermogram of Form IIa of Compound 1. Fig. 10 shows the XRD pattern of Compound 1, Form III. Fig. 11 shows a DSC thermogram of Form III of Compound 1. Fig. 12 shows a TGA thermogram of Form III of Compound 1. Fig. 13 shows the XRD pattern of Compound 1, Form IV. Fig. 14 shows a DSC thermogram of Form IV of Compound 1. Fig. 15 shows a TGA thermogram of Form IV of Compound 1. Fig. 16 shows the XRD pattern of Compound 1, Form V. Fig. 17 shows a DSC thermogram of Compound 1, Form V. Fig. 18 shows the XRD pattern of Compound 1, Form VI. Fig. 19 shows a DSC thermogram of Compound 1, Form VI. Fig. 20 shows a TGA thermogram of Compound 1, Form VI. Fig. 21 shows a diagram of Compound 1, Form VII. Fig. 22 shows a DSC thermogram of Compound 1, Form VII. Fig. 23 shows a TGA thermogram of Compound 1, Form VII. Fig. 24 shows the XRD pattern of Compound 1, Form VIII. Fig. 25 shows a DSC thermogram of Compound 1, Form VIII. Fig. 26 shows a TGA thermogram of Compound 1, Form VIII. Fig. 27 shows the XRD pattern of Compound 1, Form VIIIa. Fig. 28 shows the XRPD pattern of Compound 1, Form IX. Fig. 29 shows a DSC thermogram of Compound 1, Form IX. Fig. 30 shows a TGA thermogram of Compound 1, Form IX. Fig. 31 shows the XRD pattern of Compound 1, Form X. Fig. 32 shows a DSC thermogram of Compound 1, Form X. Fig. 33 shows a TGA thermogram of Compound 1, Form X. Fig. 34 shows the XRD pattern of Compound 1, Form XI. Fig. 35 shows a DSC thermogram of Compound 1, Form XI. Fig. 36 shows a TGA thermogram of Compound 1, Form XI. Fig. 37 shows the XRD pattern of Compound 1, Form XII. Fig. 38 shows a DSC thermogram of Compound 1, Form XII. Fig. 39 shows a TGA thermogram of Compound 1, Form XII. Fig. 40 shows the XRD pattern of Compound 1, Form XIII. Fig. 41 shows a DSC thermogram of Compound 1, Form XIII. Fig. 42 shows a TGA thermogram of Compound 1, Form XIII. Fig. 43 shows the XRD pattern of Compound 1, Form XIIIa. Fig. 44 shows a DSC thermogram of Compound 1, Form XIIIa. Fig. 45 shows the XRD pattern of Compound 1, Form XIV. Fig. 46 shows a DSC thermogram of Compound 1, Form XIV. Fig. 47 shows a TGA thermogram of Compound 1, Form XIV. Fig. 48 shows the XRD pattern of Compound 1, Form XV. Fig. 49 shows a DSC thermogram of Compound 1, Form XV. Fig. 50 shows a TGA thermogram of Compound 1, Form XV. Fig. 51 shows the XRD pattern of Compound 1, Form XVI. Fig. 52 shows a DSC thermogram of Compound 1, Form XVI. Fig. 53 shows a TGA thermogram of Compound 1, Form XVI. Fig. 54 shows the XRD pattern of Compound 1, form XVII. Fig. 55 shows a DSC thermogram of Compound 1, Form XVII. Fig. 56 shows a TGA thermogram of Compound 1, Form XVII. Fig. 57 shows the XRD pattern of Compound 1, Form XVIII. Fig. 58 shows a DSC thermogram of Compound 1, Form XVIII. Fig. 59 shows a TGA thermogram of Compound 1, Form XVIII. Fig. 60 shows the XRD pattern of Compound 1, Form XIX. Fig. 61 shows a DSC thermogram of Compound 1, Form XIX. Fig. 62 shows a TGA thermogram of Compound 1, Form XIX. Fig. 63 shows the XRD pattern of Compound 1, Form XX. Fig. 64 shows a DSC thermogram of Compound 1, Form XX. Fig. 65 shows a TGA thermogram of Compound 1, Form XX. Fig. 66 shows the XRD pattern of Compound 1, Form XXI. Fig. 67 shows a DSC thermogram of Compound 1, Form XXI. Fig. 68 shows the XRD pattern of Form XXII of Compound 1. Fig. 69 shows a DSC thermogram of Compound 1, Form XXII. Fig. 70 shows a diagram of Compound 1, Form XXIII. Fig. 71 shows a DSC thermogram of Compound 1, Form XXIII. Fig. 72 shows a TGA thermogram of Compound 1, Form XXIII. Fig. 73 shows the XRD pattern of Compound 1, Form XXIV. Fig. 74 shows a DSC thermogram of Compound 1, Form XXIV. Fig. 75 shows a TGA thermogram of Compound 1, Form XXIV. Fig. 76 shows the XRD pattern of Compound 1, Form XXV. Fig. 77 shows a DSC thermogram of Compound 1, Form XXV. Fig. 78 shows the XRD pattern of Compound 1, Form XXVI. Fig. 79 shows the best percent change in target lesion size compared to baseline in patients with CCA and FGFR2 translocations (group A) according to an independent reviewer. Fig. 80 shows the duration of treatment and confirmed response in patients with CCA and FGFR2 translocations (group A) according to an independent observer. Fig. 81 shows Kaplan-Meier estimates of progression-free survival (PFS; independent reviewer assessment) in groups A, B and C. Fig. 82 shows a summary of clinical and cytogenetic responses in patients with myeloid / lymphoid neoplasms with FGFR1 rearrangements. Fig. 83 shows the initial PET scan of a patient with myeloproliferation and T-lymphoblastic lymphoma (TLL) before treatment with Compound 1. Fig. 84 shows the initial PET scan of a patient with myeloproliferation and T-lymphoblastic lymphoma (TLL) after treatment with Compound 1. DETAILED DESCRIPTION This description is directed, inter alia, to solid forms, including crystalline forms and amorphous forms of 3-(2,6- difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo [3',2':5,6]pyrido[4,3- d]pyrimidin-2-one (Compound 1), as well as processes and intermediates for the preparation of the compound. Compound Structure 1 is shown below. NN H N About NN About About About F F Compound 1 Compound 1 is described in U.S. Patent No. 9,611,267, which is incorporated herein by reference in its entirety. Compound 1 may be isolated as one or more solid forms. Solid forms (e.g., crystalline forms) described herein may have certain advantages, for example, they may have desirable properties such as ease of handling, ease of processing, storage stability, and ease of cleaning. Moreover, crystalline forms may be useful for improving the performance of a drug. of the drug, such as dissolution profile, shelf life, and bioavailability. As used herein, unless otherwise specified, the term "near" when used in relation to a numerical value or range of values that are intended to describe a particular solid form (e.g., a specific temperature or temperature range, for example, to describe melting, dehydration, or glass transition; changes in mass, such as mass change with temperature or humidity; solvent or water content, expressed as e.g., in mass or percentage; or peak position, such as in analysis, e.g., by 13C NMR, DSC, TGA and XRPD), indicates that the value or range of values may deviate to an extent that is considered reasonable to a skilled person in this field of technology, while describing a specific solid form. In particular, the term "about," when used in this context, indicates that the numerical value or the range of values can vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or 0.1% of the stated value or range of values, while still describing a specific solid form. The term "near" when used in reference to the value of the 2-theta angle means + / - 0.2 degrees 2-theta. As used herein, the term "solid form" refers to the compound presented herein in amorphous state or crystalline state ("crystalline form", or "crystalline solid", or "crystalline solid form"), whereby the compound presented in this document in a crystalline state may optionally include solvent or water within the crystal lattice, for example, with the formation of solvated or hydrated crystalline form. In some embodiments of the invention, the compound, presented in this document is in a crystalline state, as described in this document. The term "peak" or "characteristic peak" used in this document refers to the reflection XRPD having a relative height / intensity of at least about 3% of the maximum peak height / intensity. As used herein, the term "crystalline" or "crystalline form" refers to the solid crystalline form. chemical compound, including but not limited to single-component or multi-component crystalline form, for example, including solvates, hydrates, clathrates and co-crystals. For example, crystalline means the presence of a regularly repeated arrangement and / or an ordered arrangement of molecules and the presence of a discernible crystal lattice. The term "crystalline form" is intended to refer to a specific configuration lattice of a crystalline substance. Different crystalline forms of the same substance usually have different crystal lattices (e.g., unit cells) typically have different physical properties related to their different crystal lattices, and in some cases have different water or solvent contents. Different crystal lattices can be identified by solid-state characterization methods, such as the X-ray powder diffraction (XRPD). Other characterization methods, such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), etc., additionally help identify the crystalline form, and also help determine stability and content solvent / water. Different crystalline forms of a particular substance, such as compound 1, as described herein, may include both the anhydrous forms of this substance and the solvated / hydrated forms of this substance, where each of the anhydrous forms and solvated / hydrated forms are distinguished from each other by different XRPD patterns or other methods determination of solid state characteristics, which means a different crystal lattice. In some cases, a single the crystalline form (e.g., identified by a unique XRPD pattern) may have variable water content or solvent, while the lattice remains practically unchanged (as does the XRPD diagram), despite the change composition with respect to water and / or solvent. The XRPD pattern (peaks) is usually considered a characteristic feature of a particular crystalline It is well known that the relative intensities of XRPD peaks can vary widely depending on, among other things, other, sample preparation techniques, crystal size distribution, filters used, procedures the sample environment and the specific instrument used. In some cases, they may new peaks may be observed or existing peaks may disappear, depending on the type of equipment or settings (e.g. whether a Ni filter is used or not). The term "peak" used in this document, refers to a reflection having a relative height / intensity of at least about 3% or at least about 4% of the maximum peak height / intensity. Moreover, instrument variations and other factors can affect the value of 2-theta. Thus, peak distributions such as those shown here can vary by plus or minus about 0.2° (2-theta), and the term "substantially" used in the context XRPD in this document is intended to cover the above options. Similarly, temperature readings in relation to DSC, TGA or other thermal experiments can vary by about ± 3 °C depending on the instrument, specific settings, sample preparation, etc. Accordingly, the crystalline form presented in this document, which has a DSC thermogram “substantially” as shown in any of the figures takes into account such a change. Crystalline forms of a substance can be obtained by a number of methods known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, recrystallization from a solvent, recrystallization in a confined space, for example, in nanopores or capillaries, recrystallization on surfaces or substrates to create, such as, for example, on polymers, recrystallization in the presence of additives, such as, for example, co-crystalline countermolecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, exposure to moisture, grinding and grinding by solvent droplets. The term "amorphous" or "amorphous form" as used herein is intended to indicate that the substance, component or product in question is not crystalline, as determined, for example, by XRPD or when the substance, component or product under consideration, for example, does not have a double refraction when observed under a microscope. For example, amorphous means, to a large extent, without regularly repeating arrangement of molecules or lack of long-range crystal order, i.e. amorphous form is not crystalline. The amorphous form does not have a clear X-ray diffraction pattern with sharp In some embodiments of the invention, a sample containing an amorphous form of a substance may practically free from other amorphous forms and / or crystalline forms. For example, an amorphous substance may be identified by XRPD spectrum without reflections. The term "substantially amorphous" as used herein means that a large portion of the sample mass or of the preparation of Compound 1 is amorphous, while the rest of the sample is a crystalline form of the same compound. In some In embodiments of the invention, the substantially amorphous sample has a crystallinity of less than about 5% (e.g., about 95% of the non-crystalline form of the same compound), crystallinity less than about 4% (e.g., about 96% of the non-crystalline form of the same compound), crystallinity less than about 3% (e.g., about 97% non-crystalline form of the same compound), crystallinity less than about 2% (e.g., about 98% non-crystalline form of the same compound), less than about 1% crystallinity (e.g., about 99% non-crystalline form of the same compound) or about 0% crystallinity (e.g., about 100% non-crystalline forms of the same compound). In some embodiments, the term “completely amorphous” means crystallinity of less than than about 99% or about 0%. Compound 1 can be prepared in separate portions called samples, aliquots, or preparations. Samples, specimens or preparations may include Compound 1 in any of the crystalline or non-crystalline forms described herein, including hydrated and non-hydrated forms and mixtures thereof. The compounds provided herein (e.g., Compound 1) may also include all isotopes of atoms that found in intermediate or final compounds. Isotopes include atoms that have the same atomic number, but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms compounds presented in this document may be replaced or substituted by isotopes of atoms in natural or unnatural amount. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of this description may be replaced by deuterium. In some In some embodiments of the invention, the compound includes two or more deuterium atoms. In some embodiments, of the invention the compound includes 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms. Methods of synthesis of isotope incorporation into organic compounds known in the art. In some embodiments, Compound 1 is substantially isolated. The term "substantially isolated" means that the compound is at least partially or substantially isolated from the environment in which it was formed or detected. Partial separation may include, for example, a composition enriched with a compound, salts, hydrates, solvates or solid forms presented herein. Substantial separation may include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97% or at least about 99% by weight of the compound, salts, hydrates, solvates or solid forms represented in this document. The term "hydrate" as used herein is intended to refer to the solid form of Compound 1 which includes water. Water in a hydrate may be present in a stoichiometric amount relative to the amount of salt in the solid substance or may be present in varying amounts, such as can be detected in connection with the channels hydrates. The term "substantially" as used herein refers to the characteristic figure of the crystalline form, such as- so XRPD diagram, DSC thermogram, TGA thermogram, etc., means that the shape of the object may not be identical mentioned figure depicted here, but it falls within the limits of experimental error and, thus, may be considered a derivative of the same crystalline form as disclosed herein, as judged by a qualified specialist in this field of technology. The term "substantially crystalline" as used herein means that a large portion of the sample mass or of the preparation of Compound 1 is crystalline, and the rest of the sample is a non-crystalline form (e.g., amorphous form) of the same compound. In some embodiments of the invention, a substantially crystalline sample has crystallinity of at least about 95% (e.g., about 5% of the non-crystalline form of the same compound), at least about 96% crystallinity (e.g., about 4% of the non-crystalline form of the same compound), at least about 97% crystallinity (e.g. about 3% of the non-crystalline form of the same compound), at least about 98% crystallinity (e.g. about 2% of the non-crystalline form of the same compound), at least about 99% crystallinity (e.g., about 1% non-crystalline form of the same compound) or about 100% crystallinity (e.g., about 0% non-crystalline form of the same compound). In some embodiments In the implementation, the term "fully crystalline" means a crystallinity of at least about 99% or about 100%. As used herein, the term "% crystallinity" or "crystalline purity" means the percentage content crystalline form in a preparation or sample that may contain other forms, such as an amorphous form of the same compound or at least one other crystalline form of the compound or mixtures thereof. In some embodiments of the invention crystalline forms can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments of the invention crystalline forms can be isolated with a purity of more than about 99%. As used herein, the term "interaction" is used as is known in the art and mainly concerns the combination of chemical reagents in such a way as to ensure their interaction in at the molecular level to achieve a chemical or physical transformation. In some embodiments, of the invention, the interaction involves at least two reactants, with one or more molar equivalents the second reagent is used in relation to the first reagent. In some embodiments of the invention The reaction stage of the synthesis process may include one or more substances in addition to the reactants, such as solvent and / or catalyst. The reaction steps of the processes described herein can be carried out over time and under conditions suitable for obtaining an identified product. The term "transformation" as used here refers to a change in an intermediate product or starting material. of a reactant or material in a chemical reaction refers to the effect of an intermediate or starting reactant or material on appropriate reagents and conditions (e.g. temperature, time, solvent, etc.) to effect certain changes (e.g., breaking or forming a chemical bond) to obtain the desired product. Compound 1 can be obtained in various crystalline forms, including, for example, Form I, Form II, Form II-a, Form III, Form IV, Form V, Form VI, Form VII, Form VIII, Form VIIIa, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIII-a, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, Form XIX, Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV or Form XXVI. In some embodiments In the embodiment of the invention, the solid form of Compound 1 is amorphous. Compound 1 Form I This document provides a solid form of Compound 1 which is crystalline, referred to as Form I, which is described below in the Examples. In some embodiments, Form I has at least one characteristic XRPD peak selected from about 6.8, about 12.9, about 25.4, about 25.8, about 26.2, and about 27.5 degrees 2-theta. In some embodiments, Form I has at least two characteristic XRPD peaks selected from about 6.8, about 12.9, about 25.4, about 25.8, about 26.2, and about 27.5 degrees 2-theta. In some embodiments, Form I has at least three characteristic XRPD peaks selected from with about 6.8, about 12.9, about 25.4, about 25.8, about 26.2, and about 27.5 degrees 2-theta. In some embodiments, Form I has at least one characteristic XRPD peak selected from from about 6.8, about 9.6, about 12.9, about 18.6, about 19.4, about 22.6, about 25.4, about 25.8, about 26.2 and about 27.5 degrees 2-theta. In some embodiments, Form I has at least two characteristic XRPD peaks selected from from about 6.8, about 9.6, about 12.9, about 18.6, about 19.4, about 22.6, about 25.4, about 25.8, about 26.2 and about 27.5 degrees 2-theta. In some embodiments, Form I has at least three characteristic XRPD peaks selected from from about 6.8, about 9.6, about 12.9, about 18.6, about 19.4, about 22.6, about 25.4, about 25.8, about 26.2 and about 27.5 degrees 2-theta. In some embodiments of the invention, Form I has an XRD pattern with characteristic peaks as shown in essentially shown in Figure 1. In some embodiments, Form I exhibits a DSC thermogram having endotherm peaks at temperatures of about 201 ºC and 276 ºC. In some embodiments, Form I exhibits a thermogram DSC, which has an endotherm peak at about 201 °C. In some embodiments, Form I exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, Form I has a DSC thermogram substantially as depicted in Figure 2. In some embodiments, Form I has TGA thermogram, essentially as depicted in Figure 3. In some embodiments, Form I has at least one characteristic XRPD peak selected from about 6.8, about 12.9, about 25.4, about 25.8, about 26.2, and about 27.5 degrees 2-theta; and Form I exhibits DSC thermogram, which has endotherm peaks at temperatures around 201 ºC and 276 ºC. This document also provides methods for obtaining Form I of Compound 1, including recrystallization of Compound 1 in a solvent. In some embodiments, the solvent is a mixture dichloromethane and methyl tert-butyl ether. In some embodiments, the method for preparing Form I of Compound 1 involves recrystallization of Compound 1 from a mixture of dichloromethane and methyl tert-butyl ether. In some embodiments The recrystallization process involves a) heating a solution of Compound 1 in a mixture of dichloromethane and methyl tert- butyl ether to an elevated temperature for a first period of time and b) cooling to a reduced temperature during the second period of time. In some embodiments, the elevated temperature is ≥ 30 ºC, ≥ 35 ºC, ≥ 36 ºC, ≥ 39 ºC or ≥ 40 ºC. In some embodiments, the first period is from 5 to 6 hours. In In some embodiments, the first time period exceeds 5 hours. In some embodiments, the reduced temperature represents the ambient temperature. In some implementations, the temperature is reduced the temperature is about 23 °C. In some embodiments, the second time period is from 10 to 11 hours. In some embodiments, the second time period exceeds 5, 8, or 10 hours. In some embodiments, the The second implementation period is 10.5 hours. In some embodiments, Form I can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form II This document provides a solid form of Compound 1 having Form II, which is described below in Examples. In some embodiments, Form II has at least one characteristic XRPD peak selected from about 6.8, about 9.5, about 12.8, about 13.3, and about 25.8 degrees 2-theta. In some embodiments, Form II has at least two characteristic XRPD peaks selected from about 6.8, about 9.5, about 12.8, about 13.3, and about 25.8 degrees 2-theta. In some embodiments, Form II has at least three characteristic XRPD peaks selected from about 6.8, about 9.5, about 12.8, about 13.3, and about 25.8 degrees 2-theta. In some embodiments, Form II has at least one characteristic XRPD peak selected from about 6.8, about 9.5, about 12.8, about 13.3, about 19.0, about 20.5, about 22.6, about 25.8, about 26.2 and about 27.4 degrees 2-theta. In some embodiments, Form II has at least two characteristic XRPD peaks selected from about 6.8, about 9.5, about 12.8, about 13.3, about 19.0, about 20.5, about 22.6, about 25.8, about 26.2 and about 27.4 degrees 2-theta. In some embodiments, Form II has at least three characteristic XRPD peaks selected from about 6.8, about 9.5, about 12.8, about 13.3, about 19.0, about 20.5, about 22.6, about 25.8, about 26.2 and about 27.4 degrees 2-theta. In some embodiments, Form II has an XRD pattern with characteristic peaks, essentially shown in Figure 4. In some embodiments, Form II exhibits a DSC thermogram having an endotherm peak at a temperature about 276 °C. In some embodiments, Form II has a DSC thermogram substantially as depicted in Figure 5. In In some embodiments, Form II has a TGA thermogram substantially as depicted in Figure 6. In some embodiments, Form II has at least one characteristic XRPD peak selected from about 6.8, about 9.5, about 12.8, about 13.3, and about 25.8 degrees 2-theta; and Form II shows a thermogram DSC, which has an endotherm peak at around 276 °C. This document also provides methods for obtaining Form II of Compound 1, including evaporation of a saturated solution of Form I of Compound 1 in dichloromethane at 50 ± 1 °C. In some embodiments, Form II can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Form II-a Compound 1 This document provides a solid form of Compound 1 having Form II-a, which is described below in Examples. In some embodiments, Form II-a has at least one characteristic XRPD peak selected from about 6.9, about 9.4, about 13.3, about 16.3, and about 19.9 degrees 2-theta. In some embodiments, Form II-a has at least two characteristic XRPD peaks selected from about 6.9, about 9.4, about 13.3, about 16.3, and about 19.9 degrees 2-theta. In some embodiments, Form II-a has at least three characteristic XRPD peaks selected from about 6.9, about 9.4, about 13.3, about 16.3, and about 19.9 degrees 2-theta. In some embodiments, Form II-a has at least one characteristic XRPD peak selected from about 6.9, about 9.4, about 12.9, about 13.3, about 16.3, about 17.5, about 19.0, about 19.9, about 22.5 and about 26.1 degrees 2-theta. In some embodiments, Form II-a has at least two characteristic XRPD peaks selected from about 6.9, about 9.4, about 12.9, about 13.3, about 16.3, about 17.5, about 19.0, about 19.9, about 22.5 and about 26.1 degrees 2-theta. In some embodiments, Form II-a has at least three characteristic XRPD peaks selected from about 6.9, about 9.4, about 12.9, about 13.3, about 16.3, about 17.5, about 19.0, about 19.9, about 22.5 and about 26.1 degrees 2-theta. In some embodiments, Form II-a has an XRD pattern with characteristic peaks, essentially shown in Figure 7. In some embodiments, Form II-a exhibits a DSC thermogram having an endotherm peak at a temperature about 275 °C. In some embodiments, Form II-a has a DSC thermogram substantially as depicted in Figure 8. In some embodiments, Form II-a has a TGA thermogram substantially as depicted in Figure 9. In some embodiments, Form II-a has at least one characteristic XRPD peak selected from about 6.9, about 9.4, about 13.3, about 16.3, and about 19.9 degrees 2-theta; and Form II-a shows DSC thermogram, which has an endotherm peak at a temperature of about 275 °C. This document also provides methods for obtaining Form II-a of Compound 1, including evaporation of a solution of Form I of Compound 1 in dichloromethane at 25 ± 1 °C. In some embodiments, Form II-a can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form III This document provides a solid form of Compound 1 having Form III, which is described below in Examples. In some embodiments, Form III has at least one characteristic XRPD peak selected from about 3.5, about 13.9, about 15.0, about 15.3, about 16.8 and about 18.6. In some embodiments, Form III has at least two characteristic XRPD peaks selected from about 3.5, about 13.9, about 15.0, about 15.3, about 16.8 and about 18.6. In some embodiments, Form III has at least three characteristic XRPD peaks selected from about 3.5, about 13.9, about 15.0, about 15.3, about 16.8 and about 18.6. In some embodiments, Form III has at least one characteristic XRPD peak selected from about 3.5, about 6.7, about 8.5, about 13.9, about 15.0, about 15.3, about 16.8, about 18.6, about 19.3, about 21.5, about 22.9, about 24.2, and about 25.9 degrees 2-theta. In some embodiments, Form III has at least two characteristic XRPD peaks selected from about 3.5, about 6.7, about 8.5, about 13.9, about 15.0, about 15.3, about 16.8, about 18.6, about 19.3, about 21.5, about 22.9, about 24.2, and about 25.9 degrees 2-theta. In some embodiments, Form III has at least three characteristic XRPD peaks selected from about 3.5, about 6.7, about 8.5, about 13.9, about 15.0, about 15.3, about 16.8, about 18.6, about 19.3, about 21.5, about 22.9, about 24.2, and about 25.9 degrees 2-theta. In some embodiments, Form III has an XRD pattern with characteristic peaks, essentially shown in Figure 10. In some embodiments, Form III exhibits a DSC thermogram having endotherm peaks at temperatures around 101 °C, 204 °C and 276 °C. In some embodiments, Form III exhibits a thermogram DSC, which has an endotherm peak at about 101 °C. In some embodiments, Form III exhibits DSC thermogram having an endotherm peak at about 204 °C. In some embodiments, Form III shows a DSC thermogram having an endotherm peak at about 276 ºC. In some embodiments Embodiments Form III has a DSC thermogram substantially as depicted in Figure 11. In some embodiments Form III has a TGA thermogram substantially as depicted in Figure 12. In some embodiments, Form III has at least one characteristic XRPD peak selected from about 3.5, about 13.9, about 15.0, about 15.3, about 16.8 and about 18.6; and Form III exhibits DSC thermogram having endotherm peaks at temperatures of approximately 101 °C, 204 °C, and 276 °C. This document also provides methods for preparing Form III of Compound 1, which include adding Compound 1, Form I to a solution of Compound 1, Form I in 1,4-dioxane, stirring at 25 ± 1 °C for 2 days and removing the supernatant by centrifugation. In some embodiments, Form III can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form IV This document provides a solid form of Compound 1 having Form IV, which is described below in Examples. In some embodiments, Form IV has at least one characteristic XRD peak selected from about 10.1, about 13.0, about 14.0, about 18.4, about 22.2, about 24.3, and about 26.4 degrees 2-theta. In some embodiments, Form IV has at least two characteristic XRD peaks selected from about 10.1, about 13.0, about 14.0, about 18.4, about 22.2, about 24.3, and about 26.4 degrees 2-theta. In some embodiments, Form IV has at least three characteristic XRD peaks selected from about 10.1, about 13.0, about 14.0, about 18.4, about 22.2, about 24.3, and about 26.4 degrees 2-theta. In some embodiments, Form IV has at least one characteristic XRPD peak selected from about 10.1, about 13.0, about 14.0, about 15.6, about 17.3, about 18.4, about 20.2, about 21.4, about 22.2, about 22.7, about 24.3, about 26.4, and about 26.8 degrees 2-theta. In some embodiments, Form IV has at least two characteristic XRPD peaks selected from about 10.1, about 13.0, about 14.0, about 15.6, about 17.3, about 18.4, about 20.2, about 21.4, about 22.2, about 22.7, about 24.3, about 26.4, and about 26.8 degrees 2-theta. In some embodiments, Form IV has at least three characteristic XRPD peaks selected from about 10.1, about 13.0, about 14.0, about 15.6, about 17.3, about 18.4, about 20.2, about 21.4, about 22.2, about 22.7, about 24.3, about 26.4, and about 26.8 degrees 2-theta. In some embodiments, Form IV has an XRD pattern with characteristic peaks, essentially shown in Figure 13. In some embodiments, Form IV exhibits a DSC thermogram having endotherm peaks at temperatures of about 109 ºC, 203 ºC and 278 ºC. In some embodiments, Form IV exhibits a thermogram DSC, which has an endotherm peak at about 109 °C. In some embodiments, Form IV exhibits DSC thermogram, which has an endotherm peak at a temperature of about 203 °C. Form IV exhibits a DSC thermogram, which has an endotherm peak at about 278 °C. In some embodiments, Form IV has a thermogram DSC, substantially as depicted in Figure 14. In some embodiments, Form IV has a TGA thermogram, substantially such as that shown in Figure 15. In some embodiments, Form IV has at least one characteristic XRPD peak selected from about 10.1, about 13.0, about 14.0, about 18.4, about 22.2, about 24.3, and about 26.4 degrees 2-theta; and Form IV shows a DSC thermogram having endotherm peaks at temperatures around 109 °C, 203 °C, and 278 °C. This document also provides methods for obtaining Form IV of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1, Form I in 1,4-dioxane, and stirring at 25 ± 1 °C for 6 days. In some embodiments, Form IV can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form V This document provides a solid form of Compound 1 having Form V, which is described below in Examples. In some embodiments, Form V has at least one characteristic XRPD peak selected from about 7.4, about 14.8, about 21.3, about 22.0, and about 22.3 degrees 2-theta. In some embodiments, Form V has at least two characteristic XRPD peaks selected from about 7.4, about 14.8, about 21.3, about 22.0, and about 22.3 degrees 2-theta. In some embodiments, Form V has at least three characteristic XRPD peaks selected from about 7.4, about 14.8, about 21.3, about 22.0, and about 22.3 degrees 2-theta. In some embodiments, Form V has an XRD pattern with characteristic peaks, essentially shown in Figure 16. In some embodiments, Form V exhibits a DSC thermogram having endotherm peaks at temperatures of about 91 °C, 203 °C and 276 °C. In some embodiments, Form V exhibits a DSC thermogram, which has an endotherm peak at about 91 °C. In some embodiments, Form V exhibits DSC thermogram having an endotherm peak at about 203 °C. In some embodiments, Form V shows a DSC thermogram having an endotherm peak at about 276 °C. In some embodiments Embodiment Form V has a DSC thermogram substantially as depicted in Figure 17. In some embodiments, Form V has at least one characteristic XRPD peak selected from about 7.4, about 14.8, about 21.3, about 22.0, and about 22.3 degrees 2-theta; and Form V exhibits DSC thermogram, which has endotherm peaks at temperatures around 91 °C, 203 °C, and 276 °C. This document also provides methods for obtaining Form V of Compound 1, which include exposure of a saturated solution of Form I of Compound 1 in 1,4-dioxane for more than 30 days. In some embodiments, Form V can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form VI This document provides a solid form of Compound 1 having Form VI, which is described below in Examples. In some embodiments, Form VI has at least one characteristic XRPD peak selected from about 9.1, about 9.5, about 14.4, about 17.6, about 18.6, about 19.9, and about 22.3 degrees 2-theta. In some embodiments, Form VI has at least two characteristic XRPD peaks selected from about 9.1, about 9.5, about 14.4, about 17.6, about 18.6, about 19.9, and about 22.3 degrees 2-theta. In some embodiments, Form VI has at least three characteristic XRD peaks selected from about 9.1, about 9.5, about 14.4, about 17.6, about 18.6, about 19.9, and about 22.3 degrees 2-theta. In some embodiments, Form VI has at least one characteristic XRPD peak selected from about 7.8, about 9.1, about 9.5, about 10.2, about 11.4, about 12.1, about 13.4, about 14.4, about 15.9, about 17.6, about 18.6, about 19.2, about 19.9, about 22.3, about 22.7, about 25.4 and about 26.2 degrees 2-theta. In some embodiments, Form VI has at least two characteristic XRPD peaks selected from about 7.8, about 9.1, about 9.5, about 10.2, about 11.4, about 12.1, about 13.4, about 14.4, about 15.9, about 17.6, about 18.6, about 19.2, about 19.9, about 22.3, about 22.7, about 25.4 and about 26.2 degrees 2-theta. In some embodiments, Form VI has at least three characteristic XRPD peaks selected from about 7.8, about 9.1, about 9.5, about 10.2, about 11.4, about 12.1, about 13.4, about 14.4, about 15.9, about 17.6, about 18.6, about 19.2, about 19.9, about 22.3, about 22.7, about 25.4 and about 26.2 degrees 2-theta. In some embodiments, Form VI has an XRD pattern with characteristic peaks, essentially shown in Figure 18. In some embodiments, Form VI exhibits a DSC thermogram having an endotherm peak at a temperature about 275 °C. In some embodiments, Form VI has a DSC thermogram substantially as depicted in Figure 19. In some embodiments, Form VI has a TGA thermogram substantially as depicted in Figure 20. In some embodiments, Form VI has at least one characteristic XRPD peak selected from about 9.1, about 9.5, about 14.4, about 17.6, about 18.6, about 19.9, and about 22.3 degrees 2-theta; and Form VI exhibits a DSC thermogram that has an endotherm peak at around 275 °C. This document also provides methods for preparing Form VI of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1 obtained in methanol and stirring at 25 ± 1 °C within 3 days. In some embodiments, Form VI can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form VII This document provides a solid form of Compound 1 having Form VII, which is described below in Examples. In some embodiments, Form VII has at least one characteristic XRPD peak selected from about 9.8, about 15.4, about 18.8, about 19.6, and about 20.1 degrees 2-theta. In some embodiments, Form VII has at least two characteristic XRPD peaks selected from about 9.8, about 15.4, about 18.8, about 19.6, and about 20.1 degrees 2-theta. In some embodiments, Form VII has at least three characteristic XRPD peaks selected from about 9.8, about 15.4, about 18.8, about 19.6, and about 20.1 degrees 2-theta. In some embodiments, Form VII has at least one characteristic XRPD peak selected from about 8.2, about 9.8, about 15.4, about 17.9, about 18.8, about 19.6, about 20.1, about 21.1, about 22.3 and about 24.3 degrees 2-theta. In some embodiments, Form VII has at least two characteristic XRPD peaks selected from about 8.2, about 9.8, about 15.4, about 17.9, about 18.8, about 19.6, about 20.1, about 21.1, about 22.3 and about 24.3 degrees 2-theta. In some embodiments, Form VII has at least three characteristic XRPD peaks selected from about 8.2, about 9.8, about 15.4, about 17.9, about 18.8, about 19.6, about 20.1, about 21.1, about 22.3 and about 24.3 degrees 2-theta. In some embodiments, Form VII has an XRD pattern with characteristic peaks, essentially shown in Figure 21. In some embodiments, Form VII exhibits a DSC thermogram having endotherm peaks at temperatures around 88, 201 and 276 °C. In some embodiments, Form VII exhibits a DSC thermogram that has an endotherm peak at about 88 °C. In some embodiments, Form VII exhibits DSC thermogram having an endotherm peak at about 201 °C. In some embodiments, Form VII shows a DSC thermogram having an endotherm peak at about 276 °C. In some embodiments Embodiments Form VII has a DSC thermogram substantially as depicted in Figure 22. In some embodiments Form VII has a TGA thermogram substantially as depicted in Figure 23. In some embodiments, Form VII has at least one characteristic XRPD peak selected from about 9.8, about 15.4, about 18.8, about 19.6, and about 20.1 degrees 2-theta; and Form VII exhibits DSC thermogram, which has endotherm peaks at temperatures around 88 °C, 201 °C, and 276 °C. This document also provides methods for preparing Form VII of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1, Form I obtained in methyl isobutyl ketone and stirring at 25 ± 1 °C for 3 days. In some embodiments, Form VII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form VIII This document provides a solid form of Compound 1 having Form VIII, which is described below in Examples. In some embodiments, Form VIII has at least one characteristic XRPD peak selected from about 9.1, about 16.7, about 18.2, about 18.6, and about 20.2 degrees 2-theta. In some embodiments, Form VIII has at least two characteristic XRPD peaks selected from about 9.1, about 16.7, about 18.2, about 18.6, and about 20.2 degrees 2-theta. In some embodiments, Form VIII has at least three characteristic XRPD peaks selected from about 9.1, about 16.7, about 18.2, about 18.6, and about 20.2 degrees 2-theta. In some embodiments, Form VIII has at least one characteristic XRPD peak selected from about 9.1, about 15.2, about 16.7, about 18.2, about 18.6, about 20.2, about 22.5, about 24.6, about 26.8 and about 29.8 degrees 2-theta. In some embodiments, Form VIII has at least two characteristic XRPD peaks selected from about 9.1, about 15.2, about 16.7, about 18.2, about 18.6, about 20.2, about 22.5, about 24.6, about 26.8 and about 29.8 degrees 2-theta. In some embodiments, Form VIII has at least three characteristic XRPD peaks selected from about 9.1, about 15.2, about 16.7, about 18.2, about 18.6, about 20.2, about 22.5, about 24.6, about 26.8 and about 29.8 degrees 2-theta. In some embodiments, Form VIII has an XRD pattern with characteristic peaks, essentially shown in Figure 24. In some embodiments, Form VIII exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and 277 ºC. In some embodiments, Form VIII exhibits a DSC thermogram that has an endotherm peak at about 201 °C. In some embodiments, Form VIII exhibits DSC thermogram having an endotherm peak at about 277 °C. In some embodiments, Form VIII has a DSC thermogram substantially as depicted in Figure 25. In some embodiments, Form VIII has a TGA thermogram, essentially as shown in Figure 26. In some embodiments, Form VIII has at least one characteristic XRPD peak selected from about 9.1, about 16.7, about 18.2, about 18.6, and about 20.2 degrees 2-theta; and Form VIII exhibits DSC thermogram, which has endotherm peaks at temperatures around 201 ºC and 277 ºC. This document also provides methods for preparing Form VIII of Compound 1, which include adding Compound 1, Form I to a solution of Compound 1 in acetone and stirring at 25 ± 1 °C for 3 days. In some embodiments, Form VIII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Form VIII-a Compound 1 This document provides a solid form of Compound 1 having Form VIII-a, which is described below in Examples. In some embodiments, Form VIII-a has at least one characteristic XRPD peak selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, and about 21.1 degrees 2-theta. In some embodiments, Form VIII-a has at least two characteristic XRPD peaks selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, and about 21.1 degrees 2-theta. In some embodiments, Form VIII-a has at least three characteristic XRPD peaks selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, and about 21.1 degrees 2-theta. In some embodiments, Form VIII-a has at least one characteristic XRPD peak selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, about 21.1, about 22.0, about 23.5, about 24.1, about 24.3, and about 29.5 degrees 2-theta. In some embodiments, Form VIII-a has at least two characteristic XRPD peaks selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, about 21.1, about 22.0, about 23.5, about 24.1, about 24.3, and about 29.5 degrees 2-theta. In some embodiments, Form VIII-a has at least three characteristic XRPD peaks selected from about 8.9, about 16.2, about 18.0, about 18.4, about 19.9, about 21.1, about 22.0, about 23.5, about 24.1, about 24.3, and about 29.5 degrees 2-theta. In some embodiments, Form VIII-a has an XRD pattern with characteristic peaks, essentially shown in Figure 27. This document also provides methods for preparing Form VIII-a of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1 in methyl ethyl ketone and stirring at 50 ± 1 °C for 3 days. In some embodiments, Form VIII-a can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form IX This document provides a solid form of Compound 1 having Form IX, which is described below in Examples. In some embodiments, Form IX has at least one characteristic XRPD peak selected from about 8.5, about 9.2, about 12.1, about 14.6, about 15.6, about 18.6, about 22.4 and about 22.9 degrees of 2-theta. In some embodiments, Form IX has at least two characteristic XRPD peaks selected from about 8.5, about 9.2, about 12.1, about 14.6, about 15.6, about 18.6, about 22.4 and about 22.9 degrees of 2-theta. In some embodiments, Form IX has at least three characteristic XRPD peaks selected from about 8.5, about 9.2, about 12.1, about 14.6, about 15.6, about 18.6, about 22.4 and about 22.9 degrees of 2-theta. In some embodiments, Form IX has at least one characteristic XRPD peak selected from about 8.5, about 9.2, about 12.1, about 13.9, about 14.6, about 15.6, about 16.8, about 18.6, about 19.3, about 22.4, about 22.9, about 24.6, and about 31.4 degrees 2-theta. In some embodiments, Form IX has at least two characteristic XRPD peaks selected from about 8.5, about 9.2, about 12.1, about 13.9, about 14.6, about 15.6, about 16.8, about 18.6, about 19.3, about 22.4, about 22.9, about 24.6, and about 31.4 degrees 2-theta. In some embodiments, Form IX has at least three characteristic XRPD peaks selected from about 8.5, about 9.2, about 12.1, about 13.9, about 14.6, about 15.6, about 16.8, about 18.6, about 19.3, about 22.4, about 22.9, about 24.6, and about 31.4 degrees 2-theta. In some embodiments, Form IX has an XRD pattern with characteristic peaks, essentially shown in Figure 28. In some embodiments, Form IX exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and 276 ºC. In some embodiments, Form IX exhibits a DSC thermogram that has an endotherm peak at about 201 °C. In some embodiments, Form IX exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, Form IX has a DSC thermogram substantially as depicted in Figure 29. In some embodiments, Form IX has a TGA thermogram, essentially as shown in Figure 30. In some embodiments, Form IX has at least one characteristic XRPD peak selected from about 8.5, about 9.2, about 12.1, about 14.6, about 15.6, about 18.6, about 22.4 and about 22.9 degrees 2-theta; and Form IX exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and 276 ºC. This document also provides methods for preparing Form IX of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1, Form I in methyl tert-butyl ether, and stirring at 25 ± 1 °C for 3 days. In some embodiments, Form IX can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form X This document provides a solid form of Compound 1 having Form X, which is described below in Examples. In some embodiments, Form X has at least one characteristic XRPD peak selected from about 10.1, about 14.6, about 15.4, about 15.7, about 18.1, and about 22.3 degrees 2-theta. In some embodiments, Form X has at least two characteristic XRPD peaks selected from about 10.1, about 14.6, about 15.4, about 15.7, about 18.1, and about 22.3 degrees 2-theta. In some embodiments, Form X has at least three characteristic XRPD peaks selected from about 10.1, about 14.6, about 15.4, about 15.7, about 18.1, and about 22.3 degrees 2-theta. In some In embodiments, Form X has at least one characteristic XRPD peak selected from about 4.9, about 10.1, about 11.3, about 14.6, about 15.4, about 15.7, about 17.2, about 18.1, about 19.5, about 20.0, about 22.3, about 23.8, about 25.3, about 25.7, and about 26.3 degrees 2-theta. In some embodiments, Form X has at least two characteristic XRPD peaks selected from about 4.9, about 10.1, about 11.3, about 14.6, about 15.4, about 15.7, about 17.2, about 18.1, about 19.5, about 20.0, about 22.3, about 23.8, about 25.3, about 25.7, and about 26.3 degrees 2-theta. In some embodiments, Form X has at least three characteristic XRPD peaks selected from about 4.9, about 10.1, about 11.3, about 14.6, about 15.4, about 15.7, about 17.2, about 18.1, about 19.5, about 20.0, about 22.3, about 23.8, about 25.3, about 25.7, and about 26.3 degrees 2-theta. In some embodiments, Form X has an XRD pattern with characteristic peaks, essentially shown in Figure 31. In some embodiments, Form X exhibits a DSC thermogram having endotherm peaks at temperatures around 202 ºC and 276 ºC. In some embodiments, Form X exhibits a DSC thermogram that has an endotherm peak at about 202 °C. In some embodiments, Form X exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, Form X has a DSC thermogram substantially as depicted in Figure 32. In some embodiments, Form X has a TGA thermogram, essentially as shown in Figure 33. In some embodiments, Form X has at least one characteristic XRPD peak selected from about 10.1, about 14.6, about 15.4, about 15.7, about 18.1, and about 22.3 degrees 2-theta; and Form X shows a DSC thermogram having endotherm peaks at temperatures around 202 °C and 276 °C. This document also provides methods for preparing Form X of Compound 1, comprising adding Compound 1, Form I, to a cloudy solution of Compound 1, Form I in ethyl acetate, and stirring at 25 ± 1 °C within 3 days. In some embodiments, Form X can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XI This document provides a solid form of Compound 1 having Form XI, which is described below in Examples. In some embodiments, Form XI has at least one characteristic XRPD peak selected from about 3.9, about 7.5, about 13.0, about 17.3, about 21.4, and about 22.8 degrees 2-theta. In some embodiments, Form XI has at least two characteristic XRPD peaks selected from about 3.9, about 7.5, about 13.0, about 17.3, about 21.4, and about 22.8 degrees 2-theta. In some embodiments, Form XI has at least three characteristic XRPD peaks selected from about 3.9, about 7.5, about 13.0, about 17.3, about 21.4, and about 22.8 degrees 2-theta. In some embodiments, Form XI has at least one characteristic XRPD peak selected from about 3.9, about 4.3, about 7.5, about 13.0, about 13.7, about 15.0, about 16.5, about 17.3, about 19.1, about 19.9, about 21.4, about 22.2, about 22.8, about 25.2, and about 26.9 degrees 2-theta. In some embodiments, Form XI has at least two characteristic XRPD peaks selected from about 3.9, about 4.3, about 7.5, about 13.0, about 13.7, about 15.0, about 16.5, about 17.3, about 19.1, about 19.9, about 21.4, about 22.2, about 22.8, about 25.2, and about 26.9 degrees 2-theta. In some embodiments, Form XI has at least three characteristic XRPD peaks selected from about 3.9, about 4.3, about 7.5, about 13.0, about 13.7, about 15.0, about 16.5, about 17.3, about 19.1, about 19.9, about 21.4, about 22.2, about 22.8, about 25.2, and about 26.9 degrees 2-theta. In some embodiments, Form XI has an XRD pattern with characteristic peaks, essentially shown in Figure 34. In some embodiments, Form XI exhibits a DSC thermogram having endotherm peaks at temperatures about 141 ºC and 279 ºC. In some embodiments, Form XI exhibits a DSC thermogram that has an endotherm peak at about 141 °C. In some embodiments, Form XI exhibits DSC thermogram having an endotherm peak at about 279 °C. In some embodiments, Form XI has a DSC thermogram substantially as depicted in Figure 35. In some embodiments, Form XI has a TGA thermogram, essentially as shown in Figure 36. In some embodiments, Form XI has at least one characteristic XRPD peak selected from about 3.9, about 7.5, about 13.0, about 17.3, about 21.4, and about 22.8 degrees 2-theta; and Form XI shows a DSC thermogram that has endotherm peaks at temperatures around 141 ºC and 279 °C. This document also provides methods for preparing Form XI of Compound 1, which include adding Compound 1, Form I to 5 mL of a cloudy solution of Compound 1, Form I in ethyl formate, and stirring at 25 ± 1 °C within 3 days. In some embodiments, Form XI can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XII This document provides a solid form of Compound 1 having Form XII, which is described below in Examples. In some embodiments, Form XII has at least one characteristic XRD peak selected from about 7.5, about 14.1, about 17.3, about 18.3, about 22.1, and about 22.7 degrees 2-theta. In some embodiments, Form XII has at least two characteristic XRPD peaks selected from about 7.5, about 14.1, about 17.3, about 18.3, about 22.1, and about 22.7 degrees 2-theta. In some embodiments, Form XII has at least three characteristic XRPD peaks selected from about 7.5, about 14.1, about 17.3, about 18.3, about 22.1, and about 22.7 degrees 2-theta. In some embodiments, Form XII has at least one characteristic XRPD peak selected from about 3.9, about 7.5, about 9.8, about 11.5, about 12.9, about 14.1, about 17.3, about 18.3, about 22.1, about 22.7, about 24.3, about 26.3, and about 26.9 degrees 2-theta. In some embodiments, Form XII has at least two characteristic XRPD peaks selected from about 3.9, about 7.5, about 9.8, about 11.5, about 12.9, about 14.1, about 17.3, about 18.3, about 22.1, about 22.7, about 24.3, about 26.3, and about 26.9 degrees 2-theta. In some embodiments, Form XII has at least three characteristic XRPD peaks selected from about 3.9, about 7.5, about 9.8, about 11.5, about 12.9, about 14.1, about 17.3, about 18.3, about 22.1, about 22.7, about 24.3, about 26.3, and about 26.9 degrees 2-theta. In some embodiments, Form XII has an XRD pattern with characteristic peaks, essentially shown in Figure 37. In some embodiments, Form XII exhibits a DSC thermogram having endotherm peaks at temperatures of about 105 ºC and 276 ºC. In some embodiments, Form XII exhibits a DSC thermogram that has an endotherm peak at about 105 °C. In some embodiments, Form XII exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, Form XII has a DSC thermogram substantially as depicted in Figure 38. In some embodiments, Form XII has a TGA thermogram, essentially as shown in Figure 39. In some embodiments, Form XII has at least one characteristic XRPD peak selected from about 7.5, about 14.1, about 17.3, about 18.3, about 22.1, and about 22.7 degrees 2-theta; and Form XII shows a DSC thermogram having endotherm peaks at temperatures around 105 ºC and 276 °C. This document also provides methods for preparing Form XII of Compound 1, which include adding Compound 1, Form I to a cloudy solution of Compound 1, Form I obtained in 1,4-dioxane and stirring at 50 1 °C for 2 days. In some embodiments, Form XII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XIII This document provides a solid form of Compound 1 having Form XIII, which is described below in Examples. In some embodiments, Form XIII has at least one characteristic XRPD peak selected from about 7.7, about 15.2, about 15.7, about 21.9, about 23.1, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has at least two characteristic XRPD peaks selected from about 7.7, about 15.2, about 15.7, about 21.9, about 23.1, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has at least three characteristic XRPD peaks selected from about 7.7, about 15.2, about 15.7, about 21.9, about 23.1, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has at least one characteristic XRPD peak selected from about 4.0, about 7.7, about 10.9, about 11.6, about 14.2, about 15.2, about 15.7, about 17.8, about 19.0, about 21.9, about 22.2, about 23.1, about 25.6, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has at least two characteristic XRPD peaks selected from about 4.0, about 7.7, about 10.9, about 11.6, about 14.2, about 15.2, about 15.7, about 17.8, about 19.0, about 21.9, about 22.2, about 23.1, about 25.6, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has at least three characteristic XRPD peaks selected from about 4.0, about 7.7, about 10.9, about 11.6, about 14.2, about 15.2, about 15.7, about 17.8, about 19.0, about 21.9, about 22.2, about 23.1, about 25.6, and about 26.1 degrees 2-theta. In some embodiments, Form XIII has an XRD pattern with characteristic peaks, essentially shown in Figure 40. In some embodiments, Form XIII exhibits a DSC thermogram having an endotherm peak at a temperature about 276 °C. In some embodiments, Form XIII has a DSC thermogram substantially as depicted in Figure 41. In some embodiments, Form XIII has a TGA thermogram substantially as depicted in Figure 42. In some embodiments, Form XIII has at least two characteristic XRPD peaks selected from about 7.7, about 15.2, about 15.7, about 21.9, about 23.1, and about 26.1 degrees 2-theta; and Form XIII shows a DSC thermogram having an endotherm peak at around 276 °C. This document also provides methods for preparing Form XIII of Compound 1, Form I, comprising adding Compound 1, Form I to a cloudy solution of Compound 1 in THF, and stirring at 50 ± 1 °C for 2 days. In some embodiments, Form XIII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XIII-a This document provides a solid form of Compound 1 having Form XIII-a, which is described below in Examples. In some embodiments, Form XIII-a has at least one characteristic XRPD peak selected from about 6.9, about 7.7, about 10.4, about 15.2, about 21.5, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has at least two characteristic XRPD peaks selected from about 6.9, about 7.7, about 10.4, about 15.2, about 21.5, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has at least three characteristic XRPD peaks selected from about 6.9, about 7.7, about 10.4, about 15.2, about 21.5, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has at least one characteristic XRPD peak selected from about 6.9, about 7.7, about 8.3, about 10.4, about 10.9, about 12.1, about 14.4, about 15.2, about 18.6, about 19.7, about 21.5, about 22.3, about 22.6, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has at least two characteristic XRPD peaks selected from about 6.9, about 7.7, about 8.3, about 10.4, about 10.9, about 12.1, about 14.4, about 15.2, about 18.6, about 19.7, about 21.5, about 22.3, about 22.6, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has at least three characteristic XRPD peaks selected from about 6.9, about 7.7, about 8.3, about 10.4, about 10.9, about 12.1, about 14.4, about 15.2, about 18.6, about 19.7, about 21.5, about 22.3, about 22.6, and about 26.2 degrees 2-theta. In some embodiments, Form XIII-a has an XRD pattern with characteristic peaks, essentially shown in Figure 43. In some embodiments, Form XIII-a exhibits a DSC thermogram having endotherm peaks at temperatures about 75 °C and 276 °C. In some embodiments, Form XIII-a exhibits a DSC thermogram that has an endotherm peak at about 75 °C. In some embodiments, Form XIII-a exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, the Form XIII-a has a DSC thermogram essentially as depicted in Figure 44. In some embodiments, Form XIII-a has at least one characteristic XRPD peak selected from about 6.9, about 7.7, about 10.4, about 15.2, about 21.5, and about 26.2 degrees 2-theta; and Form XIII-a shows a DSC thermogram having endotherm peaks at temperatures around 75 °C and 276 °C. This document also provides methods for obtaining Form XIII-a of Compound 1, including cooling a saturated solution of Compound 1, Form I in THF to -20 °C and maintaining the temperature at -20 °C over a period of time (e.g. 3 hours). In some embodiments, Form XIII-a can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XIV This document provides a solid form of Compound 1 having Form XIV, which is described below in Examples. In some embodiments, Form XIV has at least one characteristic XRD peak selected from about 7.0, about 14.1, about 16.1, about 20.0, about 22.0, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has at least two characteristic XRPD peaks selected from about 7.0, about 14.1, about 16.1, about 20.0, about 22.0, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has at least three characteristic XRPD peaks selected from about 7.0, about 14.1, about 16.1, about 20.0, about 22.0, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has at least one characteristic XRPD peak selected from about 7.0, about 8.6, about 9.2, about 9.6, about 10.3, about 11.5, about 12.2, about 14.1, about 14.5, about 16.1, about 17.6, about 18.3, about 18.7, about 19.3, about 20.0, about 22.0, about 22.3, about 22.9, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has at least two characteristic XRPD peaks selected from about 7.0, about 8.6, about 9.2, about 9.6, about 10.3, about 11.5, about 12.2, about 14.1, about 14.5, about 16.1, about 17.6, about 18.3, about 18.7, about 19.3, about 20.0, about 22.0, about 22.3, about 22.9, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has at least three characteristic XRPD peaks selected from about 7.0, about 8.6, about 9.2, about 9.6, about 10.3, about 11.5, about 12.2, about 14.1, about 14.5, about 16.1, about 17.6, about 18.3, about 18.7, about 19.3, about 20.0, about 22.0, about 22.3, about 22.9, and about 25.8 degrees 2-theta. In some embodiments, Form XIV has an XRD pattern with characteristic peaks, essentially shown in Figure 45. In some embodiments, Form XIV exhibits a DSC thermogram having endotherm peaks at temperatures around 78, 118 and 277 °C. In some embodiments, Form XIV exhibits a DSC thermogram that has an endotherm peak at about 78 °C. In some embodiments, Form XIV exhibits DSC thermogram having an endotherm peak at about 118 °C. In some embodiments, Form XIV shows a DSC thermogram having an endotherm peak at about 277 °C. In some embodiments Embodiments Form XIV has a DSC thermogram substantially as depicted in Figure 46. In some embodiments Form XIV has a TGA thermogram substantially as depicted in Figure 47. In some embodiments, Form XIV has at least one characteristic XRPD peak selected from about 7.0, about 14.1, about 16.1, about 20.0, about 22.0, and about 25.8 degrees 2-theta; and Form XIV shows a DSC thermogram having endotherm peaks at temperatures around 78 °C, 118 °C, and 277 °C. This document also provides methods for obtaining Form XIV of Compound 1, including evaporation of a saturated solution of Form I 1 Compound in DMF at 25 ± 1 °C. In some embodiments, Form XIV can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XV This document provides a solid form of Compound 1 having Form XV, which is described below in Examples. In some embodiments, Form XV has at least one characteristic XRD peak selected from about 8.9, about 9.2, about 15.6, about 18.5 and about 22.4. In some embodiments, Form XV has at least two characteristic XRD peaks selected from about 8.9, about 9.2, about 15.6, about 18.5 and about 22.4. In some embodiments, Form XV has at least three characteristic XRD peaks selected from about 8.9, about 9.2, about 15.6, about 18.5 and about 22.4. In some embodiments, Form XV has at least one characteristic XRPD peak selected from about 3.9, about 8.9, about 9.2, about 15.6, about 16.6, about 18.5, about 20.3, about 21.4, about 21.8, about 22.4, about 24.5, about 24.9, about 30.0, and about 31.1 degrees 2-theta. In some embodiments, Form XV has at least two characteristic XRPD peaks selected from about 3.9, about 8.9, about 9.2, about 15.6, about 16.6, about 18.5, about 20.3, about 21.4, about 21.8, about 22.4, about 24.5, about 24.9, about 30.0, and about 31.1 degrees 2-theta. In some embodiments, Form XV has at least three characteristic XRPD peaks selected from about 3.9, about 8.9, about 9.2, about 15.6, about 16.6, about 18.5, about 20.3, about 21.4, about 21.8, about 22.4, about 24.5, about 24.9, about 30.0, and about 31.1 degrees 2-theta. In some embodiments, Form XV has an XRD pattern with characteristic peaks, essentially shown in Figure 48. In some embodiments, Form XV exhibits a DSC thermogram having endotherm peaks at temperatures of about 119 ºC and 276 ºC. In some embodiments, Form XV exhibits a DSC thermogram that has an endotherm peak at about 119 °C. In some embodiments, Form XV exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, Form XV has a DSC thermogram substantially as depicted in Figure 49. In some embodiments, Form XV has a TGA thermogram, essentially as shown in Figure 50. In some embodiments, Form XV has at least one characteristic XRPD peak selected from about 8.9, about 9.2, about 15.6, about 18.5 and about 22.4; and Form XV shows a DSC thermogram that has endotherm peaks at temperatures around 119 ºC and 276 °C. This document also provides methods for obtaining Form XV of Compound 1, including evaporation of a saturated solution of Form I of Compound 1 in DMSO at 25 ± 1 °C. In some embodiments, Form XV can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XVI This document provides a solid form of Compound 1 having Form XVI, which is described below in Examples. In some embodiments, Form XVI has at least one characteristic XRD peak selected from about 6.8, about 10.7, about 14.0, about 14.9, about 16.0 and about 19.9. In some embodiments, Form XVI has at least two characteristic XRD peaks selected from about 6.8, about 10.7, about 14.0, about 14.9, about 16.0 and about 19.9. In some embodiments, Form XVI has at least three characteristic XRD peaks selected from about 6.8, about 10.7, about 14.0, about 14.9, about 16.0 and about 19.9. In some embodiments, Form XVI has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 10.7, about 14.0, about 14.9, about 16.0, about 17.5, about 18.5, about 19.2, about 19.9, about 22.2, about 23.5, about 24.5, about 25.4, about 25.7, about 26.1 and about 30.2 degrees 2-theta. In some embodiments, Form XVI has at least two characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.7, about 14.0, about 14.9, about 16.0, about 17.5, about 18.5, about 19.2, about 19.9, about 22.2, about 23.5, about 24.5, about 25.4, about 25.7, about 26.1 and about 30.2 degrees 2-theta. In some embodiments, Form XVI has at least three characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.7, about 14.0, about 14.9, about 16.0, about 17.5, about 18.5, about 19.2, about 19.9, about 22.2, about 23.5, about 24.5, about 25.4, about 25.7, about 26.1 and about 30.2 degrees 2-theta. In some embodiments, Form XVI has an XRD pattern with characteristic peaks, essentially shown in Figure 51. In some embodiments, Form XVI exhibits a DSC thermogram having an endotherm peak at a temperature about 276 °C. In some embodiments, Form XVI has a DSC thermogram substantially as depicted in Figure 52. In some embodiments, Form XVI has a TGA thermogram substantially as depicted in Figure 53. In some embodiments, Form XVI has at least one characteristic XRPD peak selected from about 6.8, about 10.7, about 14.0, about 14.9, about 16.0 and about 19.9; and Form XVI shows DSC thermogram, which has an endotherm peak at a temperature of about 276 °C. This document also provides methods for obtaining Form XVI of Compound 1, including evaporation of a saturated solution of Form I of Compound 1 in THF at 50 ± 1 °C. In some embodiments, Form XVI can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XVII This document provides a solid form of Compound 1 having Form XVII, which is described below in Examples. In some embodiments, Form XVII has at least one characteristic XRPD peak selected from about 15.7, about 18.1, about 18.4, and about 32.2 degrees 2-theta. In some embodiments, Form XVII has at least two characteristic XRPD peaks selected from about 15.7, about 18.1, about 18.4, and about 32.2 degrees 2-theta. In some embodiments, Form XVII has at least three characteristic XRPD peaks selected from about 15.7, about 18.1, about 18.4, and about 32.2 degrees 2-theta. In some embodiments, Form XVII has an XRD pattern with characteristic peaks, essentially shown in Figure 54. In some embodiments, Form XVII exhibits a DSC thermogram having endotherm peaks at temperatures of about 119 ºC and 276 ºC. In some embodiments, Form XVII exhibits a DSC thermogram that has an endotherm peak at about 119 °C. In some embodiments, Form XVII exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, the Form XVII has a DSC thermogram substantially as depicted in Figure 55. In some embodiments, Form XVII has a TGA thermogram, essentially as shown in Figure 56. In some embodiments, Form XVII has at least one characteristic XRPD peak selected from about 15.7, about 18.1, about 18.4, and about 32.2 degrees 2-theta; and Form XVII shows a DSC thermogram that has endotherm peaks at temperatures around 119 and 276 °C. This document also provides methods for obtaining Form XVII of Compound 1, including evaporation of a saturated solution of Form I of Compound 1 in DMSO at 50 ± 1 °C. In some embodiments, Form XVII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XVIII This document provides a solid form of Compound 1 having Form XVIII, which is described below in Examples. In some embodiments, Form XVIII has at least one characteristic XRPD peak selected from about 9.4, about 14.6, about 16.2, about 17.5, about 18.8, about 22.3, and about 22.7 degrees 2-theta. In some embodiments, Form XVIII has at least two characteristic XRPD peaks selected from about 9.4, about 14.6, about 16.2, about 17.5, about 18.8, about 22.3, and about 22.7 degrees 2-theta. In some embodiments, Form XVIII has at least three characteristic XRD peaks selected from about 9.4, about 14.6, about 16.2, about 17.5, about 18.8, about 22.3, and about 22.7 degrees 2-theta. In some embodiments, Form XVIII has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 10.3, about 11.9, about 12.6, about 13.4, about 14.6, about 16.2, about 17.5, about 18.3, about 18.8, about 20.8, about 22.3, about 22.7, and about 25.4 degrees 2-theta. In some embodiments, Form XVIII has at least two characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.3, about 11.9, about 12.6, about 13.4, about 14.6, about 16.2, about 17.5, about 18.3, about 18.8, about 20.8, about 22.3, about 22.7, and about 25.4 degrees 2-theta. In some embodiments, Form XVIII has at least three characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.3, about 11.9, about 12.6, about 13.4, about 14.6, about 16.2, about 17.5, about 18.3, about 18.8, about 20.8, about 22.3, about 22.7, and about 25.4 degrees 2-theta. In some embodiments, Form XVIII has an XRD pattern with characteristic peaks, essentially shown in Figure 57. In some embodiments, Form XVIII exhibits a DSC thermogram having an endotherm peak at at a temperature of about 276 °C. In some embodiments, Form XVIII has a DSC thermogram substantially as follows: depicted in Figure 58. In some embodiments, Form XVIII has a TGA thermogram substantially as follows: shown in Figure 59. In some embodiments, Form XVIII has at least one characteristic XRPD peak selected from about 9.4, about 14.6, about 16.2, about 17.5, about 18.8, about 22.3, and about 22.7 degrees 2-theta; and Form XVIII exhibits a DSC thermogram having an endotherm peak at about 276 °C. This document also provides methods for preparing Form XVIII of Compound 1, which include adding of hexane to a saturated solution of Form I of Compound 1 in chloroform. In some embodiments, Form XVIII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XIX This document provides a solid form of Compound 1 having Form XIX, which is described below in Examples. In some embodiments, Form XIX has at least one characteristic XRD peak selected from about 6.7, about 10.0, about 17.4, about 18.0, about 20.2, and about 21.4 degrees 2-theta. In some embodiments, Form XIX has at least two characteristic XRPD peaks selected from about 6.7, about 10.0, about 17.4, about 18.0, about 20.2, and about 21.4 degrees 2-theta. In some embodiments, Form XIX has at least three characteristic XRPD peaks selected from about 6.7, about 10.0, about 17.4, about 18.0, about 20.2, and about 21.4 degrees 2-theta. In some embodiments, Form XIX has at least one characteristic XRPD peak selected from about 3.9, about 6.7, about 9.4, about 10.0, about 13.6, about 17.4, about 18.0, about 20.2, about 21.4, about 22.1, and about 25.0 degrees 2-theta. In some embodiments, Form XIX has at least two characteristic XRPD peaks selected from about 3.9, about 6.7, about 9.4, about 10.0, about 13.6, about 17.4, about 18.0, about 20.2, about 21.4, about 22.1, and about 25.0 degrees 2-theta. In some embodiments, Form XIX has at least three characteristic XRPD peaks selected from about 3.9, about 6.7, about 9.4, about 10.0, about 13.6, about 17.4, about 18.0, about 20.2, about 21.4, about 22.1, and about 25.0 degrees 2-theta. In some embodiments, Form XIX has an XRD pattern with characteristic peaks, essentially shown in Figure 60. In some embodiments, Form XIX exhibits a DSC thermogram having an endotherm peak at a temperature about 276 °C. In some embodiments, Form XIX has a DSC thermogram substantially as depicted in Figure 61. In some embodiments, Form XIX has a TGA thermogram substantially as depicted in Figure 62. In some embodiments, Form XIX has at least one characteristic XRPD peak selected from about 6.7, about 10.0, about 17.4, about 18.0, about 20.2, and about 21.4 degrees 2-theta; and Form XIX shows a DSC thermogram having an endotherm peak at around 276 °C. This document also provides methods for preparing Form XIX of Compound 1, which include adding of methanol to a saturated solution of Form I of Compound 1 in dichloromethane. In some embodiments, Form XIX can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XX This document provides a solid form of Compound 1 having Form XX, which is described below in Examples. In some embodiments, Form XX has at least one characteristic XRD peak selected from about 9.2, about 14.7, about 18.6, about 22.5 and about 23.0. In some embodiments, Form XX has at least two characteristic XRD peaks selected from about 9.2, about 14.7, about 18.6, about 22.5 and about 23.0. In some embodiments, Form XX has at least three characteristic XRD peaks selected from about 9.2, about 14.7, about 18.6, about 22.5 and about 23.0. In some embodiments, Form XX has at least one characteristic XRPD peak selected from about 9.2, about 14.7, about 15.6, about 18.6, about 22.3, about 22.5, about 23.0, about 24.7 and about 29.5 degrees 2-theta. In some embodiments, Form XX has at least two characteristic XRPD peaks selected from about 9.2, about 14.7, about 15.6, about 18.6, about 22.3, about 22.5, about 23.0, about 24.7 and about 29.5 degrees of 2-theta. In some embodiments, Form XX has at least three characteristic XRPD peaks selected from about 9.2, about 14.7, about 15.6, about 18.6, about 22.3, about 22.5, about 23.0, about 24.7 and about 29.5 degrees 2-theta. In some embodiments, Form XX has an XRD pattern with characteristic peaks, essentially shown in Figure 63. In some embodiments, Form XX exhibits a DSC thermogram having endotherm peaks at temperatures around 108, 202 and 277 °C. In some embodiments, Form XX exhibits a DSC thermogram that has an endotherm peak at about 108 °C. In some embodiments, Form XX exhibits DSC thermogram having an endotherm peak at about 202 °C. In some embodiments, Form XX shows a DSC thermogram having an endotherm peak at about 277 °C. In some embodiments Embodiment Form XX has a DSC thermogram substantially as depicted in Figure 64. In some embodiments Form XX has a TGA thermogram essentially as depicted in Figure 65. In some embodiments, Form XX has at least one characteristic XRPD peak selected from about 9.2, about 14.7, about 18.6, about 22.5 and about 23.0; and Form XX exhibits a DSC thermogram that has endotherm peaks at temperatures around 108 °C, 202 °C, and 277 °C. This document also provides methods for preparing Form XX of Compound 1, which include adding of a saturated solution of Form I of Compound 1 in dichloromethane to methyl tert-butyl ether. In some embodiments, Form XX can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XXI This document provides a solid form of Compound 1 having Form XXI, which is described below in Examples. In some embodiments, Form XXI has at least one characteristic XRPD peak selected from about 10.3, about 14.2, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has at least two characteristic XRPD peaks selected from about 10.3, about 14.2, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has at least three characteristic XRPD peaks selected from about 10.3, about 14.2, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has at least one characteristic XRPD peak selected from about 3.9, about 6.5, about 10.3, about 13.2, about 14.2, about 17.5, about 19.4, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has at least two characteristic XRPD peaks selected from about 3.9, about 6.5, about 10.3, about 13.2, about 14.2, about 17.5, about 19.4, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has at least three characteristic XRPD peaks selected from about 3.9, about 6.5, about 10.3, about 13.2, about 14.2, about 17.5, about 19.4, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta. In some embodiments, Form XXI has an XRD pattern with characteristic peaks, essentially shown in Figure 66. In some embodiments, Form XXI exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and 277 ºC. In some embodiments, Form XXI exhibits a DSC thermogram that has an endotherm peak at about 201 °C. In some embodiments, Form XXI exhibits DSC thermogram having an endotherm peak at about 277 °C. In some embodiments, Form XXI has a DSC thermogram essentially as shown in Figure 67. In some embodiments, Form XXI has at least two characteristic XRPD peaks selected from about 10.3, about 14.2, about 20.7, about 22.6, about 24.2, and about 27.1 degrees 2-theta; and Form XXI shows a DSC thermogram that has endotherm peaks at temperatures around 201 ºC and 277 °C. This document also provides methods for preparing Form XXI of Compound 1, which include adding of a saturated solution of Form I of Compound 1 in dichloromethane to toluene. In some embodiments, Form XXI can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Form XXII Compound 1 This document provides a solid form of Compound 1 having Form XXII, which is described below in Examples. In some embodiments, Form XXII has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 14.3, about 17.5, about 18.5 and about 22.2 degrees 2-theta. In some embodiments, Form XXII has at least two characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 14.3, about 17.5, about 18.5 and about 22.2 degrees of 2-theta. In some embodiments, Form XXII has at least three characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 14.3, about 17.5, about 18.5 and about 22.2 degrees 2-theta. In some embodiments, Form XXII has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 13.3, about 14.3, about 15.8, about 17.5, about 18.0, about 18.5, about 19.2, about 19.8, about 22.2, about 25.3 and about 26.1 degrees of 2-theta. In some embodiments, Form XXII has at least two characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 13.3, about 14.3, about 15.8, about 17.5, about 18.0, about 18.5, about 19.2, about 19.8, about 22.2, about 25.3 and about 26.1 degrees of 2-theta. In some embodiments, Form XXII has at least three characteristic XRPD peaks selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 13.3, about 14.3, about 15.8, about 17.5, about 18.0, about 18.5, about 19.2, about 19.8, about 22.2, about 25.3 and about 26.1 degrees of 2-theta. In some embodiments, Form XXII has an XRD pattern with characteristic peaks, essentially shown in Figure 68. In some embodiments, Form XXII exhibits a DSC thermogram having an endotherm peak at at a temperature of about 276 °C. In some embodiments, Form XXII has a DSC thermogram substantially as follows: shown in Figure 69. In some embodiments, Form XXII has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 10.1, about 11.4, about 12.1, about 14.3, about 17.5, about 18.5 and about 22.2 degrees 2-theta; and Form XXII exhibits a DSC thermogram having an endotherm peak at a temperature about 276 °C. This document also provides methods for preparing Form XXII of Compound 1, which include adding of a saturated solution of Form I of Compound 1 in dichloromethane to methanol. In some embodiments, Form XXII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XXIII This document provides a solid form of Compound 1 having Form XXIII, which is described below in Examples. In some embodiments, Form XXIII has at least one characteristic XRPD peak selected from about 12.0, about 12.7, about 21.0, about 24.9, and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has at least two characteristic XRPD peaks selected from about 12.0, about 12.7, about 21.0, about 24.9, and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has at least three characteristic XRPD peaks selected from about 12.0, about 12.7, about 21.0, about 24.9, and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has at least one characteristic XRPD peak selected from about 12.0, about 12.7, about 13.2, about 14.3, about 18.9, about 19.6, about 21.0, about 24.9 and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has at least two characteristic XRPD peaks selected from about 12.0, about 12.7, about 13.2, about 14.3, about 18.9, about 19.6, about 21.0, about 24.9 and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has at least three characteristic XRPD peaks selected from about 12.0, about 12.7, about 13.2, about 14.3, about 18.9, about 19.6, about 21.0, about 24.9 and about 25.6 degrees 2-theta. In some embodiments, Form XXIII has an XRD pattern with characteristic peaks, essentially shown in Figure 70. In some embodiments, Form XXIII exhibits a DSC thermogram having an endotherm peak at at a temperature of about 277 °C. In some embodiments, Form XXIII has a DSC thermogram substantially as follows: is depicted in Figure 71. In some embodiments, Form XXIII has a TGA thermogram substantially as follows: shown in Figure 72. In some embodiments, Form XXIII has at least one characteristic XRPD peak selected from about 12.0, about 12.7, about 21.0, about 24.9, and about 25.6 degrees 2-theta; and Form XXIII exhibits DSC thermogram, which has an endotherm peak at a temperature of about 277 °C. This document also provides methods for obtaining Form XXIII of Compound 1, including cooling 10 ml of a saturated solution of Compound 1, Form I in dichloromethane to -20 °C and keeping at at a temperature of -20 °C for 3 hours. In some embodiments, Form XXIII can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XXIV This document provides a solid form of Compound 1 having Form XXIV, which is described below in Examples. In some embodiments, Form XXIV has at least one characteristic XRPD peak selected from about 8.6, about 15.6, about 18.1, about 20.4, about 22.2, about 22.9, about 24.2 and about 25.5 degrees of 2-theta. In some embodiments, Form XXIV has at least two characteristic XRPD peaks selected from about 8.6, about 15.6, about 18.1, about 20.4, about 22.2, about 22.9, about 24.2 and about 25.5 degrees of 2-theta. In some embodiments, Form XXIV has at least three characteristic XRPD peaks selected from about 8.6, about 15.6, about 18.1, about 20.4, about 22.2, about 22.9, about 24.2 and about 25.5 degrees of 2-theta. In some embodiments, Form XXIV has at least one characteristic XRPD peak selected from about 8.6, about 9.7, about 13.8, about 15.6, about 17.4, about 18.1, about 19.4, about 20.4, about 22.2, about 22.9, about 24.2, about 25.5, about 26.0, about 27.5, and about 27.9 degrees 2-theta. In some embodiments, Form XXIV has at least two characteristic XRPD peaks selected from about 8.6, about 9.7, about 13.8, about 15.6, about 17.4, about 18.1, about 19.4, about 20.4, about 22.2, about 22.9, about 24.2, about 25.5, about 26.0, about 27.5, and about 27.9 degrees 2-theta. In some embodiments, Form XXIV has at least three characteristic XRPD peaks selected from about 8.6, about 9.7, about 13.8, about 15.6, about 17.4, about 18.1, about 19.4, about 20.4, about 22.2, about 22.9, about 24.2, about 25.5, about 26.0, about 27.5, and about 27.9 degrees 2-theta. In some embodiments, Form XXIV has an XRD pattern with characteristic peaks, essentially shown in Figure 73. In some embodiments, Form XXIV exhibits a DSC thermogram having an endotherm peak at at a temperature of about 277 °C. In some embodiments, Form XXIV has a DSC thermogram substantially as follows: is depicted in Figure 74. In some embodiments, Form XXIV has a TGA thermogram substantially as follows: shown in Figure 75. In some embodiments, Form XXIV has at least one characteristic XRPD peak selected from about 8.6, about 15.6, about 18.1, about 20.4, about 22.2, about 22.9, about 24.2 and about 25.5 degrees 2-theta; and Form XXIV exhibits a DSC thermogram having an endotherm peak at a temperature of about 277 °C. This document also provides methods for obtaining Form XXIV of Compound 1 involving cyclization a saturated solution of Form I of Compound 1 in DMF at a temperature of 5-50 °C for a period of time (e.g., at least three days or at least 72 hours). In some embodiments, Form XXIV can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XXV This document provides a solid form of Compound 1 having Form XXV, which is described below in Examples. In some embodiments, Form XXV has at least one characteristic XRPD peak selected from about 16.6, about 18.4, about 20.4, about 22.4, about 24.4, about 24.9, and about 29.9 degrees 2-theta. In some embodiments, Form XXV has at least two characteristic XRPD peaks selected from about 16.6, about 18.4, about 20.4, about 22.4, about 24.4, about 24.9, and about 29.9 degrees 2-theta. In some embodiments, Form XXV has at least three characteristic XRPD peaks selected from about 16.6, about 18.4, about 20.4, about 22.4, about 24.4, about 24.9, and about 29.9 degrees 2-theta. In some embodiments, Form XXV has at least one characteristic XRPD peak selected from about 16.6, about 18.4, about 20.4, about 21.7, about 22.4, about 24.4, about 24.9, about 25.7, about 29.9, about 31.9, about 35.8, and about 38.9 degrees 2-theta. In some embodiments, Form XXV has at least two characteristic XRPD peaks selected from about 16.6, about 18.4, about 20.4, about 21.7, about 22.4, about 24.4, about 24.9, about 25.7, about 29.9, about 31.9, about 35.8, and about 38.9 degrees 2-theta. In some embodiments, Form XXV has at least three characteristic XRPD peaks selected from about 16.6, about 18.4, about 20.4, about 21.7, about 22.4, about 24.4, about 24.9, about 25.7, about 29.9, about 31.9, about 35.8, and about 38.9 degrees 2-theta. In some embodiments, Form XXV has an XRD pattern with characteristic peaks, essentially shown in Figure 76. In some embodiments, Form XXV exhibits a DSC thermogram having endotherm peaks at temperatures of about 113 ºC and 276 ºC. In some embodiments, Form XXV exhibits a DSC thermogram that has an endotherm peak at about 113 °C. In some embodiments, Form XXV exhibits DSC thermogram having an endotherm peak at about 276 °C. In some embodiments, the Form XXIV has a DSC thermogram essentially as shown in Figure 77. In some embodiments, Form XXV has at least one characteristic XRPD peak selected from about 16.6, about 18.4, about 20.4, about 22.4, about 24.4, about 24.9, and about 29.9 degrees 2-theta; and Form XXV exhibits a DSC thermogram having endotherm peaks at temperatures around 113 ºC and 276 °C. This document also provides methods for obtaining Form XXV of Compound 1 involving cyclization a saturated solution of Form I of Compound 1 in DMSO at a temperature of 5-50 °C for a period of time (e.g., at least three days or at least 72 hours). In some embodiments, Form XXV can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Compound 1 Form XXVI This document provides a solid form of Compound 1 having Form XXVI, which is described below in Examples. In some embodiments, Form XXVI has at least one characteristic XRPD peak selected from about 6.8, about 9.9, about 19.9, and about 26.1 degrees 2-theta. In some embodiments, Form XXVI has at least two characteristic XRPD peaks selected from about 6.8, about 9.9, about 19.9, and about 26.1 degrees 2-theta. In some embodiments, Form XXVI has at least three characteristic XRPD peaks selected from about 6.8, about 9.9, about 19.9, and about 26.1 degrees 2-theta. In some embodiments, Form XXVI has at least one characteristic XRPD peak selected from about 6.8, about 9.4, about 9.9, about 10.6, about 19.9, about 25.7, about 26.1 and about 27.4 degrees of 2-theta. In some embodiments, Form XXVI has at least two characteristic XRPD peaks selected from about 6.8, about 9.4, about 9.9, about 10.6, about 19.9, about 25.7, about 26.1 and about 27.4 degrees of 2-theta. In some embodiments, Form XXVI has at least three characteristic XRPD peaks selected from about 6.8, about 9.4, about 9.9, about 10.6, about 19.9, about 25.7, about 26.1 and about 27.4 degrees of 2-theta. In some embodiments, Form XXVI has an XRD pattern with characteristic peaks, essentially shown in Figure 78. This document also provides methods for obtaining Form XXVI of Compound 1, which include drying Form V of Compound 1 in vacuum at 50 °C for a period of time (e.g., 3 days). In some embodiments, Form XXVI can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments implementation Form I can be isolated with a purity of greater than about 99%. Method of obtaining Compound 1 This application further provides a method for preparing Compound 1, in which the process may be suitable for scaling. The process for preparing Compound 1 is described in U.S. Patent No. 9,611,267, which is incorporated herein by reference in its entirety. this document by reference. The present invention provides a method for preparing Compound 1 of the formula: NN H N About NN About About About F F Compound 1 or a salt thereof, comprising a) deprotecting Compound F8 having the formula: Compound F8 or a salt thereof, wherein P1 is an amino protecting group. In some embodiments, P1 is arylsulfonyl. In some embodiments, P1 is phenylsulfonyl or toluenesulfonyl. In some embodiments, the deprotection in step a) comprises reacting Compound F8 with a corresponding deprotection reagent. In some embodiments, deprotection includes treatment with a base. In some embodiments, In some embodiments, the base is sodium hydroxide or potassium hydroxide. In some embodiments, the base is sodium hydroxide or potassium hydroxide. the base is aqueous sodium hydroxide or aqueous potassium hydroxide. In some embodiments, the aqueous base is is a 1 M solution of the base. In some embodiments, deprotection is carried out in a suitable solvent at temperature of 70-90 ºC (e.g. 80 ºC). In some embodiments, the suitable solvent is 1,4- dioxane. In some embodiments, the base is present in ≥ 2, ≥ 3, or ≥ 4 molar equivalents relative to compounds of Formula II. In some embodiments, Compound 1 and Compound F8 are preferably in non-salt forms. In some embodiments, Compound F8 or a salt thereof is prepared by a method comprising b) reacting Compound F8 with F7, which has the formula: Compound F7 or its salts, where R1 represents Cl, Br or I, with a base. In some embodiments, Compound F7 and Compound F8 are preferably in non-salt forms. In some embodiments, the base in step b) is lithium hexamethyldisilazide ("LHMDS"), sodium hexamethyldisilazide ("NHMDS"), potassium hexamethyldisilazide ("KHMDS"), or lithium diisopropylamide ("LDA"). In some embodiments, the reaction of Compound F7 and base is carried out in THF at a temperature environment. In some embodiments, Compound F7 or a salt thereof is prepared by a method comprising c) reacting Compound F7 with F6, which has the formula: Compound F6 or its salts with ethyl isocyanate. In some embodiments, the method further comprises purifying Compound F7. In some embodiments, the method further comprises purifying Compound F7. purification involves mixing compound F7 with a first organic solvent at an elevated temperature with obtaining a first mixture; filtering the first mixture to obtain a first solid; mixing the first solid with water to obtain a second mixture; filtering the second mixture to obtain a second solid; and mixing the second solid with a second organic solvent. In some embodiments In one embodiment, the first organic solvent is acetonitrile and the second organic solvent is heptane. In some embodiments, the reaction in step c) is carried out in the presence of an acid. In some embodiments, the reaction in step c) is carried out in the presence of an acid. In one embodiment, the acid is methanesulfonic acid, toluenesulfonic acid, or HCl. In some embodiments, the reaction of Compound F6 with ethyl isocyanate is carried out in acetonitrile at ambient temperature. In some embodiments, Compound F6 or a salt thereof is prepared by a method comprising d) reacting Compound F6 with F4, which has the formula: Compound F4 or its salts with Compound F5 having the formula: NH2 F F About About Compound F5 or a salt thereof, in the presence of a Lewis acid and a reducing agent, where P1 represents an amino-protecting group, and R1 represents Cl, Br or I. In some embodiments, Compound F4 and Compound F5 are preferably in non-salt forms. In some embodiments, the Lewis acid in step d) is chlorotrimethylsilane. In some In embodiments, the reducing agent is a borane-THF complex (BH3-THF). In some embodiments, the reaction of Compound F4 and Compound F5 is carried out in DMF at room temperature. In some embodiments, Compound F4 or a salt thereof is prepared by a method comprising e) reacting Compound F4 with F3, which has the formula: Compound F3 or an acid salt thereof. In some embodiments, P1 is an amino protecting group. In some embodiments, implementations R1 is Cl, Br or I. In some embodiments, Compound F3 and Compound F4 are preferably in non-salt forms. In some embodiments, the acid in step e) is an aqueous acid. In some embodiments, the acid in step e) is an aqueous acid. the acid is HCl or sulfuric acid. In some embodiments, the acid is aqueous HCl or aqueous sulfuric acid. In some embodiments, the reaction of Compound F3 is carried out in dichloromethane at room temperature. In some embodiments, Compound F3 or a salt thereof is prepared by a method comprising f) reacting Compound F3 with F2, which has the formula: Compound F2 or its salts with N-formylmorpholine in the presence of a base to form a mixture; and contacting the mixture with morpholine and acid in the presence of a reducing agent. In some embodiments, Compound F2 and Compound F3 are in non-salt forms. In some embodiments, the base in step f) is lithium diisopropylamide or hexamethyldisilazide. lithium. In some embodiments, the reaction of Compound F2 with a base is carried out in THF at a reduced temperature. In in some embodiments, the temperature is ≤ -50 ºC, ≤ -60 ºC, or ≤ -70 ºC. In some embodiments, the reducing agent in step f) is sodium triacetoxyborohydride, sodium borohydride or sodium cyanoborohydride. In some embodiments, the acid in step f) is acetic acid acid. In some embodiments, the reaction in step f) is carried out at ambient temperature. environment. This invention provides a method for preparing Compound 1, comprising: a) contacting a compound of formula 2: NN Cl SO About About About Compound 2 with N-formylmorphline in the presence of base to form compound 2a, which has the formula: NN Cl CHO SO About About About Compound 2a; b) reaction of compound 2a with morpholine in the presence of an acid and a reducing agent to form compound 3, which has the formula: NN Cl N About SO About About About Compound 3; c) conversion of compound 3 into compound 4, which has the formula: NN Cl H About N About SO About Compound 4; d) the interaction of compound 4 with compound 5, which has the formula: NH2 F F About About Compound 5 in the presence of a Lewis acid and a reducing agent to form compound 6 of the formula: NN ClNH F F About About N About SO About Compound 6; e) reacting compound 6 with ethyl isocyanate to form compound 7, which has the formula: N F F About O.O. HN N Cl N S N About About About Compound 7; f) contacting compound 7 with a base to form compound 8 of the formula: NN NN About F F About About N About SO About Compound 8; g) contacting compound 8 with a base to obtain Form I of Compound 1. In some embodiments, the method further comprises recrystallizing Compound 1 in a solvent with obtaining Form I of Compound 1. In some embodiments, the solvent is a mixture of dichloromethane and methyl tert-butyl ether. In some embodiments, the base in step a) is lithium diisopropylamide. In some embodiments, the acid in step b) is acetic acid. In some embodiments, the acid in step b) is acetic acid. the reducing agent in step b) is sodium triacetoxyborohydride. In some embodiments, the acid in step b) is acetic acid and the reducing agent in step b) is triacetoxyborohydride sodium. In some embodiments, the transformation in step c) is carried out in the presence of aqueous hydrochloric acid. acids. In some embodiments, the Lewis acid in step d) is chlorotrimethylsilane. In some In some embodiments, the reducing agent is BH3-THF. In some embodiments, the Lewis acid is step d) is chlorotrimethylsilane, and the reducing agent in step d) is BH3-THF. In some embodiments, the reaction in step e) further comprises purifying Compound 7. In some embodiments, the base in step f) is lithium hexamethyldisilazide. In some embodiments, the base in step g) is NaOH. The present invention provides a method for preparing Compound 2, which has the formula: NN Cl SO About About About Compound 2 which includes: a) contacting 1H-pyrrolo[2,3-b]pyridine with an oxidizing agent to form 1H-pyrrolo[2,3- b]pyridine; b) the interaction of 1H-pyrrolo[2,3-b]pyridine 7-oxide with a chlorinating agent to form 4-chloro-1H-pyrrolo[2,3- b]pyridine; c) the interaction of 4-chloro-1H-pyrrolo[2,3-b]pyridine with triisopropylsilyl chloride in the presence of a base to form 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine; d) the interaction of 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine with N,N-dimethylformamide in the presence of bases to form 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde; e) the interaction of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde with benzenesulfonyl chloride in the presence of base to form 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde; and f) the interaction of 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo [2,3-b]pyridine-5-carbaldehyde with ethylene glycol in presence of acid with the formation of compound 2. In some embodiments, the oxidizing agent in step a) is m-chloroperoxybenzoic acid or hydrogen peroxide. In some embodiments, the reaction is carried out in a suitable solvent. In some embodiments In some embodiments, the reaction is carried out in dichloromethane. In some embodiments, the reaction is carried out at reduced temperature. In some embodiments, the reaction is carried out at a temperature between -5-15 °C or between 0-10 °C. In some embodiments, the chlorinating agent in step b) is methanesulfonyl chloride, thionyl chloride or N-chlorosuccinimide. In some embodiments, the reaction is carried out in a suitable solvent. In some In some embodiments, the reaction is carried out in DMF. In some embodiments, the reaction is carried out at elevated temperature. In some embodiments, the reaction is carried out at ≥ 70 ºC, ≥ 80 ºC, or ≥ 90 ºC. In some embodiments, the base in step c) is sodium hydride. In some embodiments, the base in step c) is sodium hydride. the reaction in step c) is carried out in a suitable solvent. In some embodiments, the reaction in step c) is carried out in THF. In some embodiments, the reaction in step c) is carried out at ambient temperature In some embodiments, the reaction in step c) is carried out at ≤ 30 °C or ≤ 25 °C. In some embodiments, the base in step d) is n-butyllithium, sec-butyllithium, or tert- butyllithium. In some embodiments, the reaction in step d) is carried out at a reduced temperature. In some In embodiments, the reaction in step d) is carried out at ≤ 30 °C, ≤ 20 °C, ≤ 10 °C or ≤ 5 °C. In some embodiments, the base in step e) is cesium carbonate. In some embodiments, the base in step e) is cesium carbonate. the reaction in step e) is carried out in a suitable solvent. In some embodiments, the reaction in step e) is carried out in dimethylformamide. In some embodiments, the reaction in step e) is carried out at a temperature ≤ 30 ºC, ≤ 20 ºC, ≤ 10 ºC, or ≤ 5 ºC. In some embodiments, the reaction in step e) is carried out at a suitable solvent in a temperature range, i.e. from 0 °C to ambient temperature. In some embodiments, the acid in step f) is p-toluenesulfonic acid or HCl. In some In some embodiments, step f) is carried out at an elevated temperature. In some embodiments, step f) carried out at reflux. The present invention provides a method for preparing Compound 4, which has the formula: NN Cl H About N About SO About Compound 4 which includes: a) contacting 2-amino-4-chloropyridine with a brominating agent to form 5-bromo-4-chloropyridine-2- amine; b) contacting 5-bromo-4-chloropyridin-2-amine with an iodinating agent to form 5-bromo-4-chloro-3- iodopyridine-2-amine; c) the interaction of 5-bromo-4-chloro-3-iodopyridin-2-amine with 4-(prop-2-ynyl)morpholine in the presence of a catalyst with formation of compound 9, which has the formula: N Cl NH2 Br N About Compound 9 a) the interaction of Compound 9 with a base to form Compound 10, which has the formula: NN H Cl BrN About Compound 10 b) the interaction of compound 10 with benzenesulfonyl chloride in the presence of a base to form compound 11, which has formula: NN Cl BrN About SO About Compound 11 c) contacting Compound 11 with an alkylmagnesium halide agent to form a mixture and adding to mixtures of N,N-dimethylformamide to obtain Compound 4. In some embodiments, the brominating agent in step a) is N-bromosuccinimide. In some embodiments, the brominating agent in step a) is N-bromosuccinimide. The contacting step a) is carried out in a suitable solvent. In some embodiments, the contacting step a) is carried out in a suitable solvent. the contacting in step a) is carried out in acetonitrile. In some embodiments, the contacting is carried out in in step a) is carried out at a reduced temperature. In some embodiments, the contacting in step a) is carried out at ≤ 20 °C or ≤ 15 °C. In some embodiments, the contacting in step a) is carried out at a temperature of 10-25 °C or 15-20 °C. In some embodiments, the iodination agent in step b) is iodine. In some embodiments, the iodination agent in step b) is iodine. the contacting in step b) is carried out in the presence of one or more acids. In some embodiments The contacting in step b) is carried out in the presence of sulfuric acid and iodic acid. In some In some embodiments, the contacting in step b) is carried out at an elevated temperature. In some embodiments, The contacting in step b) is carried out at a temperature of 75-85 °C or 77-83 °C. In some embodiments, the catalyst in step c) is a transition metal catalyst. In some embodiments, the catalyst in step c) comprises a combination of CuI and Pd(PPh3)4. In some embodiments, In some embodiments, the reaction in step c) is carried out in a suitable solvent. In some embodiments, the reaction in stage c) is carried out in toluene. In some embodiments, the reaction in stage c) is carried out at elevated temperature. In some embodiments, the reaction in step c is carried out at ≥ 40 ºC, ≥ 50 ºC, or ≥ 60 ºC. In some embodiments, the base in step d) is KOtBu. In some embodiments, the reaction in step d) is carried out in a suitable solvent. In some embodiments, the reaction in step d) is carried out in THF. In certain embodiments, the reaction in step d) is carried out at an elevated temperature. In some embodiments In the implementation, the reaction in step d) is carried out at a temperature of 25-40 °C or 30-35 °C. In some embodiments, the base in step e) is NaH. In some embodiments, the reaction is carried out in step e) is carried out in a suitable solvent. In some embodiments, the reaction in step e) is carried out in THF. In some embodiments, the reaction in step e) is carried out at a temperature between -5-10 °C or 0-5 °C. In some embodiments, the alkylmagnesium halide in step e) is isopropylmagnesium chloride. In some In some embodiments, the contacting in step f) is carried out in a suitable solvent. In some embodiments, The contacting step f) is carried out in THF. In some embodiments, the contacting step in stage f) is carried out at a temperature between -15-5 ºC or -10-0 ºC. The present invention provides a method for preparing Compound 5, which has the formula: F H2N F OMe OMe Compound 5 which includes: a) contacting pentafluorobenzoic acid with an alkyl alcohol in the presence of thionyl chloride with formation of methyl pentafluorobenzoate; b) the interaction of pentafluorobenzoate with benzylamine in the presence of a base to form methyl-4-(benzylamino)- 2,3,5,6-tetrafluorobenzoate; c) contacting methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate with sodium methoxide to form mixture and adding water to the mixture to form 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid; d) heating 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid to form N-benzyl-2,6- difluoro-3,5-dimethoxyaniline; and e) the interaction of N-benzyl-2,6-difluoro-3,5-dimethoxyaniline with ammonium formate in the presence of palladium on carbon with the formation of compound 5. In some embodiments, the alkyl alcohol in step a) is methanol. In some embodiments, the alkyl alcohol in step a) is methanol. the contacting in step a) is carried out at an elevated temperature. In some embodiments, the the contacting in step a) is carried out at reflux. In some embodiments, the base in step b) is a tertiary amine. In some embodiments, the base in step b) is a tertiary amine. the base in step b) is N,N-diisopropylethylamine. In some embodiments, the reaction in step b) is carried out in a suitable solvent. In some embodiments, the reaction in step b) is carried out in N- methylpyrrolidinone. In some embodiments, the reaction in step b) is carried out at an elevated temperature. In In some embodiments, the reaction in step b) is carried out at ≥ 55 ºC, ≥ 60 ºC, ≥ 65 ºC or ≥ 70 ºC. In some embodiments, the contacting in step c) is carried out in a suitable solvent. In In some embodiments, the contacting in step c) is carried out in methanol. In some embodiments, the contacting in step c) is carried out in methanol. the contacting in step c) is carried out at an elevated temperature. In some embodiments the contacting in step c) is carried out at a temperature of 60 to 75 °C or 76-70 °C. In some embodiments, the heating in step d) is carried out at a temperature of 65-95 °C, 70-90 °C or 75- 85 °C. In some embodiments, the heating in step d) is performed neat. In some embodiments the heating in step d) is carried out without solvent. In some embodiments, the reaction in step e) is carried out in a suitable solvent. In some embodiments, In some embodiments, the reaction in step e) is carried out in a mixture of ethanol and acetic acid. In some embodiments, the reaction in step e) is carried out in a mixture of ethanol and acetic acid, 6:1. In some embodiments, the reaction in step e) is carried out at an elevated temperature. In some embodiments, the reaction in step e) is carried out at ≥ 40 ºC, ≥ 50 ºC or ≥ 60 ºC. The processes described herein can be observed by any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear radiation spectroscopy magnetic resonance (e.g. 1H or 13C), infrared spectroscopy, spectrophotometry (e.g. UV- visible region), mass spectrometry or chromatographic methods such as high-performance liquid chromatography (HPLC) or thin layer chromatography. Compounds obtained through the reactions can be purified by any by a suitable method known in the art. For example, chromatography (medium pressure) on a suitable adsorbents (e.g. silica gel, alumina, etc.), HPLC or preparative thin layer chromatography; distillation; sublimation, trituration or recrystallization. The purity of compounds is usually determined by physical methods such as measuring the melting point (in the case of a solid), obtaining an NMR spectrum, or perform separation by HPLC. If the melting point decreases, if unwanted signals in in the NMR spectrum are reduced or if extraneous peaks in the HPLC curve are removed, the compound can be said to be purified. In some embodiments, the compounds are substantially purified. The preparation of compounds may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, as well as the selection of suitable protecting groups, can be readily determined by one skilled in the art. This field of technology. The chemical composition of protecting groups can be found, for example, in Wuts and Greene, Greene's Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons: New York, 2006, which is incorporated in its entirety into this document by reference. As used herein, the term "amino protecting group" refers to any protecting group for amine protection. Examples of amino protecting groups include, but are not limited to, phenylsulfonyl, benzyloxycarbonyl (Cbz), 2,2,2-trichloroethoxycarbonyl (Troc), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(4- trifluoromethylphenylsulfonyl)ethoxycarbonyl (Tsc), tert-butoxycarbonyl (BOC), 1-adamantyloxycarbonyl (Adoc), 2-adamantylcarbonyl (2-Adoc), 2,4-dimethylpent-3-yloxycarbonyl (Doc), cyclohexyloxycarbonyl (Hoc), 1,1-dimethyl-2,2,2-trichloroethoxycarbonyl (TcBOC), vinyl, 2-chloroethyl, 2-phenylsulfonylethyl, allyl, benzyl, 2- nitrobenzyl, 4-nitrobenzyl, diphenyl-4-pyridylmethyl, N',N'-dimethylhydrazinyl, methoxymethyl, tert-butoxymethyl (Bum), benzyloxymethyl (BOM) or 2-tetrahydropyranyl (THP), tri(C1-4 alkyl)silyl (e.g., tri(isopropyl)silyl), 1,1-diethoxymethyl or N-pivaloyloxymethyl (POM). The reactions of the methods described herein can be carried out at appropriate temperatures, which can be easily The reaction temperature will depend, for example, on melting and boiling points of the reactants and solvent, if present; thermodynamics of the reaction (for example, it may require highly exothermic reactions at low temperatures); and reaction kinetics (e.g., elevated temperatures may be required to create a barrier with a high activation energy). In some embodiments of the invention, concentrating a solution as described herein refers to a solution whose volume is reduced by evaporation of the solvent, heating the solution, exposure to a solution reduced pressure or any combination thereof. In this context, the phrase "transition metal catalyst" refers to a metal catalyst in which in which the metal is an element of group VIII in the periodic table (for example, palladium or nickel catalyst) suitable for catalyzing a carbon-carbon coupling reaction. Examples of catalysts based on transition metal include, but are not limited to, PdCl2(PPh3)2, Pd(PPh3)4, dichloro(bis{di-tert-butyl[4- (dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), NiCl2(dppf), and NiCl2(dppp), where (dppf) refers to 1,1'- bis(diphenylphosphino)ferrocene, and (dppp) refers to 1,3-bis(diphenylphosphino)propane. Examples of palladium catalysts include, but are not limited to, PdCl2(PPh3)2, Pd(PPh3)4, dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), palladium on carbon, PdCl2, Pd(OAc)2, PdCl2(MeCN)2 tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 4-(di-tert-butylphosphino)-N,N- dimethylaniline-dichloropalladium (2:1), Pd(dppf)Cl2 (e.g., Pd(dppf)Cl2-CH2Cl2), and tetrakis(tri(o- tolyl)phosphine)palladium(0). In some embodiments of the invention, an antisolvent as described herein refers to solvent in which Compound 1 is less soluble compared to another solvent or mixture of solvents in solution. For example, the antisolvent may include, but is not limited to, benzene, cyclohexane, pentane, hexane, heptane (e.g. n-heptane), toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o- or p- xylene, octane, indane, nonane or naphthalene. The reactions of the methods described herein can be carried out in suitable solvents which can be readily selected. by a qualified specialist in the field of organic synthesis. Suitable solvents can be largely non-reactive towards starting materials (reagents), intermediates or products when temperatures at which reactions are carried out, for example, temperatures which may range from the freezing point of the solvent to the boiling point of the solvent. This reaction can be carried out in in a single solvent or in a mixture of more than one solvent. Depending on the specific stage of the reaction, there may be suitable solvents are selected for a particular reaction step. In some embodiments of the invention, the reactions can be be carried out in the absence of a solvent, for example, when at least one of the reactants is a liquid or a gas. Suitable solvents may include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane (methylene chloride), tetrachlorethylene, trichloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1- dichloroethane, 2-chloropropane, α,α,α-trifluorotoluene, 1,2-dichloroethane, 1,2-dibromoethane, hexafluorobenzene, 1,2,4- trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, their mixtures, etc. Suitable ethereal solvents include: dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, tetrahydrofuran (THF), diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, Diethylene glycol dimethyl ether (diglyme), diethylene glycol diethyl ether, dimethyl ether triethylene glycol, anisole, tert-butyl methyl ether, mixtures thereof, etc. Suitable protic solvents may include, by way of example and without limitation, water, methanol, ethanol, 2- nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1- butanol, 2-butanol, isobutyl alcohol, tert-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2- or 3- pentanol, neopentyl alcohol, tert-pentyl alcohol, diethylene glycol monomethyl ether, monoethyl diethylene glycol ether, cyclohexanol, benzyl alcohol, phenol or glycerin. Suitable aprotic solvents may include, by way of example and without limitation, N,N-dimethylformamide. (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2- imidazolidinone (DMI), N-methylpyrrolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethyl sulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene or hexamethylphosphoramide. Suitable hydrocarbon solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o- or p-xylene, octane, indane, nonane or naphthalene. The reactions described here can be carried out in air or in an inert atmosphere. Typically, reactions that containing reagents or products that essentially react with air can be carried out using sensitive to air synthesis methods that are well known to a person skilled in the art. The expressions "ambient temperature" and "room temperature" as they are used here, are understood in the art and usually refer to temperature, e.g., reaction temperature, which is approximately equals the temperature of the room in which the reaction is carried out, for example, from about 20 ºC to about 30 ºC. The term "elevated temperature" as used herein is understood in the art and generally refers to a temperature, e.g., a reaction temperature, which is above room temperature, e.g., above 30 °C. Compounds This document proposes a compound of Formula F1: F1 where: P1 represents an amino-protecting group; R1 represents Cl, Br or I; R2 and R3, each independently, are C1-6 alkoxy; or R2 and R3, taken together with the carbon atom to which they are attached, form 1,3-dioxolan-2-yl or 1,3-dioxane- 2-il; or R2 and R3 together form oxo. In some embodiments, the compound of Formula F1 has the formula F3: F3. In some embodiments, the compound of Formula F1 has the formula F4: F4. In some embodiments, a compound having Formula F6 is provided herein: F6. where: P1 represents an amino-protecting group; R1 represents Cl, Br or I. In some embodiments, the compound having Formula F6 is Compound 6: NN ClNH F F About About N About SO About Compound 6. This document proposes a compound of Formula F7: F7 where: P1 represents an amino-protecting group; R1 represents Cl, Br or I. In some embodiments, the compound having formula F7 is Compound 7: N F F About O.O. HN N Cl N S N About About About Compound 7. In some embodiments, the present document provides a compound of Formula F8: F8 where P1 represents an amino protecting group; In some embodiments, the compound of Formula F8 is Compound 8: NN NN About F F About About N About SO About Compound 8. In some embodiments, the present document provides a compound of Formula F9: N R2 NH2 R5 N About F9 where R2 and R5 each independently represent Br, Cl or I. In some embodiments, the compound of Formula F9 is compound 9: N Cl NH2 Br N About Compound 9. In some embodiments, the present document provides a compound of Formula F10: F10 where R1 and R4 each independently represent Br, Cl or I; and R6 represents H or benzenesulfonyl. In some embodiments, the compound having Formula F10 is Compound 10: NN H Cl BrN About Compound 10 In some embodiments, the compound having Formula F10 is Compound 11: NN Cl BrN About SO About Compound 11. Methods of application Compound 1 or its solid forms described herein can inhibit the activity of the FGFR enzyme. For example, Compound 1 can be used to inhibit the activity of the FGFR enzyme in a cell or in an individual or patient in need of enzyme inhibition by administering an inhibitory amount of Compound 1 to cell, individual or patient. As FGFR inhibitors, Compound 1 is useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR enzyme or FGFR ligands. Compounds that inhibit FGFR will be useful for providing a means of preventing growth or inducing apoptosis in tumors, in particular by inhibiting angiogenesis. Therefore, Compound 1 is expected to be useful for the treatment or prevention of proliferative disorders such as cancer. In particular, tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to inhibitors. In some embodiments, the disclosure provides a method of treating an FGFR-mediated disorder in a patient, which requires this, comprising the step of administering to said patient Compound 1 or its pharmaceutically acceptable acceptable composition. For example, Compound 1 or solid forms thereof are useful in the treatment of cancer. Examples of Cancers include bladder cancer, breast cancer (e.g., hormone R-positive, triple negative), cancer cervical cancer, colorectal cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, stomach cancer (e.g., gastrointestinal stromal tumors), head and neck cancer (e.g. cancer of the larynx, hypopharynx, nasopharynx, oropharynx, lip and mouth, squamous cell carcinoma of the head and neck), kidney cancer (e.g., renal cell carcinoma, urothelial carcinoma, sarcoma, Williams tumor), cancer liver (e.g. hepatocellular carcinoma, cholangiocellular carcinoma, hepatic angiosarcoma, hepatoblastoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer, or non-small cell lung carcinomas, paired and unpaired cell carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, cancer gallbladder, pancreatic cancer (e.g., exocrine pancreatic carcinoma), cancer stomach cancer, thyroid cancer, parathyroid cancer, neuroendocrine cancer (e.g., pheochromocytoma, Merkel cell carcinoma, neuroendocrine carcinoma), skin cancer (e.g. squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer) and brain cancer (e.g. astrocytoma, medulloblastoma, ependymoma, neuroectodermal tumors, pineal tumors). Additional examples of cancers include hematopoietic malignancies, such as: leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B- cell lymphoma, cutaneous T-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma myeloplastic lymphoma, myeloproliferative neoplasms (e.g., 8p11 myeloproliferative syndrome, polycythemia vera, essential thrombocythemia, and primary myelofibrosis), myelodysplastic syndrome, chronic eosinophilic leukemia, Waldenström macroglobulinemia, hairy cell lymphoma, chronic myelogenous lymphoma, acute lymphoblastic lymphoma, AIDS-associated lymphomas, and Burkitt's lymphoma. In some embodiments, this document provides a method of treating myeloid / lymphoid neoplasms in a patient in need thereof. In some embodiments, myeloid / lymphoid neoplasms represent myeloproliferative syndrome 8p11. The term "myeloproliferative syndrome" as used herein 8p11 syndrome (EMS) is intended to refer to myeloid / lymphoid neoplasms associated with eosinophilia and FGFR1 abnormalities or myeloid / lymphoid neoplasms (MLN) with rearrangement FGFR1. Myeloproliferative syndrome 8p11 is reviewed in Jackson, Courtney C., et.al. Human Pathology, 2010, 41, 461-476. The defining feature of EMS is the presence of a translocation involving the FGFR1 gene, located in locus of chromosome 8p11, and at least 10 additional translocations and 1 insertion have been identified in EMS, each with which disrupts FGFR1 and creates new fusion genes with different partners. See Jackson, Courtney C., et.al. Human Pathology, 2010, 41, 461-476. In some embodiments, the myeloid / lymphoid neoplasm is characterized by a genetic alteration FGF / FGFR. In some embodiments, the myeloid / lymphoid neoplasm exhibits a FGFR1 fusion. Fusion FGFR1 may be a translocation, interstitial deletion, or chromosomal inversion. In some embodiments In some embodiments, the FGFR1 fusion is a FGFR1 translocation. In some embodiments, the myeloid / lymphoid the neoplasm exhibits an 8p11 translocation. In some embodiments, the 8p11 translocation is associated with activation of FGFR1. In some embodiments, the myeloid / lymphoid neoplasm exhibits FGF / FGFR alterations, other than FGFR1 translocations. In some embodiments, the patient has failed at least one previous treatment for myeloid / lymphoid neoplasms (e.g., 8p11 myeloproliferative syndrome). In In some embodiments, the prior treatment is surgery or radiation therapy. In In some embodiments, the patient has a history of hepatitis. In some embodiments, the hepatitis is chronic hepatitis B or hepatitis C. In some embodiments of the invention, the patient does not have hepatitis in anamnesis. In certain embodiments, this document provides a method of treating cancer comprising administering to a patient in need thereof, a therapeutically effective amount of Compound 1 or a solid form thereof. In some in embodiments the cancer is selected from bladder cancer, breast cancer, cervical cancer, small bowel cancer, colorectal cancer, endometrial cancer, stomach cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma, Waldenström macroglobulinemia, myeloproliferative neoplasm, chronic myelogenous lymphoma, acute lymphoblastic lymphoma, T lymphoblastic lymphoma, hairy cell lymphoma, Burkitt lymphoma, glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma and osteosarcoma. In some embodiments, the cancer is bladder cancer (e.g., urothelial carcinoma, squamous cell carcinoma, adenocarcinoma). In some embodiments, the liver cancer is cholangiocellular carcinoma (e.g., intrahepatic, hilar or perihilar, distal extrahepatic). In the context of this description Cholangiocarcinoma is similar to cholangiocarcinoma or bile duct cancer. In some embodiments The cholangiocarcinoma is an advanced or metastatic cholangiocarcinoma. In some embodiments, cholangiocarcinoma is inoperable. In some embodiments, the cholangiocarcinoma is intrahepatic. In In some embodiments, the cholangiocarcinoma is extrahepatic. In some embodiments, the cholangiocarcinoma is extrahepatic. Cholangiocarcinoma exhibits FGFR2 tyrosine kinase fusions that define a specific molecular subtype, such as described in Arai, Yasuhito, et. al. Hepatology, 2014, 59, 1427-1434. In some embodiments, cholangiocarcinoma is characterized by tumors genetically altered by FGF / FGFR. In some embodiments, the tumors exhibit FGFR2 fusions. FGFR2 fusions can be translocations, interstitial deletions, or chromosomal inversion. In some embodiments, the FGFR2 fusion is a FGFR2 translocation. FGFR2 translocations may be selected from the group including, but not limited to, FGFR2-BICC1, FGFR2- AHCYL1, FGFR2-MACF1, FGFR2 intron 17 rearrangement. In some embodiments, the tumor exhibits alterations FGF / FGFR other than FGFR2 translocations. In some embodiments, cholangiocarcinoma does not exhibit tumors genetically altered by FGF / FGFR. Other types of cancer that can be treated with Compound 1 or its solid forms include eye tumors, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, leiomyosarcoma, urothelial carcinoma (e.g., ureter, urethra, bladder, urethra) and osteosarcoma. Compound 1 or its solid forms may also be useful for inhibiting tumor metastasis. In some embodiments, compound 1 or its solid forms as described herein can be be used to treat Alzheimer's disease, HIV or tuberculosis. In addition to oncogenic neoplasms, the compounds of this invention may be useful in the treatment of diseases skeletal and chondrocyte disorders, including, but not limited to, achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beer-Stevenson spiral cutis syndrome, Pfeiffer syndrome and craniosynostosis syndromes. The compounds presented herein may be additionally useful in the treatment of fibrotic diseases, such as symptoms or disorders, that are characterized by fibrosis. Examples of fibrotic diseases include cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing. In some embodiments, the compounds presented herein can be used for treatment of hypophosphatemic disorders, such as X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets and autosomal dominant hypophosphatemic rickets or tumor-induced osteomalacia. In some embodiments, this document provides a method for increasing survival or survival without progression of a disease in a patient, comprising administering to the patient a compound provided herein document. In some embodiments, the patient has cancer. In some embodiments, the patient has the described herein disease or disorder. In some embodiments, the patient has cholangiocarcinoma. In some embodiments implementation, this document provides a method for increasing survival or progression-free survival in a patient who has cholangiocarcinoma, wherein the cholangiocarcinoma is characterized by an FGFR2 fusion that comprises administering to a patient a compound as disclosed herein. In this context, disease-free survival progression refers to the length of time during and after treatment for a solid tumor during which a patient living with this disease, but their condition is not getting worse. Progression-free survival may refer to the duration of time from the first administration of the compound to the onset of death or disease progression. Disease progression can be determined using RECIST v. 1.1 (Response Evaluation Criteria in solid tumors) that are evaluated by an independent central radiological review committee. In some In embodiments, administration of the compound results in progression-free survival, which exceeds about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, about 12 months, about 16 months or about 24 months. In In some embodiments, administration of the compound results in progression-free survival, which is at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, or about 12 months; and less than about 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months, or about 2 months. In some embodiments, the administration of the compound leads to an increase in progression-free survival of at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months or about 12 months; and less than about 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months or about 2 months. The term "cell" as used herein is intended to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, the ex vivo cell may be part of a tissue sample excised from organism, such as a mammal. In some embodiments, the in vitro cell may be a cell in cell culture. In In some embodiments, an in vivo cell is a cell that lives in an organism, such as a mammal. The term "contacting" used here refers to the union of said fragments in a system in vitro or in vivo system For example, "contacting" the FGFR enzyme with a compound described herein (e.g., Compound 1) comprises administering a compound described herein to an individual or patient, such as a human having FGFR, and also, for example, administering a compound described herein (e.g., Compounds 1), into a sample containing a cell or purified preparation containing the FGFR enzyme. The terms "individual" or "patient" used interchangeably herein refer to any animal, in particular mammals, mainly mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses or primates, and most preferably humans. In the context of this description, the phrase "therapeutically effective amount" refers to the amount of active compound or of a pharmaceutical agent, such as an amount of any of its solid forms or salts disclosed herein, that induces a biological or medicinal response in a tissue, system, animal, patient, or person in need researcher, veterinarian, physician or other clinician. The appropriate “effective” amount in any individual case can be determined using methods known to a person skilled in the art. The phrase "pharmaceutically acceptable" is used herein to refer to those compounds that materials, compositions and / or dosage forms that, within the framework of rational medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, immunogenicity or other problem or complication proportionate to a reasonable benefit / risk ratio. The phrase "pharmaceutically acceptable carrier or excipient" in the context of this document means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid excipient, diluent or encapsulating material. Fillers or carriers are generally safe, non-toxic, and not biologically undesirable. or other point of view and include excipients or carriers that are acceptable for veterinary use, as well as for use in pharmaceuticals. In one embodiment, each component is "pharmaceutically acceptable," as defined here. See, for example, Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009. As used herein, the term "treatment" or "therapy" refers to the suppression of disease; for example, inhibition of a disease, condition or disorder in a patient experiencing or exhibiting pathology or symptomatology of a disease, condition or disorder (i.e., stopping further development of the pathology and / or symptomatology); or alleviation of disease; for example, alleviation of a disease, condition, or disorder in a patient who experiences or exhibits pathology or symptoms of a disease, condition, or disorder (i.e., change in pathology and / or symptomatology), such as a decrease in disease severity. It is understood that certain features of the invention, which for clarity are described in the context of individual embodiments, also may be provided in combination in a single embodiment (whereas embodiments are intended to be combined, as if they were written in plural dependent form). On the contrary, the various features of the invention, which for brevity are described in in the context of one embodiment, may also be provided separately or in any suitable subcombination. Combination therapy One or more additional pharmaceutical agents or treatments, such as antivirals agents, chemotherapeutic or other anticancer agents, immune system enhancers, immunosuppressants, radiation, antitumor and antiviral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and / or inhibitors tyrosine kinases can be used in combination with Compound 1 for the treatment of FGFR-related diseases, disorders or conditions or diseases or conditions as described herein. The agents can be combined with these compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms. Compound 1 or its solid forms as described herein can be used in combination with one or several other kinase inhibitors to treat diseases, such as cancer, that are affected by multiple signaling pathways. For example, the combination may include one or more inhibitors of the following kinases for cancer treatment: Akt1, Akt2, Akt3, TGF-R, Pim, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFR, PDGFR, CSFIR, KIT, FLK-II, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In addition, The solid forms of the FGFR inhibitor described herein can be combined with inhibitors of signaling-related kinases. through the PIK3 / Akt / mTOR pathway, such as PI3K, Akt (including Akt1, Akt2, and Akt3), and mTOR kinases. In some embodiments, Compound 1 or its solid forms as described herein can be be used in combination with one or more enzyme or protein receptor inhibitors, such as HPK1, SBLB, TUT4, A2A / A2B, CD47, CDK2, STING, ALK2, LIN28, ADAR1, MAT2a, RIOK1, HDAC8, WDR5, SMARCA2 and DCLK1 for the treatment of diseases and disorders. Examples of diseases and disorders include cancer, infection, inflammation and neurodegenerative disorders. In some embodiments, Compound 1 or its solid forms as described herein can be used in combination with a therapeutic agent targeting an epigenetic regulator. Examples epigenetic regulators include bromodomain inhibitors, histone lysine methyltransferases, histone arginine methyltransferases, histone demethylases, histone deacetylases, histone acetylases and DNA- methyltransferases. Histone deacetylase inhibitors include, for example, vorinostat. For the treatment of cancer and other proliferative diseases Compound 1 or its solid forms as described in this document, can be used in combination with targeted therapies, including kinase inhibitors JAK (Ruxolitinib, additional JAK1 / 2 and JAK1-selective, baricitinib or INCB39110), Pim kinase inhibitors (e.g. INCB53914), PI3 kinase inhibitors, including selective PI3K-delta and broad-spectrum PI3K inhibitors spectrum of action (e.g. INCB50465 and INCB54707), PI3K-gamma inhibitors, such as selective PI3K-gamma inhibitors, MEK inhibitors, CSF1R inhibitors, TAM receptor tyrosine kinase inhibitors (Tyro-3, Axl and Mer; e.g., INCB81776), angiogenesis inhibitors, interleukin receptor inhibitors, cyclin-dependent kinase inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (Bortezomib, Carfilzomib), HDAC inhibitors (panobinostat, vorinostat), DNA methyltransferase inhibitors, dexamethasone, bromo and extraterminal family member inhibitors (e.g. bromodomain inhibitors or BET inhibitors such as INCB54329 or INCB57643), LSD1 inhibitors (e.g. INCB59872 or INCB60003), arginase inhibitors (e.g. INCB1158), indoleamine-2,3- dioxygenase inhibitors (e.g. epacadostat, NLG919 or BMS-986205) and PARP inhibitors (e.g. olaparib or rucaparib). For the treatment of cancer and other proliferative diseases Compound 1 or its solid forms as described in herein, can be used in combination with chemotherapeutic agents, agonists or nuclear receptor antagonists or other antiproliferative agents. Compound 1 or its solid forms can also be used in combination with medical therapy, such as surgery or radiation therapy, for example, gamma radiation, neutron beam therapy, electron beam therapy, proton therapy, brachytherapy and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of the following: which of the following: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, baricitinib, bendamustine, bevacizumab, bexarotene, bleomycin, bortezomib, intravenous busulfan, oral busulfan, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alpha 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxalen, mitomycin C, mitotane, mitoxantrone, nandrolone fenpropionate, nelarabine, niraparib, nofetumomab, olaparib, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, acriquine, rasburicase, rituximab, rucaparib, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, veliparib, talazoparib and zoledronate. In some embodiments, Compound 1 or its solid forms as described herein can be used in combination with immune checkpoint inhibitors. Typical immune checkpoint inhibitors checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3 (eg INCAGN2385), TIM3 (eg INCB2390), VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a molecule a stimulatory checkpoint selected from CD27, CD28, CD40, ICOS, OX40 (e.g., INCAGN1949), GITR (e.g., INCAGN1876) and CD137. In some embodiments, the immune checkpoint molecule is is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD- 1, TIM3 and VISTA. In some embodiments, the compounds provided herein can be used in combinations with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR inhibitors. In some embodiments, the immune checkpoint molecule inhibitor is an anti-PD1 antibody, anti-PD-L1 antibody or anti-CTLA-4 antibody. In some embodiments, the immune checkpoint molecule inhibitor is a low molecular weight PD-L1 inhibitor. In some embodiments, the small molecule PD-L1 inhibitor has an IC50 of less than 1 μM, less than 100 nM, less than 10 nM, or less than 1 nM in the PD-L1 assay described in U.S. Patent Publication Nos. US 20170107216, US 20170145025, US 20170174671, US 20170174679, US 20170320875, US 20170342060, US 20170362253 and US 20180016260, each of which is incorporated by reference in its entirety for all purposes. In some embodiments, the immune checkpoint molecule inhibitor is a PD-1 inhibitor, for example, a monoclonal antibody against PD-1. In some embodiments, the monoclonal antibody against PD- 1 represents MGA012, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is nivolumab. In In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. the monoclonal antibody against PD-1 is MGA012. In some embodiments, the antibody against PD1 is SHR-1210. Other anticancer agents include therapeutic antibodies such as 4-1BB (e.g., urelumab, utomilumab. In some embodiments, the immune checkpoint molecule inhibitor is a PD-L1 inhibitor, for example, a monoclonal antibody against PD-L1. In some embodiments, the monoclonal antibody against PD-L1 is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446) or MSB0010718C. In some In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736. In embodiments, the PD-L1 inhibitor is INCB086550. In some embodiments, the immune checkpoint molecule inhibitor is a CTLA-4 inhibitor, for example, an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab. In some embodiments, the immune checkpoint molecule inhibitor is a LAG3 inhibitor, for example, an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the immune checkpoint molecule inhibitor is a GITR inhibitor, for example, an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK- 4166. In some embodiments, the immune checkpoint molecule inhibitor is an OX40 inhibitor, for example, an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562. In some embodiments, the OX40L fusion protein is MEDI6383. In some embodiments, salts of Compound 1 as described herein can be used in combinations with one or more agents for the treatment of diseases such as cancer. In some embodiments In one embodiment, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). Suitable antiviral agents for use in combination with Compound 1 may include: nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs. Examples of suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH- 10652; emtricitabine [(-)-FTC]; beta-L-FD4 (also known as beta-L-D4C and beta-L-2',3'-dicleoxy-5- fluorocytidine); DAPD, ((-)-beta-D-2,6,-diaminopyridioxolane) and lodenasin (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delavirdine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione) and (+)-calanolide A (NSC- 675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfinavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378 and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Yissum Project No. 11607. Suitable agents for use in combination with Compound 1 for the treatment of cancer include: chemotherapeutic agents, targeted cancer therapies, immunotherapy or radiotherapy. Compound 1 may be effective in combination with antihormonal agents for the treatment of breast cancer and other tumors. Suitable examples are antiestrogenic agents, including, but not limited to, tamoxifen and toremifene, aromatase inhibitors including, but not limited to, letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g., prednisone), progestins (e.g., megestrol acetate), and antagonists estrogen receptor antagonists (e.g. fulvestrant). Suitable antihormonal agents used for treatment of prostate cancer and other cancers, can also be combined with Compound 1. These include antiandrogens, including but not limited to flutamide, bicalutamide, and nilutamide, hormone analogs, luteinizing hormone-releasing hormone (LHRH), including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g., degarelix), androgen receptor blockers (e.g., enzalutamide), and agents that inhibit androgen production (e.g., abiraterone). Compound 1 can be combined with other agents against membrane receptor kinases or sequentially with them, especially for patients who have developed primary or acquired resistance to targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR c-Met, RET, IGFR1 or Flt-3 and against cancer-associated fusion protein kinases, such as Bcr-Abl and EML4-Alk. EGFR inhibitors include gefitinib and erlotinib, and EGFR / Her2 inhibitors include, but are not limited to, dacomitinib, afatinib, lapatinib, and neratinib. Anti-EGFR antibodies include, but are not limited to, cetuximab, panitumumab, and necitumumab. c-Met inhibitors can be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib and INC-280. Anti-Abl (or Bcr-Abl) agents include imatinib, dasatinib, nilotinib and ponatinib, and anti-Abl agents include Anti-Alk (or EML4-ALK) drugs include crizotinib. Angiogenesis inhibitors may be effective in some tumors in combination with FGFR inhibitors. These include include antibodies against VEGF or VEGFR or inhibitors of VEGFR kinases. Antibodies or other therapeutic proteins Anti-VEGF agents include bevacizumab and aflibercept. VEGFR kinase inhibitors and other anti-angiogenesis inhibitors include, but are not limited to, sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib and vandetanib. Activation of intracellular signaling pathways is common in cancer, and agents targeting components of these pathways are combined with receptor-targeted agents to enhance efficacy and reducing resistance. Examples of agents that can be combined with Compound 1 include inhibitors of the PI3K-AKT pathway. mTOR, Raf-MAPK pathway inhibitors, JAK-STAT pathway inhibitors, and protein chaperone and progression inhibitors cell cycle. Anti-PI3 kinase agents include, but are not limited to, topiramate, idealalisib, buparlisib. mTOR inhibitors, such as rapamycin, sirolimus, temsirolimus, and everolimus, can be combined with FGFR inhibitors. Other suitable examples include, but are not limited to, vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib, and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g. tanespimycin), cyclin-dependent kinases (e.g. palbociclib), HDAC (e.g. panobinostat), PARP (e.g. olaparib) and proteasomes (e.g. bortezomib, carfilzomib) can also be combined with Compound 1. In some embodiments, the JAK inhibitor is selective regarding JAK1 compared to JAK2 and JAK3. Other suitable agents for use in combination with Compound 1 include combinations of chemotherapeutic agents. agents, such as platinum-based doublets, which are used to treat lung cancer and other solid tumors tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed), or gemcitabine plus particles associated with paclitaxel (Abraxane®). Suitable chemotherapeutic or other anticancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas and triazenes), such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine and temozolomide. Other suitable agents for use in combination with Compound 1 include: dacarbazine (DTIC), optionally, together with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; "regimen Dartmouth, consisting of DTIC, BCNU, cisplatin, and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compound 1 can also be combined with immunotherapeutic agents, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF). Suitable chemotherapeutic or other anticancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogues, purine analogues and inhibitors adenosine deaminases), such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin and gemcitabine. Suitable chemotherapeutic or other anticancer agents further include, for example, certain natural products and their derivatives (e.g., periwinkle alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins), such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide and teniposide. Other cytotoxic agents include navelbine, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine. Cytotoxic agents such as epidophyllotoxin; antitumor enzyme; inhibitor are also suitable. topoisomerases; procarbazine; mitoxantrone; platinum coordination complexes such as cisplatin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur and hematopoietic growth factors. Other anticancer agents include therapeutic antibodies such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4-1BB, antibodies to PD-1 and PD-L1 or antibodies to cytokines (IL-10, TGF- etc). Other anticancer agents also include those that block immune cell migration, such as antagonists chemokine receptors, including CCR2 and CCR4. Other anticancer agents also include those that strengthen the immune system, such as adjuvants or adoptive T-cell transfer. Cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses. Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. areas. In addition, their application is described in the standard literature. For example, the introduction of many chemotherapeutic agents are described in the Physicians' Desk Reference (PDR, eg, 1996 edition, Medical Economics Company, Montvale, NJ), the description of which is incorporated herein by reference as if set forth in its entirety. completeness. Pharmaceutical compositions and dosage forms When used as pharmaceuticals, Compound 1 of the present invention can be administered in the form of pharmaceutical compositions belonging to the combination of Compound 1 described herein, and at least one pharmaceutically acceptable carrier. These compositions may be prepared by methods well known in the art. field of pharmaceuticals, and can be administered by different routes depending on whether local or systemic administration is desired treatment, and the area to be treated. Administration may be local (including ophthalmic and to mucous membranes, including intranasal, vaginal and rectal administration), pulmonary (e.g., by inhaling or blowing powders or aerosols, including using a nebulizer; intratracheally, intranasally, epidermally and transdermally), ocular, oral or parenteral. Methods of delivery to the eye may include topical administration (eye drops), subconjunctival, periocular, or intravitreal injection or administration using a balloon catheter or ophthalmic inserts that surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration may be administered in the form of a single bolus dose or may be administered, for example, by continuous perfusion pump. Pharmaceutical compositions for topical use may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Common pharmaceutical carriers, aqueous, powder or oil bases, thickeners, etc. may be necessary or desirable. This description also includes pharmaceutical compositions that contain Compound 1 as an active ingredient in combinations with one or more pharmaceutically acceptable carriers. In preparing the compositions herein In the invention, the active ingredient is usually mixed with a filler, diluted with a filler, or encapsulated in such a carrier, for example in the form of a capsule, sachet, paper or other container. When the filler serves solvent, it can be a solid, semi-solid or liquid material that acts as a carrier, vehicle or medium for the active ingredient. Thus, the compositions may be in the form of tablets, pills, powders, lozenges, sachets, wafers, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid or liquid form) medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatinous capsules, suppositories, sterile solutions for injection or sterile packaged powders. When preparing the drug, the active compound can be ground to obtain particles of suitable size. size before combining with other ingredients. If the active compound is practically insoluble, it can be grind to a particle size of less than 200 mesh. If the active compound is substantially water-soluble, the particle size particles can be adjusted by grinding to ensure a virtually uniform distribution in the composition, for example, about 40 mesh. Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The compositions may additionally include: lubricants agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives, such as methyl and propyl hydroxybenzoates; sweeteners; and flavorings. The compositions described herein can be formulated to provide rapid, sustained or delayed release of the active ingredient after administration to the patient using procedures known in the art. The compositions may be formulated in a unit dosage form, each dose containing from about 5 to about 100 mg, more often from about 10 to about 30 mg of active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unit doses for humans and other mammals, each the unit contains a predetermined amount of active material calculated to obtain the desired therapeutic effect, in combination with a suitable pharmaceutical excipient. The active compound may be effective over a wide range of doses and is usually administered in a pharmaceutically acceptable effective amount. However, it should be understood that the amount of compound actually administered is usually determined by the physician according to the circumstances, including the condition to be treated, the chosen route of administration, the compound to be actually administered, the age, weight, response of the individual patient, the severity of the patient's symptoms, etc. To prepare solid compositions, such as tablets, the main active ingredient is mixed with pharmaceutical excipient to form a solid pre-composition containing a homogeneous mixture Compounds 1. When these previous compositions are considered homogeneous, the active ingredient is usually uniformly distributed. dispersed throughout the composition, so that the composition can be easily divided into equally effective standard dosage forms such as tablets, pills and capsules. This solid pre-composition is then divided into standard dosage forms of the type described above, containing, for example, from 0.1 to about 500 mg of active ingredient ingredient of this invention. Tablets or pills of the present invention may be coated or otherwise formulated to obtaining a dosage form that provides the advantage of prolonged action. For example, a tablet or pill can contain an internal dose component and an external dose component, the latter being in the form of a shell, covering the first. The two components may be separated by an enteric layer that serves to prevents disintegration in the stomach and allows the internal component to pass intact into the duodenum or delayed in release. For such enteric layers or coatings Various materials can be used, including a range of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol and cellulose acetate. Liquid forms into which Compound 1 and the compositions described herein may be incorporated for oral or injectable administration, include aqueous solutions, flavored syrups, aqueous or oily suspensions, and flavored emulsions with edible oils, such as cottonseed oil, sesame oil, coconut oil, or peanut oil oil, as well as elixirs and similar pharmaceutical carriers. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous solutions. or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain the appropriate pharmaceutically acceptable excipients described above. In some embodiments, the compositions are administered orally or by nasal respiratory route for local or systemic effect. The compositions can be applied by spraying using inert gases. Spray solutions can be inhaled directly from the sprayer, or the sprayer can be attached to the tent with face mask or intermittent positive pressure breathing apparatus. Compositions in the form of a solution, suspension or powder can be administered orally or nasally using devices that provide delivery of the composition in an appropriate manner. The amount of compounds or compositions administered to a patient will vary depending on what is being administered, on the purpose of administration, such as prophylaxis or therapy, the patient's condition, the route of administration, etc. For therapeutic purposes the compositions can be administered to a patient already suffering from the disease in an amount sufficient to cure or at least partial relief of the symptoms of the disease and its complications. Effective doses will depend on the medical condition being treated, as well as the judgment of the treating physician based on factors such as severity of the disease, age, weight and general condition of the patient, etc. The compositions administered to the patient may be in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization methods or may be sterilized Aqueous solutions can be packaged for use as is or lyophilized, with The lyophilized preparation is combined with a sterile aqueous vehicle before administration. pH of the compound preparations is usually from 3 to 11, more preferably from 5 to 9 and most preferably from 7 to 8. It should be understood that the use of some of the above auxiliary fillers, carriers or stabilizers will lead to formation of pharmaceutical salts. The therapeutic dose of Compound 1 may vary depending on, for example, the particular application, for which treatment is being administered, the method of administration of the compound, the health and condition of the patient, and the medical opinion of the treating physician The proportion or concentration of Compound 1 in the pharmaceutical composition may vary depending on a number of factors, including dosage, chemical characteristics (e.g., hydrophobicity), and route of administration. For example, Compound 1 may be presented in an aqueous physiological buffer solution containing from about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges range from about 1 μg / kg to about 1 g / kg body weight per day. In some embodiments, the dose range is from about 0.01 mg / kg to about 100 mg / kg body weight per day. The dosage will likely depend on variables such as the type and degree of progression of the disease or disorder, the general health of the specific the patient, the relative biological efficacy of the selected compound, the composition of the excipient and the route of administration. Effective doses can be extrapolated from dose-response curves obtained from in vitro or model test systems. animals. Compound 1 may be formulated in combination with one or more additional active ingredients which may contain any pharmaceutical agent, such as antiviral agents, vaccines, antibodies, immune enhancers, immunosuppressants, anti-inflammatory agents, etc. In one embodiment, Compound 1 is administered orally. In some embodiments, Compound 1 is administered once daily. In some embodiments, Compound 1 is administered at a daily dose of from about 5 mg to about 20 mg. mg. In some embodiments, Compound 1 is administered at a daily dose of from about 10 mg to about 15 mg. In some In some embodiments, Compound 1 is administered at a daily dose of about 9 mg. In some embodiments, Compound 1 administered in a daily dose of about 13.5 mg. In some embodiments, Compound 1 is administered in tablet form. In In some embodiments, the tablet contains from about 0.5 mg to about 10 mg of Compound 1. In some embodiments, In some embodiments, the tablet contains from about 0.5 mg to about 5 mg of Compound 1. In some embodiments, the tablet contains about 2 mg, about 4.5 mg, about 9 mg, about 13.5 mg, or about 18 mg of Compound 1. In some In some embodiments, the tablet contains about 0.5 mg of Compound 1. In some embodiments, the tablet contains about 2 mg of Compound 1. In some embodiments, the tablet contains about 4.5 mg of Compound 1. In some In some embodiments, the tablet contains about 9 mg of Compound 1. In some embodiments, the tablet contains about 13.5 mg of Compound 1. In some embodiments, the tablet contains about 18 mg of Compound 1. In some embodiments, Compound 1 is administered once daily in a continuous dosing regimen. In In some embodiments, Compound 1 is administered on a 21-day dosing regimen, where the 21-day dosing regimen includes: (a) a first period in which Compound 1 is administered once daily for 14 days; and (b) a second period where Compound 1 is not administered for 7 days. In some embodiments, Compound 1 is administered in consecutive 21-day dosing regimens, The 21-day dosing regimen includes: (a) a first period in which Compound 1 is administered once daily for 14 days; and (b) a second period where Compound 1 is not administered for 7 days. EXAMPLES In the examples below, analysis using X-ray powder diffractometry was performed on a Rigaku MiniFlex X-ray powder diffractometer (XRPD). General The experimental procedures for XRPD were as follows: (1) copper X-ray emission at 1.054056 Å with K filter; (2) X-ray power at 30 kV, 15 mA; and (3) sample powder was dispersed on a sample holder with zero background. The general XRPD measurement conditions were as follows: initial angle 3 degrees; Stop angle 45 degrees; Sampling 0.02 degrees; and scan speed 2 degrees / min. Differential scanning calorimetry (DSC) was performed on a TA Instruments Differential Scanning Calorimetry (DSC) instrument. Calorimetry, Model Q200 with autosampler. DSC conditions were as follows: 30 - 300C at 10 C / min; Aluminum Tzero cuvette and lid; and a nitrogen gas flow of 50 mL / min. Thermogravimetric analysis (TGA) was performed on a TA Instrument thermogravimetric analyzer, model Q500. The general experimental conditions for TGA were as follows: temperature change from 20 to 600 °C at a rate of 20C / min.; nitrogen purging, gas flow at a rate of 40 ml / min. with subsequent balancing of the purge flow; sample purge flow at a rate of 60 ml / min; platinum sample tray. Example 1 Synthesis of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H- pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (Compound 1) Scheme 1 NN S About About Cl About About NO H About S About About Cl About About CHO NH O NN S About About Cl About About N About LDA THF. - 70 0C Stage 1 NaB(OAc)3H HOAc,rt NN S Cl About About N About H AT About F NH 2 F About NN S Cl About About N About NH F About About Faq. HCl DCM, rt Stage 2 + O=O=NEt / MSA acetonitrile, n Stage 4 DCM, rt Stage 3 TMSCl / BH3-THF NN S About About N About Cl N F About About F NH ON F About About F About NN S About About N About Cl N F About About F About N NH N About N Stage 5 LHMDS THF, rt aq., NaOH 1,4-dioxaneb 80 0C Stage 6 Stage 1. Synthesis of 4-((4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2, 3-b]pyridin-2-yl)methyl) morpholine 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (50.0 g, 137 mmol) (see, for example, Example 2) and tetrahydrofuran (THF, 266 g, 300 mL) under N2 atmosphere. To this mixture At -70 °C, 2.0 M lithium diisopropylamide in a mixture of THF / heptane / ethylbenzene (77.4 g, 95 mL, 190 mmol, 1.4 The mixture was stirred at -70 ºC for 1 hour. N-formylmorpholine (29.7 g, 258 mmol, 1.9 equiv.) in THF (22.2 g, 25 mL). The reaction was carried out 30 min after addition. LC / MS showed that The desired product, 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carbaldehyde, was formed cleanly. The reaction was quenched with acetic acid (16.4 g, 15.6 mL, 274 mmol, 2.0 equiv.) and cooled to dry was removed with ice. Morpholine (33.7 g, 33.5 mL, 387 mmol, 2.83 equiv.) was added to the mixture, followed by acetic acid (74.0 g, 70 mL, 1231 mmol, and 9.0 equiv.) at 0 °C (internal temperature increased from 0 °C to 18 ºC) and was stirred overnight. Sodium triacetoxyborohydride (52.50 g, 247.7 mmol, 1.8 equiv.) was added and The temperature of the reaction mixture was increased from 20 °C to 32 °C. The mixture was stirred at room temperature for 30 min. HPLC & LC / MS showed that the reaction was complete. Water (100 g, 100 mL) was added, followed slowly (gas, which (separates!) 2.0 M sodium carbonate (Na2CO3) was added to water (236 g, 200 mL, 400 mmol, 2.9 equiv.). The mixture stirred for about 30 min. The organic layer was separated and water (250 g, 250 ml) and heptane (308 g, 450 ml) were added. The resulting suspension was stirred for 1 h and the solid was collected by filtration. The wet precipitate was washed twice with washed with heptane (75.00 mL x 2, 51.3 g x 2) before drying in an oven at 50 ºC overnight to give of the desired product 4-((4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2- (( C21H23ClN2O5S [M+H]+: 464.00; Found: 464.0; 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1 H), 8.38 (m, 2H), 7.72 (m, 1H), 7.64 (m, 2H), 6.83 (s, 1H), 6.13 (s , 1H), 4.12 (m, 2H), 4.00 (m, 2H), 3.92 (s, 2H), 3.55 (m, 4H), 2.47 (m, 4H). Step 2: Synthesis of 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde. A 2-liter reactor equipped with a thermocouple, dropping funnel, and mechanical stirrer was charged with 4-((4- chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine (20.00 g, 43.1 mmol) and dichloromethane (265 g, 200 mL) at room temperature. The resulting mixture was stirred at room temperature temperature (internal temperature 19.5 ºC) until a solution was obtained. To the resulting solution was added aqueous hydrochloric acid solution (0.5 M, 240 g, 200.0 mL, 100 mmol, 2.32 equiv.) at room temperature for 7 minutes. After more than 23 h of stirring at room temperature, the two-layer reaction mixture turned into a thick colorless suspension. When HPLC showed that the reaction was complete, the suspension cooled to 0-5 ºC and an aqueous solution of sodium hydroxide (1 N, 104 g, 100 mL, 100 mmol and 2.32 equiv.) was added for about 10 minutes to adjust the pH of the reaction mixture to 10-11. n-Heptane (164 g, 240 mL) was added, and The reaction mixture was stirred at room temperature for 1 hour. The solid was collected by filtration, and the wet residue was washed with water (2 x 40 mL), heptane (2 x 40 mL) before drying in an oven. oven at 50 ºC under vacuum to obtain the desired product, 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)- 1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde as a light brown solid (16.9 g, 93% yield): LCMS calcd for C19H19ClN3O4S [M+H]+: 420.00; Found: 420.0; 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.76 (s, 1H), 8.42 (m, 2H), 7.74 (m, 1H), 7.65 (m, 2H), 6.98 (s , 1H), 3.96 (m, 2H), 3.564 (m, 4H), 2.51 (m, 4H). Stage 3. Synthesis of N-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2, 3-b]pyridin-5-yl)methyl) - 2,6-difluoro-3,5-dimethoxyaniline In a 2-liter reactor equipped with a thermocouple, nitrogen inlet, and mechanical stirrer, N,N-dimethylformamide (450 ml, 425 g), 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo [2,3-b]pyridine-5-carbaldehyde (30.0 g, 71.45 mmol) and 2,6-difluoro-3,5-dimethoxyaniline (14.2 g, 75.0 mmol). To this Chlorotrimethylsilane (19.4 g, 22.7 ml, 179 mmol) was added dropwise to the suspension (internal temperature 20 ºC) for 10 minutes at room temperature (internal temperature 20-23 ºC). The suspension was converted into solution 5 min after addition of chlorotrimethylsilane. The solution was stirred at room temperature for 1.5 h, then cooled to 0-5 °C in an ice bath. Borane-THF complex in THF (1.0 M, 71.4 mL, 71.4 mmol, 64.2 g, 1.0 equiv.) was added dropwise through an addition funnel over 30 min, maintaining the temperature at 0-5 °C. After addition, the mixture was stirred for 4 hours. Water (150 g, 150 ml) was added at cooling in an ice bath for 20 minutes followed by slow addition of ammonium hydroxide solution (28% NH3, 15.3 g, 17 ml, 252 mmol, 3.53 equiv.) to pH 9-10 while maintaining the temperature below 10 ºС. After Additional water (250 mL, 250 g) was added to the addition funnel. The suspension was stirred for 30 minutes, and the solids The solids were collected by filtration. The wet residue was washed with water (90 g × 2, 90 mL × 2) and heptane (61.6 g × 2, 90 mL × 2). The product was dried under vacuum overnight to give the desired product N-((4-chloro-2-(morpholinomethyl)- 1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2,6-difluoro-3,5-dimethoxyaniline (41.6 g, yield 96%): LCMS calcd for C27H28ClF2N4O5S[M+H]+: 593.10; Found: 593.1; 1H NMR (400 MHz, DMSO-d6) δ 8.36 (m, 2H), 8.28 (s, 1H), 7.72 (m, 1H), 7.63 (m, 2H), 6.78 (s, 1H), 6.29 (m, 1H), 5.82 (m, 1H), 4.58 (m, 2H), 3.91 (s, 2H), 3.76 (s, 6H), 3.56 (m, 4H), 2.47 (m, 4H). Stage 4. Synthesis of 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1- (2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea In a 2-liter three-necked round-bottom flask equipped with a thermocouple, a nitrogen bubbler inlet, and magnetic stirrer, N-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine- 5-yl)methyl)-2,6-difluoro-3,5-dimethoxyaniline (67.0 g, 113 mmol) and acetonitrile (670 mL, 527 g). The suspension cooled to 0-5 ºC. Ethyl isocyanate (17.7 ml, 15.9 g, 224 mmol, 1.98 equiv.) was charged into the mixture over a period of 30 seconds. After loading, the temperature did not change and was 0.7 ºC. Methanesulfonic acid (16.1 ml, 23.9 g, 248 mmol, 2.2 equiv.) was added dropwise over 35 minutes, maintaining the temperature below 2 °C. The mixture was warmed to room temperature and stirred overnight. 24 hours after addition it was shown that product is 93.7%, unreacted SM is 0.73%, and the main impurity (bis-isocyanate adduct) is 1.3%. The mixture was cooled in an ice bath and quenched with sodium hydroxide (NaOH) solution (1.0 M, 235 mL, 244 g, 235 mmol, 2.08 equiv.) for 20 minutes, followed by saturated aqueous sodium bicarbonate (NaHCO3) (1.07 M, 85 mL, 91 g, 0.091 mol, 0.80 equiv.) after 10 min. water (550 mL, 550 g) was added and the liquid became The mixture was stirred for 2 h, and the solids were collected by filtration, washed with water (165 ml, 165 g), giving 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1- (2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea (70.3 g, yield 93.7%). Crude 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1-(2,6- difluoro-3,5-dimethoxyphenyl)-3-ethylurea (68.5 g, 103 mmol) was added to acetonitrile (616 mL, 485 g). The mixture was heated to 60-65 °C and a thin amber suspension was obtained. The solid was filtered off through celite, and the celite was washed with acetonitrile (68.5 mL, 53.8 g). To the pale yellow filtrate was added water (685 g, 685 ml) to form a suspension. The suspension was stirred overnight at room temperature and filtered. The solid was added to water (685 mL, 685 g) and stirred at 60 °C for 2 hours. The solid filtered and re-stirred in heptane (685 mL, 469 g) overnight. The product was dried in an oven at 50 ºC under vacuum for 48 hours to obtain 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl) -1H- pyrrolo[2,3-b]pyridin-5-yl)methyl)-1-(2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea as a colorless solid of the substance (62.2 g, yield 90.8%, purity 99.9% by HPLC area%). KF was 0.028%. Acetonitrile (by 1H NMR) was about 1.56%, DCM (by 1H NMR) 2.0%: LCMS calculated for C30H33ClF2N5O6S [M+H]+: EM: 664.17; Found: 664.2; 1H NMR (400 MHz, DMSO-d6) δ 8.33 (m, 2H), 8.31 (s, 1H), 7.72 (m, 1H), 7.64 (m, 1H), 6.96 (m, 2H), 6.73 (s, 1H), 6.43 (m, 1H), 4.87 (s, 2H), 3.90 (s, 2H), 3.77 (s, 6H), 3.54 (m, 4H), 3.03 (m, 2H), 2.46 (m, 4H), 0.95 (m, 3H). Stage 5: Synthesis of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)- 1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2-one In a 2000 ml flask equipped with a thermocouple, nitrogen inlet and mechanical stirrer, Dry 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1- (2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea (30.0 g, 45.2 mmol, KF=0.11%) and tetrahydrofuran (1200 ml, 1063 g). 1.0 M lithium hexamethyldisilazide in THF (62.3 ml, 55.5 g, 62.3 mmol, 1.38 equiv.). After addition of base, the mixture turned into a solution. The reaction mixture was stirred for 2 h and HPLC showed no starting material. To this mixture was added 1.0 M hydrochloric acid (18.1 mL, ~18.1 g, 18.1 mmol, 0.4 equiv.). The solution was concentrated to 600 mL and water (1200 ml, 1200 g) was added. After adding water, a suspension was formed. The suspension was stirred for 30 minutes at room temperature and the solid was collected by filtration. The wet precipitate was washed twice water (60 mL×2, 60 g×2) and dried at 50 ºC overnight to give 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1- ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2- one as a light brown solid (26.58 g, yield 93.7% as is): THF by 1H NMR 0.32%, KF 5.26%. Adjusted yield was 88.5%: LCMS calcd for C30H32F2N5O6S [M+H]+: EM: 628.20; Found: 628.2; 1H NMR (400 MHz, DMSO-d6) δ 8.41 (m, 2H), 8.07 (s, 1H), 7.70 (m, 1H), 7.63 (m, 2H), 7.05 (m, 1H), 6.89 (s, 1H), 4.76 (s, 2H), 4.09 (m, 2H), 3.93 (s, 2H), 3.89 (s, 6H), 3.60 (m, 4H), 2.50 (m, 4H), 1.28 (m, 3H). Stage 6: Synthesis of 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3, 4,7-tetrahydro-2H- pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one To a stirred suspension of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7- (phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (10.0 g, 15.93 mmol) in 1,4- dioxane (100 ml, 103 g) into a 500 ml flask equipped with a nitrogen inlet, condenser, thermocouple and heating jacket, 1 M aqueous sodium hydroxide (63.7 mL, 66.3 g, 63.7 mmol) was added. The reaction mixture was heated at 75 °C for 18 hours. HPLC showed that the reaction was complete. water (100 ml, 100 g) to obtain a thick suspension. This suspension was stirred at room temperature for 1 h and filtered. The precipitate was washed with water (3 × 10 mL, 3 × 10 g) and heptane (2 × 10 mL, 2 × 6.84 g). The precipitate dried overnight by applying a vacuum through the filter cake and then dried in an oven at 50 °C under vacuum overnight to give 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3, 4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (6.8 g, yield 87.6%): LCMS, calculated for C24H28F2N5O4 [M+H]+: 488.20; Found: 488.2. Example 2. Synthesis of 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine Scheme 2 N NH N + N H About N NH Cl NN Cl TIPS Stage 1 mCPBA Stage 2 MsCl TIP-Cl Stage 3 N NH ClO H About S About N ClO H NO S About N Cl N About About Stage 4 c-BuLi / DMF aq. HCl PhSO2Cl CsCO3 / DMF 0 0С-rt Stage 5 HOCH2CH2OH p-TsCH / toluene reflux Stage 6 Step 1. Synthesis of 1H-pyrrolo[2,3-b]pyridine-7-oxide. m-Chloroperoxybenzoic acid (105.5 kg, 612 mol, 1.2 equiv.) was added to a solution of 1H-pyrrolo[2,3-b]pyridine (60 kg, 507.6 mol) in dichloromethane (600 L) for 5 h with stirring at 0-10 ℃. After completion After addition, the mixture was stirred at 0-10℃ for 3 hours. The resulting solid was collected by filtration, washed with heptane and dried to obtain 1H-pyrrolo[2,3-b]pyridine-7-oxide. The mother liquor was concentrated, and The residue was treated with a mixture of dichloromethane:heptane (2:3) and filtered to remove additional materials. Crude 1H-pyrrolo [2,3-b] pyridine-7-oxide (72 kg, purity 96%) was obtained, which was used in the next stage without purification. Step 2: Synthesis of 4-chloro-1H-pyrrolo[2, 3-b] pyridine. Crude 1H-pyrrolo[2,3-b]pyridine-7-oxide (72 kg, 253 mol) was dissolved in DMF (360 L) and heated at 50 ℃. A solution of methanesulfonyl chloride (85.2 kg, 746 mol, 3.0 equiv.) was added dropwise to the solution, maintaining temperature below 70℃. After stirring at 90℃ for 2 hours, the reaction solution was cooled to room temperature and 720 kg of ice / water were added. The mixture was neutralized with 6.0 M NaOH at 0 ℃. The resulting precipitate was collected by filtration and washed with water. The solid was mixed with 72 L of water, 48 L of ethanol and 29 L of 30% NaOH and was stirred at room temperature for 1-2 hours. Water (144 L) was added and the mixture was treated with 37% HCl, to bring the pH to ~1. The product was collected by filtration and dried to give 4-chloro-1H-pyrrolo[2,3-b]pyridine (crude 26 kg, purity 97%, used without purification): 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 1H), 8.25 (m, 1H), 7.44 (m, 1H), 7.16 (m, 1H), 6.65 (m, 1H). Stage 3. Synthesis of 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine. A solution of crude 4-chloro-1H-pyrrolo[2,3-b]pyridine (24 kg, 155.2 mol) in THF (216 L) was stirred at 0 ℃ in the form of NaH (60%, 7.56 kg, 188.6 mol, 1.3 equiv.) was added portionwise under N2 atmosphere. After addition, the mixture was stirred at room temperature for 1 hour. Triisopropylsilyl chloride (39.6 kg, 188.6 mol, 1.3 equiv.), maintaining the temperature below 25 ℃. After stirring for 20 hours, the mixture quenched with 144 L of water and extracted with 144 L of heptane. The aqueous layer was again extracted with 72 L of methyl tert-butyl ether. ether. The combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo to give crude 4- chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine in liquid form. The material was used without purification, but its water content was controlled below 0.1%. Stage 4: Synthesis of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde Crude 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3- b]pyridine (50 kg, ~138 mol) and anhydrous THF (150 kg). The mixture was cooled to -75 ℃ and stirred under atmosphere N2, when S-BuLi (1.3 M in cyclohexane, 230 L, 300 mol, 2.2 equiv.) was added dropwise over about 6.0 h, maintaining the internal temperature below -60℃. The mixture was stirred at -75℃ for another 2 hours. N, N- Dimethylformamide (30.4 kg, 416.1 mol, 3.0 equiv.) was added dropwise over ~3.0 h to control internal temperature below -65 ℃. After stirring at -65~-75 ℃ for 2 hours, the mixture was quenched by adding dropwise a 20% solution HCl in isopropyl alcohol (115 kg, 635 mol, 4.5 equiv.). The mixture was then stirred at room temperature (20- 25 ℃) overnight. The pH was adjusted to 7-8 by loading saturated NaHCO3. The precipitate formed was collected The filter cake was washed with 76 L of water to give 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde. (14 kg, 58% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.54 (s, 1H), 10.35 (s, 1H), 8.67 (s, 1H), 7.74 (m, 1H), 6.72 (m, 1H). Stage 5: Synthesis of 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde A 500-liter reactor is charged with N,N-dimethylformamide (108 liters) and 4-chloro-1H-pyrrolo[2,3-b]pyridine-5- carbaldehyde (10.8 kg, 59.8 mol) and cooled to 0-5 °C. The resulting thick suspension was charged with carbonate cesium (39 kg, 120 mol) at 0-5 ℃. The suspension was stirred at 0 ℃ for about 20 minutes, and the mixture turned into a thin amber suspension. To a thin suspension at a temperature below 10 ℃ by Benzenesulfonyl chloride (11.6 kg, 65.8 mol, 1.1 equiv.) was added dropwise through a dropping funnel. The resulting The suspension was stirred for 1 h at a temperature below 10℃, and HPLC showed that the reaction was complete. Prolonged stirring at room temperature overnight had little effect on the profile of the reaction mixture. To Water (160 mL) was added to this mixture and the suspension was stirred for 1 hour. The solid was collected filtration (slow). The filter cake was washed with water and dried in a drying cabinet under vacuum with obtaining 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde as a light brown solid (17.8 kg, 93% yield): LCMS calcd for C14H10ClN2O3S [M+H]+: 321.00; Found: 320.9; 1HNMR (400 MHz, DMSO-d6) δ: 10.34 (s, 1H), 8.78 (s, 1H), 8.18 (m, 3H), 7.77 (m, 1H), 7.66 (m, 2H), 7.05 (m, 1H). Stage 6. Synthesis of 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine) Toluene (270 l), 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5- carbaldehyde (27 kg, 84.2 mmol), p-toluenesulfonic acid monohydrate (217 g, 1.26 mol, 0.015 equiv.) and 1,2- ethanediol (73.7 kg, 1187 mol, 14.1 equiv.). The mixture was stirred and heated to reflux to remove water (some ethylene glycol was also removed during the reaction) for 9 hours (LCMS showed the reaction was complete). After stirring overnight at room temperature, the mixture was diluted ethyl acetate (135 L) and washed with saturated NaHCO3 solution. The layers were separated and the organic layer was washed with 10% aq. NaCl solution and concentrated. Heptane (108 L) was added and a suspension was formed. The solid The solid was dissolved in dichloromethane (108 L) and filtered to remove mechanical impurities. The filtrate was concentrated, then dissolved in 67.5 l (2.5 V) of hot ethyl acetate and was stirred for 2 hours. The mixtures were allowed to cool as a solid formed. The solid collected by filtration to give 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine as an off-white solid (22 kg, 70% yield): LCMS calcd for C16H14ClN2O4S [M+H]+: 365.03; Found: 365.1; 1H NMR (400 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.13 (m, 2H), 8.07 (m, 1H), 7.73 (m, 1H), 7.63 (m, 2H), 6.90 (m, 1H), 6.13 (s, 1H), 4.12 (m, 2H), 3.98 (m, 2H). Example 3. Alternative synthesis of 4-chloro-2-(morpholin-4-ylmethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3- b]pyridine-5-carbaldehyde Scheme 3 N Cl NH 2 N Cl Br NH 2 N Cl Br NH 2 I N Cl Br NH 2 N About N About Stage 1 NBS Stage 2 l2 / H5IO6 Pd / Cu-cat Stage 3 N Cl BrN About S N Cl Br N N About About About S N Cl N N About About About About H Stage 4 KOtBu Stage 5 Stage 6 NaH PhSO2Cl iPrMgCl,DMF Step 1. Synthesis of 5-bromo-4-chloropyridin-2-amine. To a suspension of 2-amino-4-chloropyridine (100 g, 777.8 mmol, 1.0 equiv.) in acetonitrile (500 mL, 5 rel. vol.) at 15-20 ºC, N-bromosuccinimide (131.5 g, 738.9 mmol, 0.95 equiv.) was added portionwise over 2 h, maintaining temperature 15–20 °C. The reaction mixture was stirred for 30 min and the conversion was checked using HPLC. Depending on the conversion, 0–5 mol% additional N-bromosuccinimide was added and the mixture was stirred for another 15 min. After HPLC showed that the conversion was complete, the reaction mixture was heated and the acetonitrile was distilled off. (300 ml) at normal pressure. Water (250 ml) was added, the temperature was brought to 50–55 ºC, and a suspension. The resulting suspension was stirred for 30 minutes and water (350 ml) was added over 1 hour. The suspension was cooled to 20–25 ºC, stirred for 1 h, and the solid was collected by filtration. The wet residue was washed with a mixture of water (75 ml) and acetonitrile (25 ml) to obtain a wet product of 5-bromo-4- chloropyridin-2-amine (191 g, 92.1% purity by HPLC). The wet product was dissolved in acetic acid (500 ml, 5 rel. vol. in 2-amino-4-chloropyridine, 55-70 ºC), and the solution was directly used in the next step. Step 2: Synthesis of 5-bromo-4-chloro-3-iodopyridin-2-amine. Solution of 5-bromo-4-chloropyridin-2-amine in acetic acid (191 g, 5-bromo-4-chloropyridin-2-amine in 500 ml acetic acid acid) was distilled under reduced pressure at 40–60 ºC to remove the solvent. Then sulfuric acid was added acid (39.7 g, 96% w / w, 388.9 mmol, 0.5 equiv) and iodine (76.2 g, 300.3 mmol, 0.386 equiv) and temperature was brought to 77–83 °C. At this temperature, a solution of iodic acid (50% w / w, 54.89 g, 120.4 mmol, 0.155 equiv.). The reaction mixture was stirred for 2–3 hours at 77–83 ºC and the conversion was checked by HPLC (SM <1.0% -a / a). At 75-85 °C the reaction mixture was quenched by addition of solid ammonium sulfite in 4.53 g (0.05 eq.) portions until the KI / starch test was negative. It was usually two portions (0.1 equiv.) of ammonium sulfite are required. The end of hardening can also be seen by the absence of purple iodine color. The reaction mixture was then diluted with water (200 mL, 2.0 rel. vol., at room temperature) temperature), and the temperature was reduced to ~ 50 °C. The product precipitated. At 45–60 ºC, the pH was adjusted to 3.0–3.5 with ammonia (25% w / w in water, ca. 63.6 g, 0.93 mol, 1.2 equiv). Neutralization was strongly The suspension was stirred for 30 minutes at 45–50 ºC, and then the solid was collected The filter cake was usually washed with about 600 ml of water and then washed with 2-propanol (200 The wet product was dried in a vacuum oven at 60 °C to obtain 5-bromo-4-chloro-3-iodopyridin-2-amine in as a yellow to beige solid (213.5 g, yield 82.3%): LCMS calculated for C5H4BrClIN2 [M+H]+: 332.82; Found: 332.8; 1H NMR (400 MHz, DMSO-d6) δ 8.09 (s, 1H), 6.60 (s, 2H). Stage 3. Synthesis of 5-bromo-4-chloro-3-(3-morpholinoprop-1-yn-1-yl)pyridin-2-amine. 5-Bromo-4-chloro-3-iodopyridin-2-amine (50 g, 150 mmol, 1.0 equiv), 4-(prop-2-ynyl)morpholine (22.5 g, 180 mmol, 1.20 equiv.), diisopropylamine (18.2 g, 180 mmol, 1.2 equiv.) and 150 mL of toluene were charged into the reactor. The solution was carefully was degassed using 3 cycles of argon evacuation. Then CuI (0.29 g, 1.5 mmol, 1 mol%) was added and Pd(PPh3)4 and the flask was purged with argon again. The mixture was stirred at 50 °C overnight (17 h). One Water (50 mL, 1 volume) was added portionwise and the mixture was cooled to 20-25 °C. The crude product was filtered and washed sequentially with 10% ammonia (50 ml, 1.0 vol.), water (50 ml, 1 vol.), toluene (25 ml, 0.5 vol.) and 2-isopropanol (50 ml, 1.0 vol.). After drying in vacuum at 50 °C, 5-bromo-4-chloro-3-(3- Morpholinoprop-1-yn-1-yl)pyridin-2-amine as a light brown solid (41.6 g, 87% yield. ): LCMS calculated for C12H14BrClIN5O [M+H]+: 329.99; Found: 330.0; 1H NMR (400 MHz, DMSO-d6) δ 8.13 (s, 1H), 6.69 (s, 2H), 3.64 (s, 2H), 3.61 (m, 4H), 2.54 (m, 4H). Step 4: Synthesis of 4-((5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine. A solution of KOtBu (18.1 g, 1.4 equiv., 112.21 mmol) in tetrahydrofuran (114 mL, 3 volumes) was heated to 30-35 °C in in the form of 5-bromo-4-chloro-3-(3-morpholinoprop-1-yn-1-yl)pyridin-2-amine (38 g, 114.9 mmol, 1.0 equiv.) was added portions for 1.0 hour at 30-35 °C. After stirring for 2 hours, the reaction was quenched with a solution acetic acid (10.4 g, 172.4 mmol, 1.5 equiv.) in water (76 mL, 2 volumes) and 76 mL of THF (76 mL) were removed by distillation. The solution was then heated to reflux and MeOH (38 mL, 1 volume) was added, and the resulting suspension cooled to 23 °C over 1 hour. After stirring for 0.5 h at 23 °C, the solid filtered and washed with water (38 mL, 1 volume) and MeOH (38 mL, 1 volume). 4-((5-Bromo-4-chloro-1H-pyrrolo[2,3- b]pyridin-2-yl)methyl)morpholine in the form of a light brown powder 4-((5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine-2- (( C12H14BrClIN5O [M+H]+: 329.99; Found: 329.8; 1H NMR (400 MHz, DMSO-d6) δ 12.22 (s, 1H), 8.34 (s, 1H), 6.40 (s, 1H), 3.65 (s, 2H), 3.58 (m, 4H), 2.42 (m, 4H). Step 5: Synthesis of 4-((5-bromo-4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine. A suspension of 4-((5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine (10 g, 30.25 mmol, 1.0 equiv., analysis 94% w / w) and NaH (1.69 g, 60%, 42.35 mmol, 1.4 equiv) in 38 mL of tetrahydrofuran was cooled to 0-5 °C by adding PhSO2Cl (7.48 g, 42.35 mmol, 1.4 equiv.) over 1 hour. After 1.5 hours, HPLC showed that The reaction was not complete. Additional NaH (0.34 g, 0.3 equiv.) was added, after which gas evolution was observed. When HPLC showed that the reaction was complete, the reaction mixture was quenched with acetic acid (0.5 g) and a mixture of water (15 ml) and methanol (15 ml). The pH was adjusted to 6.5 with caustic soda and the product was isolated by filtration. The wet residue was washed with 2-isopropanol (20 ml) and water (20 ml), and the wet product (14.8 g) was dried in a vacuum oven. cabinet to obtain 4-((5-bromo-4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine in as a brown solid (12.57 g, 86% yield): LCMS calculated for C18H18BrClIN3O3S [M+H]+: 469.99; Found: 470.0; 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.33 (m, 2H), 7.73 (m, 1H), 7.65 (m, 2H), 6.83 (s, 1H), 3.91 (s, 2H), 3.53 (m, 4H), 2.46 (m, 4H). Stage 6. Synthesis of 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde. To a suspension of 4-((5-bromo-4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine (5.0 g, 10.6 mmol, 1.0 equiv.) in 50 ml of tetrahydrofuran at a temperature from -10 °C to 0 °C was added iPrMgCl (6.9 ml, 2M in tetrahydrofuran, 13.80 mmol, 1.3 equiv.). After stirring for 2 hours to the reaction solution N,N-dimethylformamide (1.55 g, 21.2 mmol, 2.0 equiv.) was added over 0.5 h at a temperature of -5 °C to 0 °C. The mixture was stirred for 0.5 h at a temperature of -5 °C to 0 °C, then heated to 23 °C for 0.5 hour and stirred for 1 hour at 23 °C. The pH was adjusted to 6-7 by adding 1.5 ml of acetic acid and 10 ml of water. 25 ml of MeOH and 15 ml of water were added to the two-phase mixture. After stirring for 1 h, the product was filtered and washed with 20 mL MeOH / water (1 / 1) and 30 mL water. After drying in vacuo at 50 °C, the 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde as an off-white powder (3.39 g, 76% yield): LCMS calcd for C19H19ClN3O4S [M+H]+: 420.07; Found: 420.0; 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.76 (s, 1H), 8.42 (m, 2H), 7.74 (m, 1H), 7.65 (m, 2H), 6.98 (s, 1H), 3.96 (m, 4H), 3.564 (m, 4H), 2.51 (m, 4H). Example 4. Synthesis of 2,6-difluoro-3,5-dimethoxyaniline Scheme 4 F F F F F CO 2 HN F F F F CO 2 Me F BnHN F CO 2 MeF F F BnHN CO 2 MeF OMe OMe Stage 1 MeOH / SOCl2 Stage 2 BnNH2 Stage 3 MeONa F BnHN F CO 2 MeF F F BnHN F OMe OMe F NH 2 F OMe OMe Stage 4 Stage 5 decarboxylation HCO2NH4 / Pd / C EtOH / AcOH Stage 1: Synthesis of methyl pentafluorobenzoate To a solution of pentafluorobenzoic acid (40 kg, 188.6 mol) in 68 L of methanol, dropwise over 4.0 hours at 20-50 ℃. SOCl2 (29.2 kg, 245.2 mol, 1.3 equiv.) was added. The mixture was then refluxed for 17 hours. The methanol was removed by distillation in vacuo and the residue was dissolved in methyl t-butyl ether (77 The solution was washed with saturated NaHCO3 (37 L), dried over MgSO4 and evaporated to give methyl pentafluorobenzoate as a colorless oil (39 kg, yield 91%): 1H NMR (400 MHz, CDCl3) δ 3.90 (s, 3H). Stage 2: Synthesis of methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate. Methyl pentafluorobenzoate (39 kg, 172.5 mol) and N,N-diisopropylethylamine (26.8 kg, 207 mol, 1.2 equiv.) were dissolved in N-methylpyrrolidinone (39 L). A solution of benzylamine (18.5 kg, 172.5 mol, 1.0 equiv.) in 19.5 L of N-methylpyrrolidinone was added dropwise over 3.5 hours, maintaining the internal temperature below 50 ℃. The resulting thick yellow The suspension was heated to 65℃ and stirred for another 1 hour. The mixture was poured into 195 L of aqueous acetic acid solution. (10% acetic acid and 90% H2O), the suspension was stirred for 1 hour and filtered. The precipitate on the filter washed with water and heptane and dried at 35 ºC in vacuum, yielding methyl-4-(benzylamino)-2,3,5,6- tetrafluorobenzoate (38 kg, yield 70%): 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 5H), 4.67 (m, 2H), 4.58 (m, 1H), 3.93 (s, 3H). Stage 3. Synthesis of 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid. Methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate (38 kg, 121.3 mol) in methanol (72 L) was stirred at at room temperature in an N2 atmosphere as a solution of NaOMe in methanol (25 wt.%, 110.8 kg, 545.85 mol, 4.5 equiv.) was added dropwise over 3.0 h, maintaining the temperature below 50 ºC. After heating to 65-70 ºC 18 L of water was added to the reaction mixture over 18 hours and the resulting solution was stirred for 1 hour. Solvent was removed by vacuum distillation. Water (54 L) was added and the resulting solution was acidified to pH 2 with 37% HCl. The mixture was extracted three times with ethyl acetate (54 kg each). The combined organic extracts were washed water (43 L) and concentrated to dryness to give a solid. The solid was triturated with heptane (43 l) to remove impurities. The solid was collected and dried at 40 °C in vacuo to give 4-(benzylamino)- 3,5-difluoro-2,6-dimethoxybenzoic acid (35 kg, yield 86%): 1H NMR (400 MHz, CDCl3) δ 12.74 (s, 1H), 7.37 (m, 5H), 6.62 (s, 1H), 4.67 (m, 2H), 3.96 (s, 6H). Step 4: Synthesis of n-benzyl-2,6-difluoro-3,5-dimethoxyaniline. 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid (17 kg) was heated in its pure form to 75-85 °C in under nitrogen atmosphere for 3-4 hours. After the reaction was complete, 40 l of methyl tert-butyl ether and 20 l of 1 M NaOH. The mixture was stirred at room temperature for 30 min. The organic layer was separated and washed with water. (20 L) and brine (20 L). The organic phase was concentrated under reduced pressure to give the crude product. The crude product was triturated with heptane and dried at 35 °C in vacuo to give N-benzyl-2,6-difluoro-3,5- of dimethoxyaniline (12 kg, yield 82%): 1H NMR (400 MHz, CDCl3) δ 7.35 (m, 5H), 6.09 (m, 1H), 4.53 (m, 2H), 4.00 (s, 1H), 3.85 (s, 6H). Step 5: Synthesis of 2,6-difluoro-3,5-dimethoxyaniline. N-Benzyl-2,6-difluoro-3,5-dimethoxyaniline (24 kg, 85.9 mol) was dissolved in mixed solvents of ethanol (120 l) and acetic acid (20 l) in the form of ammonium formate (13.2 kg) and 1.68 kg of Pd / C were added. The mixture was heated at 50 ºC for 2-3 hours. The reaction mixture was then filtered through a pad of Celite®, washed with ethanol (1.2 L × 2) and concentrated. The crude product was added to 80 L of water, and the resulting suspension was filtered. The crude The product was added to 60 L of methyl tert-butyl ether and 2.5 kg of activated carbon, and the mixture was boiled with reflux for 3 hours. After filtration and concentration, the resulting solid was added to 36 L of heptane and stirred for 2 hours at room temperature. The mixture was filtered and dried at 35 °C in vacuum to give 2,6-difluoro-3,5-dimethoxyaniline as a light brown solid substance (15.2 kg, yield 93%): LCMS, calcd for C8H10F2NO2 [M+H]+: 190.16; Found: 190.1; 1H NMR (400 MHz, DMSO-d6) δ 6.16 (m, 1H), 5.18 (s, 2H), 3.78 (s, 6H). Example 5 Preparation and characterization of Form I A 100L glass reactor and a 200L glass reactor were assembled with an overhead stirrer, condenser, thermocouple, dropping funnel, and nitrogen inlet, and each device was purged with nitrogen. Methanol (1.39 L), methylene chloride (21.7 L) and crude 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholine-4- ylmethyl)-1,3, 4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (3330 g) was charged sequentially into reactor with a capacity of 100 L, and the reaction mixture was heated to about 33 C and stirred at about 33 C for about 43 minutes until a clear solution was obtained. The reaction mixture was filtered through an in-line filter, using methylene chloride (2.1 L) to rinse the reactor through the filter. The filtrate was partially concentrated (with using 2 rotary evaporators for convenience) in vacuum at about 30 C to the target residual total volume 15.5 l (~ 4.6 l per kg of product loaded). The residue after distillation (15.5 l) was loaded into a 200 L reactor using filtered methylene chloride (1.3 L) to facilitate transfer. The reaction mixture was heated to about 39°C and stirred for about 3 minutes until a clear solution was obtained. solution. Polished filtered methyl tert-butyl ether (23.1 L) was charged, maintaining The reaction temperature was raised to about 39°C. The reaction mixture was stirred at about 36°C for about 5.25 h. h, cooled to about 30 C and stirred at about 23 C for about 10.5 hours. The reaction The mixture was filtered, and the filter cake was washed with methyl tert-butyl ether (3.3 L), filtered to polishing. The product was air-dried on a filter for about 3.25 h and then dried in vacuum at 25-50 C to obtain 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H- pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one as a white to off-white solid (3002 g, yield 91.0%): LCMS calcd for C24H28F2N5O4 [M+H]+: 488.20; found: 488.2; 1H NMR (400 MHz, DMSO- dd6) δ 11.74 (s, 1H), 7.92 (s, 1H), 7.05 (m, 1H), 6.48 (s, 1H), 4.75 (s, 2H), 4.15 (m, 2H), 3.90 (s, 6H), 3.60 (m, 6H), 2.44 (m, 4H), 1.33 (m, 3H). According to XRPD analysis, the solid product was confirmed as a crystalline solid having the Form I. The XRD pattern of Form I is shown in Figure 1 and the peak data are given below in Table 1. Table 1 XRPD peak data for Form I 2-Theta Height I% 3,8 194 2,5 6,8 7767 100 7,9 105 1,4 9,6 563 7,2 10,1 70 0,9 11,4 96 1,2 12,2 56 0,7 12,9 1131 14,6 13,4 132 1,7 14,4 327 4,2 15,9 181 2,3 17,6 217 2,8 18,2 91 1,2 18,6 723 9,3 19,4 550 7,1 19,9 174 2,2 20,5 192 2,5 21,8 77 1 22,3 197 2,5 22,6 752 9,7 24,0 133 1,7 24,8 127 1,6 25,4 1761 22,7 25,8 3393 43,7 26,2 5024 64,7 27,5 1568 20,2 28,4 120 1,5 29,5 205 2,6 30,0 88 1,1 30,7 75 1 31,0 81 1 31,8 112 1,4 32,7 64 0,8 33,7 69 0,9 34,5 62 0,8 36,6 72 0,9 37,9 76 1 39,1 119 1,5 43,8 51 0,7 Form I exhibits a DSC thermogram with endotherm peaks at temperatures around 201 ºC and around 276 ºC. Fig. 2 shows a DSC thermogram of Form I. Fig. 3 shows a TGA thermogram of Form I. Example 6 Methods and results of screening of crystalline forms New crystalline forms of the compound of Formula I were obtained by various screening methods described below. Form I, as described above in Example 5, was used as the starting material for the sieves unless otherwise specified. other. Solubility measurement Form I was saturated in different solvent systems (Table 2) at 25 °C and 50 °C, which were stirred for 24 h and its solubility was measured by HPLC. Form I was found to be completely soluble (> 50 mg / mL) in many solvents including DMF (50 °C), DCM, chloroform, DMSO and DCM / MeOH (9 / 1) at 25 °C and 50 °C. It has also been found to be soluble in most other solvents, but is almost insoluble in in water, heptane and hexane, slightly soluble in MTBE, toluene, IPAc, methanol and IPA at 25oC. Its solubility is usually increases in all solvents at 50 °C. Table 2 Solubility screening Solvent Solubility at 25 °C (mg / mL) Solubility at 50 °C (mg / mL) MeCN 5.39 8.39 Chloroform >50 >50 Dichloromethane >501 >50 DCM / MeOH (9 / 1) >50 >50 DMF 41.99 >50 1,4-Dioxane 2,232 5,692 Methanol 0.643 2.05 2-Methoxyethanol 15.28 20.49 MIBK 0.434 1.12 Toluene 0.45 0.82 Hexane 0.00 0.00 THF 4.11 10,045 Acetone 2,686 6.67 n-BuOH 0.82 1.65 MTBE 0.057 0.19 DMSO >508 >50 EtOH 0.97 2.73 EtOAc 0.709 2.26 Ethyl formate 4.1610 15.29 Heptane 0.00 0.00 Isobutyl acetate 0.46 0.58 IPAc 0.88 1.33 1-Propanol 1.16 2.50 IPA 0.56 1.37 IPA / water (4 / 1) 5.35 8.77 MEK 1.20 3.22 Note: 1. Solubility of Form II in DCM; 2. Solubility of Form III in 1,4-Dioxane; 3. Solubility of Form VI in methanol; 4. Solubility of Form VII in MIBK; 5. Solubility of Form XIII in THF; 6. Solubility of Form VIII in acetone; 7. Solubility of Form IX in MTBE; 8. After stirring a clear solution of 60 mg of Form I in 1 mL of DMSO a suspension was obtained, and the solubility of the saturated solution was 6.13 mg / mL. 9. Solubility of Form X in 10. Solubility of Form XI in ethyl formate Phase equilibrium screen at 25, 40 and 50 °C Phase equilibration studies were designed to obtain information about the predominant crystalline form for phase identification. Based on its solubility in various solvent systems (Table 2), Form I was equilibrated in a typical solvent group at 251 °C (Table 3), 40 °C (Table 4a) and 501 °C (Table 4). After After equilibration, the supernatant was removed by centrifugation or the solid was filtered. XRPD used to study the morphology of crystalline forms in the solid state. Phase equilibration at 25 °C resulted in several polymorphic forms, including Form II (DCM, 9:1 DCM-MeOH), Form III (1,4-dioxane, centrifuged), Form IV ((1,4-dioxane, filtered), Form V (1,4- dioxane, crystalline solid from saturated solution), Form VI (MeOH), Form VII (MIBK), Form VIII (acetone and MEK), Form IX (MTBE), Form X (ethyl acetate), Form XI (ethyl formate), as well as partially amorphous or amorphous forms (DMF, DMSO and water). Phase equilibration at 40 °C resulted in Form II (DCM, DCM / MeOH). Phase equilibration at 50 °C resulted in the formation of two new polymorphic forms, including Form XII. (1,4-dioxane) and Form XIII (THF). Form VII was obtained from MIBK. Table 3 Crystal form for phase equilibration at 25 °C Solvent Solid form No data I MeCN I Chloroform I Dichloromethane II DCM / MeOH (9 / 1) II DMF Some crystals + amorphous 1,4-Dioxane III 1,4-Dioxane IV 1,4-Dioxane V Methanol VI 2-Methoxyethanol I MIBK VII Toluene I Hexane I THF I Acetone VIII n-BuOH I MTBE IX DMSO Amorphous + crystalline form EtOH I EtOAc X Ethyl formate XI Heptane I Isobutyl acetate I IPAc I 1-Propanol I IPA I IPA / water (4 / 1) I Water Amorphous MEK VIII Table 4 Crystal shape for phase equilibration at 50 °C Solvent Solid form No data I MeCN I 1,4-Dioxane XII MeOH I 2-Methoxyethanol I MIBK VII Toluene I Hexane I THF XIII Acetone I n-BuOH I MTBE I EtOH I EtOAc I Ethyl formate I Heptane I Isobutyl acetate I IPAc I 1-Propanol I IPA I IPA / water (4 / 1) I Water I MEK VIII-a Table 4a Crystal shape for phase equilibration at 40 °C Form I (mg) Solvent (ml) Result (Solid form) 100.2 DCM (0.5 mL) Liquid solution (Form II) 100.3 DCM / MeOH (9 / 1, 0.5 ml) Liquid solution (Form II) 100.4 DCM / MeOH / MTBE (0.47 / 0.03 / 0.7; 1.2 ml) 0.5 ml of DCM / MeOH was added to obtaining a clear solution when 25 °C, MTBE was added to obtain suspension (Form I). 100.1 DCM / MeOH (0.47 / 0.03, 0.5 mL) Liquid solution (Form II) 99.01 DCM / MeOH (0.47 / 0.03; 0.6 ml) Clear solution Evaporation grid at 25 and 50 °C Evaporation studies were conducted to determine the predominant crystalline form during uncontrolled precipitation. Experiments that did not result in the formation of solid particles (i.e., transparent thin films and oils), were not further investigated. XRPD was used to study the morphology solid crystalline forms of the samples after evaporation at 25 °C and 50 °C. The results are presented in Table 5 (25 °C) and Table 6 (50 °C). Table 5 Identification of the crystalline form by evaporation at 25 °C Solvent Solid form No data I MeCN I Chloroform I+IV Dichloromethane II-a DCM / MeOH (9 / 1) II-a DMF I DMF XIV 1,4-Dioxane Amorphous + crystalline form Methanol No data available 2-Methoxy-ethanol No data available MIBK No data Toluene No data available Hexane No data available THF I Acetone I n-BuOH I MTBE II-a DMSO XV EtOH I EtOAc I Ethyl formate I Heptane No data available Isobutyl acetate I IPAc I 1-Propanol I IPA I IPA / water (4 / 1) I Water No data MEK I N / A: No data. Clear ether solution or amount of precipitate too small for analysis by XRPD. Table 6 Identification of the crystalline form by evaporation at 50 °C Solvent Solid form No data I MeCN I Chloroform I Table 6 Identification of the crystalline form by evaporation at 50 °C Solvent Solid form DCM II DCM / MeOH (9 / 1) I DMF I 1,4-Dioxane I Methanol I 2-Methoxyethanol I MIBK I Toluene No data available Hexane No data available THF XVI Acetone I n-BuOH I MTBE No data available DMSO XVII EtOH I EtOAc I Ethyl formate I Heptane No data available Isobutyl acetate I IPAc I 1-Propanol I IPA I IPA / water (4 / 1) I Water No data MEK I N / A: No data. Clear ether solution or amount of precipitate too small for analysis by XRPD. Anti-solvent addition screen Saturated or nearly saturated solutions of Compound 1 were prepared by adding Form I to the solvent. antisolvent to induce precipitation. Heptane, hexane, MTBE, water, were chosen as antisolvents. MeOH, IPA, IPAc, ethyl acetate, and toluene. Experiments that did not produce solids upon addition antisolvent, were not further investigated. The addition of antisolvent resulted in several polymorphic forms, including Form XVIII. (chloroform / hexane, DCM / toluene and DCM-MeOH / toluene) and Form XIX (DCM / MeOH). Table 7 Adding antisolvent Solvent / Antisolvent Form MeCN (0.5 ml) / MTBE (4 ml) No data MeCN (0.5 ml) / water (4 ml) No data Chloroform (1 ml) 1 / Heptane (3 ml) I Chloroform (1 ml) 1 / Hexane (3 ml) XVIII Chloroform (1 mL) 1 / MTBE (3 mL) I DCM (0.5 ml)2 / Heptane (0.5 ml) I DCM (0.5 ml)2 / Hexane (0.5 ml) I DCM (0.5 mL) 2 / MTBE (1 mL) I DCM (0.5 ml) 2 / Toluene (4 ml) XVIII DCM (0.5 ml)2 / IPA (4 ml) I DCM (0.5 mL) 2 / MeOH (5 mL) XIX DCM-MeOH (9 / 1, 0.5 ml) 3 / Heptane (0.5 ml) I DCM-MeOH (9 / 1, 0.5 ml) 3 / Hexane (0.5 ml) I DCM-MeOH (9 / 1, 0.5 mL) 3 / MTBE (1.0 mL) I DCM-MeOH (9 / 1, 0.5 mL) 3 / Toluene (4.0 mL) XVIII DCM-MeOH (9 / 1, 0.5 mL) 3 / IPA (4.0 mL) I DCM-MeOH (9 / 1, 0.5 mL)3 / MeOH (3.0 mL) I DMF (saturated, 0.8 mL) / water (4 mL) I (basic) + amorphous 2-methoxyethanol (saturated, 0.7 ml) / water (4 ml) No data THF (saturated, 1.4 mL) / Heptane (3.6 mL) I Table 7 Adding antisolvent Solvent / Antisolvent Form THF (saturated, 1.5 mL) / Hexane (4 mL) I THF (saturated, 1.5 mL) / MTBE (4 mL) No data THF (saturated, 1.5 mL) / water (4 mL) No data Notes: N / A: no data, samples were too small for analysis by XRPD. 1. The concentration of Compound 1 in chloroform is 83.7 mg / mL. 2. The concentration of Compound 1 in DCM is 92 mg / mL. 3. The concentration of Compound 1 in DCM / MeOH (9:1) is 80 mg / mL. Refolding screen Saturated or nearly saturated solutions of Compound 1 were prepared in the solvents listed in Table 8, and added to a larger volume of miscible antisolvent (i.e. heptane, hexane, MTBE, water, toluene, MeOH, IPA and ethyl acetate). Experiments that did not produce solid particles when added to the antisolvent, in were not further investigated. Back addition resulted in several polymorphic forms, including Form XX (DCM / MTBE), Form XXI (DCM / toluene) and Form XXII (DCM-MeOH / MeOH) and Form IX (THF / MTBE). Table 8 Reverse assembly Solvent / Antisolvent Form MeCN / MTBE No data available MeCN / water No data available Chloroform (1 ml) 1 / Heptane (2 ml) I Chloroform (1 ml) 1 / Hexane (2.0 ml) I Chloroform (1 mL) 1 / MTBE (2.0 mL) I DCM (0.8 mL) 2 / Heptane (4.0 mL) I DCM (0.8 ml) 2 / Hexane (4.0 ml) I DCM (0.8 mL) 2 / MTBE (4.0 mL) XX DCM (0.8 mL) 2 / Toluene (4.0 mL) XXI DCM (0.8 mL)2 / IPA (4.0 mL) I DCM (0.8 mL) 2 / MeOH (4 mL) I DCM (0.8 mL) 2 / IPAc (4 mL) I DCM (0.8 mL) 2 / EtOAc (4 mL) I DCM-MeOH (9 / 1, 0.8 mL) 3 / Heptane (4.0 mL) I DCM-MeOH (9 / 1, 0.8 mL) 3 / Hexane (4.0 mL) I DCM-MeOH (9 / 1, 0.8 mL) 3 / MTBE (4.0 mL) I DCM-MeOH (9 / 1, 0.8 mL) 3 / Toluene (4.0 mL) I DCM-MeOH (9 / 1, 0.8 mL) 3 / IPA (4.0 mL) I DCM-MeOH (9 / 1, 0.8 mL)3 / MeOH (4.0 mL) XXII DMF (saturated, 0.8 mL) / water (4 mL) I (basic) + amorphous Sample 1922-120-7-2-8 was air-dried for 18 hours. I THF (saturated, 1.5 mL) / Heptane (4.0 mL) I THF (saturated, 1.5 mL) / Hexane (4.0 mL) I THF (saturated, 1.5 mL) / MTBE (4 mL) IX THF (saturated, 1.5 mL) / water (4 mL) No data Notes: N / A: no data, samples were too small for analysis by XRPD. 1. The concentration of Compound 1 in chloroform is 83.7 mg / mL. 2. The concentration of Compound 1 in DCM is 55 mg / mL. 3. The concentration of Compound 1 in DCM / MeOH (9:1) is 80 mg / mL. Cooling of a saturated solution Saturated solutions were quenched to close to -20 °C to induce precipitation of more high energy forms. Typical solvents were selected based on solubility data measured at 25 °C and 50 °C. The solvents studied and the crystalline form of the sample in each solvent are presented in Table 4. Upon rapid cooling of saturated solutions, Form XXIII (dichloromethane) was obtained. Table 9 Identification of crystal shape after quenching Solvent Form MeCN (filtered after cooling for 5 h at -20 °C.) I Chloroform No data available Dichloromethane (filtered after cooling for 3 h at -20 °C.) XXIII DCM / MeOH (9 / 1) No data available DMF No data 1,4-Dioxane No data 2-Methoxyethanol No data available THF (filtered after cooling for 3 h at -20 °C.) XIII-a Ethyl formate No data available IPA / water (4 / 1) No data N / A: ether - clear solution or amount of precipitate too small for analysis by XRPD. Example 7 Stability of crystalline forms. Crystallization of a saturated solution with heating and cooling cycles Saturated solutions were prepared at 30 °C or 50 °C and cooled slowly in a bath using The resulting suspension was then heated to 50 °C for 2 hours and then cooled to 5 °C over 2 hours. This process was repeated for 3 days, and the solid was filtered for further analysis. The results are shown in Table 10. Two new Forms were identified in the heating and cooling cycles (Table 10), including Form XXIV. (DMF) and Form XXV (DMSO). Table 10 Crystallization of a saturated solution with heating and cooling cycles Solvent Solid form MeCN I DMF XXIV 1,4-Dioxane XIII 2-Methoxyethanol I THF I Acetone VIII DMSO (an almost saturated solution was stirred and a suspension was obtained) XXV Ethyl formate I IPA / WATER (4 / 1) I Mixed samples of polymorphs of Compound 1 in IPA, EtOH and acetonitrile To assess the transformation of solid forms of Compound 1, competition experiments with suspensions were performed as follows. To a saturated solution of Form I in the solvent as indicated in Table 11, Form I (5 mg), then 5 mg of each of Forms II to Form XXVI. The suspension was stirred overnight, filtered and analyzed by XRPD. The results in Table 11 showed that Form I appears to be the most stable in IPA, ethanol and acetonitrile. Table 11 Mixed samples in different solvents (comparative suspensions) Solvent Solid form Iso-propanol (1.7 ml) Form I Ethanol (1.7 ml) Form I Acetonitrile (1.7 ml) Form I Mixed samples of polymorphs of Compound 1 in dichloromethane / methanol (9 / 1) A comparative experiment with a suspension was carried out in a dichloromethane / methanol mixture (9 / 1) according to procedure given in Table 12. The mixture of forms (Form I to Form XXVI) was converted to Form II via 15 minutes as shown by XRPD at various time points including 15 minutes, 1 hour, 18 hours and 3 days, indicating stable preparation of Form II. Form II is a stable polymorphic form in the solvent system. Table 12 Comparative experiment with suspension OP# Action Result 1 A cloudy solution of 97 mg of Form I in DCM / MeOH (9:1, 0.6 mL) was added to mixtures of 5 mg of each of the polymorphs of Compound 1 (Form I to Form XXVI). 2 Stir for 15 min, XRPD (Form II). Form II 3 Stir for 60 min, XRPD (Form II). Form II 4 Stir for 18 h, XRPD (Form II). Form II 5 Stir for 3 days, XRPD (Form II). Form II Conversion of Form II to Form I in various solvents Form II was converted to Form I in acetonitrile, ethanol and IPA, respectively, as described in Table 13. Table 13 Conversion of Form II to Form I in various solvents OP# Form II Diluent (mL) Result 1 18 mg MeCN (0.7) Form I 2 18 mg IPA (0.7 ) Form I 3 18 mg EtOH (0.7) Form I Example 8 Preparation and characterization of Form II About 3 mL of a saturated solution of Form I in DCM was evaporated in air without stirring at 50 ± 1 °C with obtaining a solid, which was characterized by XRPD, DSC and TGA as Form II. Table 14 XRPD peak data for Form II 2-Theta Height I% 6.8 3218 100 8.0 46 1.4 9.5 412 12.8 12.8 134 4.2 13.3 118 3.7 16.3 102 3.2 17.5 53 1.6 19.0 134 4.2 19.4 63 2 20.5 115 3.6 22.6 382 11.9 25.8 505 15.7 26.2 679 21.1 27.4 247 7.7 29.4 63 2 Form II exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 5 shows DSC thermogram of Form II. Fig. 6 shows a TGA thermogram of Form II. Example 9 Preparation and characterization of Form II-a About 3 mL of a saturated solution of Form I of Compound 1 in DCM was evaporated in air without stirring at 25 ± 1 °C to give a solid, which was characterized by XRPD, DSC and TGA as Form II-a. Table 15 XRPD peak data for Form II-a 2-Theta Height I% 4.6 43 2.5 6.9 1742 100 9.4 751 43.1 10.1 53 3 Table 15 XRPD peak data for Form II-a 2-Theta Height I% 12.9 197 11.3 13.3 246 14.1 14.5 115 6.6 15.1 131 7.5 16.3 391 22.4 17.5 265 15.2 19.0 221 12.7 19.9 449 25.8 22.0 196 11.3 22.5 577 33.1 24.3 116 6.7 26.1 977 56.1 27.4 260 14.9 30.6 106 6.1 36.6 75 4.3 Form II-a shows a DSC thermogram with an endotherm peak at around 275 °C. Fig. 8 Fig. 9 shows a DSC thermogram of Form IIa. Fig. 9 shows a TGA thermogram of Form IIa. Example 10 Preparation and characterization of Form III To about 5 ml of a cloudy solution of Form I of Compound 1 prepared in 1,4-dioxane was added about 20 mg Compound 1, Form I with subsequent stirring at 25 ± 1 °C for 2 days, from which the supernatant was removed The solid was analyzed by XRPD as Form III. Table 16 XRPD peak data for Form III 2-Theta Height I% 3.5 532 50.1 6.7 151 14.2 7.4 37 3.5 8.5 203 19.1 9.3 56 5.3 9.9 113 10.7 10.7 109 10.3 11.3 38 3.6 13.9 627 59.1 15.0 388 36.6 15.3 493 46.5 16.0 170 16 16.8 366 34.5 18.6 1061 100 19.3 209 19.7 20.5 104 9.8 21.5 478 45.1 22.1 98 9.2 22.9 253 23.8 23.4 193 18.2 24.2 392 36.9 25.2 58 5.5 25.9 257 24.2 26.5 107 10.1 27.6 71 6.7 28.2 115 10.8 29.3 136 12.8 30.2 96 9 30.9 60 5.7 Table 16 XRPD peak data for Form III 2-Theta Height I% 31.2 62 5.8 32.5 60 5.7 33.1 73 6.9 34.4 54 5.1 36.1 60 5.7 41.0 70 6.6 42.7 42 4 43.2 36 3.4 Form III shows a DSC thermogram having endotherm peaks at temperatures around 101 ºC, around 204 ºC and about 276 ºC. Fig. 11 shows the DSC thermogram of Form III. Fig. 12 shows the TGA thermogram of Form III. Example 11 Preparation and characterization of Form IV To about 5 mL of saturated or opaque solutions of Form I of Compound 1 prepared in 1,4-dioxane, about 20 mg of Compound 1, Form I was added followed by stirring at 25 ± 1 °C for 6 days, which filtered and analyzed by XRPD as Form IV. Table 17 XRPD peak data for Form IV 2-Theta Height I% 5.8 83 2.2 10.1 1486 39.4 11.5 374 9.9 13.0 1078 28.6 14.0 2326 61.6 14.8 426 11.3 15.6 1027 27.2 17.3 928 24.6 18.4 2315 61.3 20.2 567 15 21.0 162 4.3 21.4 523 13.9 22.2 3642 96.5 22.7 1261 33.4 23.5 225 6 24.3 3775 100 26.4 2703 71.6 26.8 1150 30.5 28.0 515 13.6 29.3 140 3.7 30.0 322 8.5 30.5 471 12.5 32.1 233 6.2 32.7 326 8.6 34.0 726 19.2 34.6 218 5.8 36.1 305 8.1 37.9 506 13.4 39.6 323 8.6 40.6 106 2.8 41.4 81 2.1 43.6 183 4.8 44.1 126 3.3 Form IV shows a DSC thermogram having endotherm peaks at temperatures around 109 ºC, around 203 ºC and about 278 ºC. Fig. 14 shows a DSC thermogram of Form IV. Fig. 15 shows a TGA thermogram of Form IV. Example 12 Preparation and characterization of Form V A saturated solution of Form I of Compound 1 was placed in a fume hood for more than 30 days to obtain crystalline solid, which was filtered and analyzed by XRPD as Form V. Table 18 XRPD peak data for Form V 2-Theta Height I% 6.7 833 1.3 7.4 64827 100 9.5 70 0.1 10.9 518 0.8 11.5 823 1.3 12.4 104 0.2 13.8 761 1.2 14.8 17728 27.3 15.3 750 1.2 16.1 243 0.4 17.0 268 0.4 17.4 850 1.3 18.2 140 0.2 19.2 226 0.3 20.2 219 0.3 20.5 840 1.3 21.3 2445 3.8 22.0 1989 3.1 22.3 11335 17.5 23.2 478 0.7 23.9 313 0.5 24.2 148 0.2 25.9 331 0.5 26.3 217 0.3 26.7 649 1 27.2 195 0.3 28.1 331 0.5 29.2 690 1.1 30.0 88 0.1 30.4 94 0.1 31.6 137 0.2 33.1 219 0.3 34.4 87 0.1 35.2 91 0.1 36.8 184 0.3 37.6 829 1.3 42.9 219 0.3 Form V shows a DSC thermogram having endotherm peaks at temperatures around 91 ºC, around 203 ºC and about 276 ºC. Fig. 17 shows the DSC thermogram of Form V. Example 13 Preparation and characterization of Form VI To about 5 ml of saturated or cloudy solutions of Form I of Compound 1 prepared in methanol was added about 20 mg of Compound 1, Form I, followed by stirring at 25 ± 1 °C for 3 days, which was filtered and analyzed by XRPD as Form VI. Table 19 XRPD peak data for Form VI 2-Theta Height I% 7.8 102 10.3 9.1 757 76.6 Table 19 XRPD peak data for Form VI 2-Theta Height I% 9.5 388 39.3 10.2 230 23.3 11.4 279 28.2 12.1 278 28.1 12.6 106 10.7 13.4 188 19 14.4 464 47 15.9 234 23.7 17.6 514 52 18.6 458 46.4 19.2 324 32.8 19.9 443 44.8 20.4 77 7.8 21.0 75 7.6 22.3 716 72.5 22.7 265 26.8 23.4 66 6.7 24.1 83 8.4 25.4 536 54.3 26.2 988 100 27.5 207 21 29.1 136 13.8 31.1 67 6.8 36.6 64 6.5 Form VI exhibits a DSC thermogram having an endotherm peak at about 275 °C. Fig. 19 shows DSC thermogram of Compound 1, Form VI. Fig. 20 shows a TGA thermogram of Compound 1, Form VI. Example 14 Preparation and characterization of Form VII about 5 ml of saturated or opaque solutions of Form I of Compound 1 prepared in methyl isobutyl ketone, about 20 mg of Compound 1, Form I was added followed by stirring at 25 ± 1 °C for 3 days, which filtered and analyzed by XRPD as Form VII. Table 20 XRPD peak data for Form VII 2-Theta Height I% 8.2 116 15.1 9.8 768 100 12.3 96 12.5 15.4 519 67.6 16.0 84 10.9 16.2 132 17.2 17.4 93 12.1 17.9 223 29 18.8 375 48.8 19.6 554 72.1 20.1 357 46.5 21.1 266 34.6 22.3 191 24.9 22.8 127 16.5 23.1 130 16.9 23.7 112 14.6 24.3 236 30.7 25.5 139 18.1 26.7 74 9.6 27.6 48 6.3 Table 20 XRPD peak data for Form VII 2-Theta Height I% 29.3 62 8.1 29.7 67 8.7 30.5 40 5.2 32.1 37 4.8 35.9 32 4.2 38.6 58 7.6 42.1 56 7.3 Figure VII shows a DSC thermogram having endotherm peaks at temperatures around 88 ºC, around 201 ºC and about 276 ºC. Fig. 22 shows a DSC thermogram of Form VII. Fig. 23 shows a TGA thermogram of Form VII. Example 15 Preparation and characterization of Form VIII To about 5 ml of cloudy solutions of Form I of Compound 1 obtained in acetone was added about 20 mg of Compound 1, Form I, followed by stirring at 25 ± 1 °C for 3 days, which were filtered and analyzed using XRPD as Form VIII. Table 21 XRPD peak data for Form VIII 2-Theta Height I% 9.1 953 39.6 9.9 196 8.1 15.2 409 17 16.7 650 27 18.2 2409 100 18.6 589 24.4 20.2 2079 86.3 21.4 196 8.1 22.5 768 31.9 23.8 64 2.7 24.6 701 29.1 25.4 83 3.4 26.8 376 15.6 27.5 123 5.1 29.8 376 15.6 30.6 64 2.7 31.4 239 9.9 32.0 61 2.5 34.8 87 3.6 35.9 162 6.7 40.0 50 2.1 Form VIII exhibits a DSC thermogram having endotherm peaks at temperatures around 201 °C and around 277 °C. Fig. 25 shows a DSC thermogram of Compound 1, Form VIII. Fig. 26 shows a TGA thermogram of Compound 1, Form VIII. VIII. Example 16 Preparation and characterization of Form VIII-a To about 5 ml of cloudy solutions of Form I of Compound 1 obtained in methyl ethyl ketone was added about 30 mg Compounds 1, Form I with subsequent stirring at 50 ± 1 °C for 2 days, which were filtered and analyzed by by XRPD as Form VIII-a. Table 22 XRPD peak data for Form VIII-a 2-Theta Height I% 7.7 104 1.7 8.9 1887 30.7 9.7 311 5.1 14.6 346 5.6 15.0 492 8 15.5 230 3.7 16.2 1484 24.1 18.0 6145 100 18.4 1644 26.8 19.3 291 4.7 19.9 6032 98.2 21.1 1654 26.9 22.0 2276 37 22.9 144 2.3 23.5 804 13.1 24.1 1923 31.3 24.3 1489 24.2 25.3 429 7 25.8 202 3.3 26.3 846 13.8 27.1 516 8.4 28.0 144 2.3 28.5 100 1.6 29.1 317 5.2 29.5 1196 19.5 30.2 84 1.4 30.9 570 9.3 31.3 541 8.8 31.6 271 4.4 32.1 90 1.5 32.6 439 7.1 34.1 187 3 35.5 643 10.5 36.1 172 2.8 36.9 143 2.3 38.0 187 3 39.4 276 4.5 40.4 82 1.3 41.0 116 1.9 42.1 181 2.9 42.7 92 1.5 Example 17 Obtaining and characterizing Form IX To about 5 ml of cloudy solutions of Form I of Compound 1 obtained in MTBE was added about 20 mg of Compound 1, Form I, followed by stirring at 25 ± 1 °C for 3 days, which were filtered and analyzed using XRPD as Form IX. Table 23 XRPD peak data for Form IX 2-Theta Height I% 8.5 424 31 9.2 982 71.8 12.1 521 38.1 13.9 304 22.2 14.6 813 59.5 15.6 692 50.6 16.8 361 26.4 18.6 893 65.3 19.3 413 30.2 22.4 1188 86.9 22.9 1367 100 Table 23 XRPD peak data for Form IX 2-Theta Height I% 24.6 528 38.6 26.1 107 7.8 29.4 259 18.9 30.1 98 7.2 31.4 339 24.8 32.8 62 4.5 35.7 67 4.9 Form IX exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and around 276 ºC. Fig. 29 shows a DSC thermogram of Form IX. Fig. 30 shows a TGA thermogram of Form IX. Example 18 Preparation and characterization of Form X To about 5 ml of cloudy solutions of Form I of Compound 1 prepared in ethyl acetate was added about 20 mg Compounds 1, Form I with subsequent stirring at 25 ± 1 °C for 3 days, which were filtered and analyzed by using XRPD as Form X. Table 24 XRPD peak data for Form X 2-Theta Height I% 4.9 113 9.6 10.1 971 82.7 11.3 167 14.2 12.3 95 8.1 13.7 63 5.4 14.6 696 59.3 15.4 603 51.4 15.7 1174 100 17.2 186 15.8 18.1 974 83 19.5 245 20.9 20.0 637 54.3 22.3 912 77.7 23.8 234 19.9 25.3 370 31.5 25.7 495 42.2 26.3 579 49.3 30.3 56 4.8 30.9 56 4.8 32.0 128 10.9 34.4 101 8.6 37.8 46 3.9 Form X exhibits a DSC thermogram that has endotherm peaks at temperatures around 202 °C and around 276 °C. Fig. 32 shows a DSC thermogram of Form X. Fig. 33 shows a TGA thermogram of Form X. Example 19 Preparation and characterization of Form XI To about 5 ml of cloudy solutions of Form I of Compound 1 prepared in ethyl formate was added about 20 mg Compounds 1, Form I with subsequent stirring at 25 ± 1 °C for 3 days, which were filtered and analyzed by by XRPD as Form XI. Table 25 XRPD peak data for Form XI 2-Theta Height I% 3.9 381 42.9 4.3 231 26 7.5 548 61.6 8.6 70 7.9 11.8 70 7.9 13.0 889 100 13.7 167 18.8 15.0 156 17.5 16.5 104 11.7 17.3 377 42.4 19.1 207 23.3 19.9 340 38.2 21.4 557 62.7 22.2 117 13.2 22.8 442 49.7 23.7 86 9.7 24.6 68 7.6 25.2 646 72.7 26.2 418 47 26.9 255 28.7 27.7 178 20 29.4 131 14.7 30.3 115 12.9 31.0 83 9.3 31.5 66 7.4 33.3 125 14.1 33.9 67 7.5 35.7 78 8.8 37.4 54 6.1 40.3 59 6.6 42.6 56 6.3 Form XI exhibits a DSC thermogram having endotherm peaks at temperatures around 141 °C and around 279 °C. Fig. 35 shows a DSC thermogram of Form XI. Fig. 36 shows a TGA thermogram of Form XI. Example 20 Preparation and characterization of Form XII To about 5 ml of opaque solutions of Form I of Compound 1 prepared in 1,4-dioxane was added about 30 mg Compounds 1, Form I with subsequent stirring at 50 ± 1 °C for 2 days, which were filtered and analyzed by by XRPD as Form XII. Table 26 XRPD peak data for Form XII 2-Theta Height I% 3.9 151 12.4 7.5 161 13.3 9.8 199 16.4 11.5 112 9.2 12.9 233 19.2 14.1 721 59.4 14.9 87 7.2 17.3 391 32.2 18.3 797 65.7 20.5 128 10.6 22.1 1213 100 22.7 719 59.3 23.6 140 11.5 24.3 408 33.6 26.3 844 69.6 26.9 178 14.7 28.3 69 5.7 30.5 138 11.4 32.6 71 5.9 Table 26 XRPD peak data for Form XII 2-Theta Height I% 34.1 154 12.7 36.3 89 7.3 37.8 119 9.8 39.5 70 5.8 Form XII exhibits a DSC thermogram having endotherm peaks at temperatures around 105 °C and around 276 °C. Fig. 38 shows a DSC thermogram of Form XII. Fig. 39 shows a TGA thermogram of Form XII. Example 21 Preparation and characterization of Form XIII To about 5 ml of cloudy solutions of Form I of Compound 1 prepared in THF was added about 30 mg of Compound 1, Form I with subsequent stirring at 50 ± 1 °C for 2 days, which were filtered and analyzed using XRPD as Form XIII. Table 27 XRPD peak data for Form XIII 2-Theta Height I% 4.0 162 11.3 7.7 1438 100 10.9 166 11.5 11.6 175 12.2 14.2 302 21 15.2 629 43.7 15.7 1150 80 16.6 78 5.4 17.8 368 25.6 19.0 424 29.5 21.9 922 64.1 22.2 436 30.3 23.1 1034 71.9 25.6 595 41.4 26.1 1333 92.7 31.6 89 6.2 34.8 80 5.6 37.0 143 9.9 Form XIII exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 41 shows a DSC thermogram of Form XIII. Fig. 42 shows a TGA thermogram of Form XIII. Example 22 Preparation and characterization of Form XIII-a About 10 mL of a saturated solution of Form I of Compound 1 in THF, prepared at 35 °C, was quenched to a temperature of about -20 °C and kept at that temperature for 3 hours to obtain a fine suspension, which was filtered and analyzed by XRPD as Form XIII-a. Table 28 XRPD peak data for Form XIII-a 2-Theta Height I% 3.6 132 4.8 6.9 1047 38.2 7.7 2739 100 8.3 289 10.6 9.5 156 5.7 10.4 760 27.7 10.9 208 7.6 11.4 169 6.2 12.1 259 9.5 Table 28 XRPD peak data for Form XIII-a 2-Theta Height I% 14.4 241 8.8 15.2 864 31.5 17.3 223 8.1 18.6 425 15.5 19.7 565 20.6 20.1 177 6.5 20.6 113 4.1 21.5 687 25.1 22.3 297 10.8 22.6 562 20.5 23.0 459 16.8 25.5 541 19.8 26.2 942 34.4 27.5 233 8.5 28.3 160 5.8 31.2 88 3.2 Form XIII-a exhibits a DSC thermogram with endotherm peaks at temperatures around 75 ºC and around 276 ºC. Fig. 44 shows the DSC thermogram of Form XIIIa. Example 23 Preparation and characterization of Form XIV Approximately 2.0 mL of a saturated solution of Form I of Compound 1 in DMF was evaporated in air without stirring. at 25 ± 1 °C and the resulting solid was analyzed by XRPD as Form XV. Table 29 XRPD peak data for Form XIV 2-Theta Height I% 7.0 722 84.5 8.6 175 20.5 9.2 179 21 9.6 249 29.2 10.3 241 28.2 11.5 218 25.5 12.2 173 20.3 12.8 79 9.3 13.5 62 7.3 14.1 854 100 14.5 289 33.8 16.1 488 57.1 16.8 55 6.4 17.6 246 28.8 18.3 240 28.1 18.7 198 23.2 19.3 283 33.1 20.0 805 94.3 20.9 136 15.9 22.0 661 77.4 22.3 407 47.7 22.9 339 39.7 23.6 123 14.4 24.0 70 8.2 25.8 774 90.6 26.2 365 42.7 27.5 97 11.4 29.0 106 12.4 Table 29 XRPD peak data for Form XIV 2-Theta Height I% 30.2 66 7.7 33.2 45 5.3 34.7 90 10.5 36.7 47 5.5 Form XIV shows a DSC thermogram having endotherm peaks at temperatures around 78 °C, around 118 °C and about 277 °C. Fig. 46 shows a DSC thermogram of Form XIV. Fig. 47 shows a TGA thermogram of Form XIV. Example 24 Preparation and characterization of Form XV Approximately 2.0 mL of a saturated solution of Form I of Compound 1 in DMSO was evaporated in air without stirring. at 25 ± 1 °C and the resulting solid was analyzed by XRPD as Form XV. Table 30 XRPD peak data for Form XV 2-Theta Height I% 3.9 120 8.1 8.9 172 11.6 9.2 419 28.2 14.3 59 4 15.2 59 4 15.6 279 18.8 16.6 183 12.3 18.5 1485 100 19.8 74 5 20.3 294 19.8 21.1 122 8.2 21.4 470 31.6 21.8 289 19.5 22.4 1467 98.8 23.2 86 5.8 23.8 133 9 24.5 221 14.9 24.9 220 14.8 25.5 129 8.7 25.8 218 14.7 27.2 136 9.2 28.0 97 6.5 29.4 129 8.7 30.0 320 21.5 31.1 339 22.8 31.9 267 18 32.4 208 14 33.2 342 23 33.7 135 9.1 35.1 93 6.3 36.0 55 3.7 36.7 109 7.3 37.2 70 4.7 38.7 83 5.6 40.0 56 3.8 42.8 160 10.8 43.1 126 8.5 Form XV exhibits a DSC thermogram having endotherm peaks at temperatures around 119 °C and around 276 °C. Fig. 49 shows a DSC thermogram of Form XV. Fig. 50 shows a TGA thermogram of Form XV. Example 25 Preparation and characterization of Form XVI Approximately 4.0 mL of a saturated solution of Form I of Compound 1 in THF was evaporated in air without stirring. at 50 ± 1 °C and the resulting solid was analyzed by XRPD as Form XVI. Table 31 XRPD peak data for Form XVI 2-Theta Height I% 6.8 907 68.7 9.4 327 24.8 10.1 170 12.9 10.7 440 33.3 11.4 169 12.8 12.1 143 10.8 12.8 66 5 13.3 62 4.7 14.0 758 57.4 14.9 1320 100 16.0 364 27.6 17.5 277 21 18.2 150 11.4 18.5 209 15.8 19.2 222 16.8 19.9 951 72 20.9 218 16.5 22.2 691 52.3 22.7 168 12.7 23.5 335 25.4 24.5 276 20.9 25.4 338 25.6 25.7 573 43.4 26.1 529 40.1 27.3 241 18.3 29.0 72 5.5 30.2 603 45.7 32.5 49 3.7 36.6 168 12.7 Form XVI exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 52 shows a DSC thermogram of Form XVI. Fig. 53 shows a TGA thermogram of Form XVI. Example 26 Preparation and characterization of Form XVII Approximately 2.0 mL of a saturated solution of Form I of Compound 1 in DMSO was evaporated in air without stirring. at 50 ± 1 °C and the resulting solid was analyzed by XRPD as Form XVII. Table 32 XRPD peak data for Form XVII 2-Theta Height I% 3.8 135 0.6 7.9 96 0.4 8.8 52 0.2 10.1 57 0.3 14.1 86 0.4 15.7 3210 14.8 15.9 179 0.8 16.2 178 0.8 16.5 240 1.1 18.1 2253 10.4 18.4 21691 100 18.8 292 1.3 20.1 304 1.4 21.0 52 0.2 21.7 817 3.8 22.3 117 0.5 24.0 153 0.7 24.5 736 3.4 24.8 56 0.3 25.6 147 0.7 28.4 107 0.5 29.3 339 1.6 29.9 148 0.7 30.1 95 0.4 31.7 81 0.4 32.2 3360 15.5 32.5 259 1.2 33.0 61 0.3 33.5 75 0.3 34.9 270 1.2 35.8 88 0.4 36.4 59 0.3 37.0 174 0.8 38.7 286 1.3 39.7 276 1.3 40.7 185 0.9 41.9 242 1.1 43.2 46 0.2 Form XVII exhibits a DSC thermogram having endotherm peaks at temperatures around 119 °C and around 276 °C. Fig. 55 shows a DSC thermogram of Form XVII. Fig. 56 shows a TGA thermogram of Form XVII. Example 27 Preparation and characterization of Form XVIII To about 1 ml of a saturated solution of Form I of Compound 1 prepared in chloroform was added 3.0 ml hexane to obtain a suspension, which was filtered and analyzed by XRPD as Form XVIII. Table 33 XRPD peak data for Form XVIII 2-Theta Height I% 6.8 958 17.2 9.4 5580 100 10.3 985 17.7 11.9 1397 25 12.6 792 14.2 13.4 798 14.3 13.9 389 7 14.6 3188 57.1 16.2 1820 32.6 17.5 1759 31.5 18.3 939 16.8 18.8 3352 60.1 19.7 288 5.2 20.8 744 13.3 21.4 545 9.8 22.3 2328 41.7 22.7 3594 64.4 23.6 360 6.5 24.0 557 10 24.6 73 1.3 25.4 1582 28.4 26.0 506 9.1 Table 33 XRPD peak data for Form XVIII 2-Theta Height I% 26.6 1676 30 27.0 101 1.8 27.9 219 3.9 28.5 303 5.4 29.4 671 12 29.9 447 8 30.8 626 11.2 31.5 136 2.4 33.4 157 2.8 33.7 232 4.2 34.4 116 2.1 34.8 77 1.4 36.1 594 10.6 36.8 108 1.9 38.0 154 2.8 38.2 269 4.8 40.4 141 2.5 40.9 81 1.5 41.4 91 1.6 42.0 77 1.4 42.6 91 1.6 43.0 98 1.8 44.0 126 2.3 Form XVIII exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 58 shows a DSC thermogram of Form XVIII. Fig. 59 shows a TGA thermogram of Form XVIII. Example 28 Preparation and characterization of Form XIX To about 0.5 mL of a saturated solution of Form I of Compound 1 prepared in DCM was added 5.0 mL of methanol with obtaining a suspension, which was filtered and analyzed by XRPD as Form XIX. Table 34 XRPD peak data for Form XIX 2-Theta Height I% 3.9 188 4.2 4.7 44 1 6.7 986 22.1 8.5 83 1.9 9.4 459 10.3 10.0 1260 28.3 11.3 189 4.2 12.0 151 3.4 12.6 106 2.4 13.6 593 13.3 14.3 257 5.8 14.9 232 5.2 15.7 106 2.4 16.7 205 4.6 17.4 971 21.8 18.0 4459 100 19.4 186 4.2 20.2 1645 36.9 20.5 420 9.4 21.4 1036 23.2 22.1 980 22 Table 34 XRPD peak data for Form XIX 2-Theta Height I% 22.8 252 5.7 23.4 161 3.6 24.0 186 4.2 24.8 397 8.9 25.0 682 15.3 26.0 263 5.9 26.9 357 8 27.3 105 2.4 28.1 77 1.7 28.6 216 4.8 30.2 207 4.6 31.3 188 4.2 31.7 362 8.1 33.8 108 2.4 34.6 53 1.2 35.7 56 1.3 37.3 91 2 39.0 112 2.5 40.1 67 1.5 41.8 63 1.4 42.2 57 1.3 Form XIX exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 61 shows a DSC thermogram of Form XIX. Fig. 62 shows a TGA thermogram of Form XIX. Example 29 Preparation and characterization of Form XX To 4.0 mL of MTBE was added 0.8 mL of a saturated solution of Form I of Compound 1 prepared in dichloromethane, with obtaining a suspension, which was filtered and analyzed by XRPD as XX. Table 35 XRPD peak data for Form XX 2-Theta Height I% 3.6 121 1.4 9.2 8874 100 12.1 349 3.9 13.9 395 4.5 14.7 3145 35.4 15.6 1104 12.4 16.9 507 5.7 18.6 2044 23 19.4 187 2.1 21.1 84 0.9 22.3 1340 15.1 22.5 2189 24.7 23.0 5723 64.5 24.7 1414 15.9 25.5 232 2.6 26.1 140 1.6 28.3 66 0.7 29.5 1207 13.6 30.1 146 1.6 31.4 456 5.1 32.0 219 2.5 32.8 326 3.7 34.8 56 0.6 Table 35 XRPD peak data for Form XX 2-Theta Height I% 36.0 185 2.1 37.1 121 1.4 38.2 113 1.3 38.8 63 0.7 41.9 265 3 Form XX shows a DSC thermogram having endotherm peaks at temperatures around 108 ºC, around 202 ºC and about 277 ºC. Fig. 64 shows a DSC thermogram of Form XX. Fig. 65 shows a TGA thermogram of Form XX. Example 30 Preparation and characterization of Form XXI To 4.0 mL of toluene was added 0.8 mL of a saturated solution of Form I of Compound 1 prepared in a mixture of dichloromethane, to obtain a suspension, which was filtered and analyzed by XRPD as XXI. Table 36 XRPD peak data for Form XXI 2-Theta Height I% 3.9 150 5.9 6.5 158 6.3 6.9 116 4.6 9.2 81 3.2 10.3 2523 100 11.3 130 5.2 12.2 187 7.4 13.2 319 12.6 14.2 1367 54.2 17.5 439 17.4 19.4 379 15 20.7 1031 40.9 21.5 112 4.4 22.6 1331 52.8 24.2 2072 82.1 26.5 149 5.9 27.1 458 18.2 28.5 147 5.8 33.3 57 2.3 35.8 77 3.1 36.8 125 5 42.9 102 4 Form XXI exhibits a DSC thermogram having endotherm peaks at temperatures around 201 ºC and around 277 ºC. Fig. 67 shows a DSC thermogram of Compound 1, Form XXI. Example 31 Preparation and characterization of Form XXII To 4.0 mL of methanol was added 0.8 mL of a saturated solution of Form I of Compound 1 prepared in a mixture dichloromethane and methanol (9:1), to obtain a suspension, which was filtered and analyzed by XRPD as XXII. Table 37 XRPD peak data for Form XXII 2-Theta Height I% 3.5 118 6.1 4.7 70 3.6 6.8 1950 100 7.9 59 3 9.4 861 44.2 Table 37 XRPD peak data for Form XXII 2-Theta Height I% 10.1 553 28.4 11.4 533 27.3 12.1 407 20.9 12.6 152 7.8 13.3 230 11.8 14.3 571 29.3 15.8 301 15.4 17.5 620 31.8 18.0 229 11.7 18.5 620 31.8 19.2 399 20.5 19.8 521 26.7 20.3 154 7.9 20.9 97 5 22.2 874 44.8 22.6 291 14.9 23.5 71 3.6 24.0 93 4.8 25.3 599 30.7 26.1 1022 52.4 27.4 214 11 29.0 159 8.2 30.9 79 4.1 31.6 51 2.6 34.5 47 2.4 36.4 64 3.3 39.5 46 2.4 40.0 50 2.6 Form XXII exhibits a DSC thermogram having an endotherm peak at about 276 °C. Fig. 69 shows a DSC thermogram of Compound 1, Form XXII. Example 32 Preparation and characterization of Form XXIII about 2 ml of a saturated solution of Form I of Compound 1 in DCM was quenched to a temperature of about -20 °C and was kept at temperature for 3 hours to obtain a suspension, which was filtered and analyzed by by XRPD in the form of Form XXIII. Table 38 XRPD peak data for Form XXIII 2-Theta Height I% 6.7 251 2.9 8.7 59 0.7 12.0 6208 72.1 12.7 7944 92.2 13.2 817 9.5 14.3 714 8.3 16.4 360 4.2 17.3 214 2.5 18.9 1521 17.7 19.6 923 10.7 21.0 3317 38.5 22.7 520 6 24.9 2536 29.4 25.6 8613 100 26.5 311 3.6 28.7 293 3.4 Table 38 XRPD peak data for Form XXIII 2-Theta Height I% 29.6 78 0.9 30.7 193 2.2 31.1 187 2.2 34.5 72 0.8 35.4 90 1 36.4 150 1.7 37.6 145 1.7 39.9 84 1 42.8 104 1.2 43.7 217 2.5 Form XXIII exhibits a DSC thermogram having an endotherm peak at about 277 °C. Fig. 71 shows a DSC thermogram of Form XXIII. Fig. 72 shows a TGA thermogram of Form XXIII. Example 33 Preparation and characterization of Form XXIV Approximately 3 mL of saturated solutions of Form I of Compound 1 in DMF were obtained at temperatures between 30 °C and 50 °C. and slowly cooled to 25 °C in a bath using a programmed circulating bath. The resulting solution heated to 50 °C for 2 hours, then cooled to 5 °C for 2 hours. This process was repeated for 76 hours, and the solid was isolated by filtration and analyzed by XRPD as Form XXIV. Table 39 XRPD peak data for Form XXIV 2-Theta Height I% 8.6 1794 38.4 9.7 659 14.1 11.5 97 2.1 13.8 325 7 15.6 4674 100 16.1 102 2.2 16.5 95 2 17.4 566 12.1 18.1 1472 31.5 18.6 95 2 19.4 1000 21.4 20.4 2789 59.7 21.1 545 11.7 22.2 1511 32.3 22.9 3619 77.4 23.6 524 11.2 24.2 1442 30.9 24.9 488 10.4 25.5 1577 33.7 26.0 1382 29.6 27.5 916 19.6 27.9 1312 28.1 28.7 874 18.7 29.1 179 3.8 29.8 658 14.1 30.7 359 7.7 31.0 402 8.6 32.8 153 3.3 33.5 435 9.3 34.3 464 9.9 35.3 490 10.5 36.0 361 7.7 36.4 237 5.1 Table 39 XRPD peak data for Form XXIV 2-Theta Height I% 38.1 82 1.8 38.9 189 4 39.3 218 4.7 40.3 141 3 40.6 230 4.9 41.4 225 4.8 43.1 248 5.3 43.9 210 4.5 44.2 131 2.8 Form XXIV exhibits a DSC thermogram having an endotherm peak at about 277 °C. Fig. 74 shows a DSC thermogram of Form XXIV. Fig. 75 shows a TGA thermogram of Form XXIV. Example 34 Preparation and characterization of Form XXV Approximately 2 mL of saturated solutions of Form I of Compound 1 in DMSO were obtained at temperatures ranging from 30 °C to 50 °C and slowly cooled to 25 °C in a bath using a programmed circulating bath. The formed The solution was heated to 50 °C for 2 hours, then cooled to 5 °C for 2 hours. This process was repeated for 76 hours, and the solid was isolated by filtration and analyzed by XRPD as Form XXV. Table 40 XRPD peak data for Form XXV 2-Theta Height I% 16.6 190 22.7 18.4 837 100 20.4 374 44.7 21.7 181 21.6 22.4 572 68.3 24.4 423 50.5 24.9 300 35.8 25.7 149 17.8 26.6 60 7.2 27.1 166 19.8 29.9 331 39.5 31.1 142 17 31.9 162 19.4 32.4 108 12.9 33.3 130 15.5 33.8 67 8 35.2 67 8 35.8 203 24.3 36.8 108 12.9 38.9 202 24.1 41.9 116 13.9 42.7 157 18.8 43.1 105 12.5 Form XXV exhibits a DSC thermogram having endotherm peaks at temperatures around 113 °C and around 276 °C. Fig. 77 shows the DSC thermogram of Form XXV. Example 35 Preparation and characterization of Form XXVI Form V was dried in vacuum at 50 °C for 3 days to give Form XXVI. Table 41 XRPD peak data for Form XXVI 2-Theta Height I% 6.8 1089 98.6 9.4 198 17.9 9.9 1104 100 10.6 74 6.7 12.7 66 6 13.3 49 4.4 17.5 50 4.5 19.9 246 22.3 21.8 51 4.6 22.5 64 5.8 25.7 115 10.4 26.1 216 19.6 27.4 112 10.1 30.2 33 3 39.9 53 4.8 Example 36 Preparation and characterization of amorphous Compound 1 To about 5 ml of cloudy solutions of Form I of Compound 1 prepared in water was added about 30 mg of Compound 1, Form I with subsequent stirring at 25 ± 1 °C for 2 days, which was filtered and determined to be amorphous by using XRPD. Example A FGFR enzymatic assay The inhibitory efficacy of Compound 1 was measured in an enzyme assay that measures phosphorylation peptide using FRET measurements to detect product formation. Compound 1 was serially diluted in DMSO and 0.5 μl were transferred to the wells of a 384-well plate. For FGFR3, 10 μl of enzyme was added to the plate. FGFR3 (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) and pre-incubated for 5-10 minutes. Appropriate controls (blank enzyme and enzyme without inhibitor) were included in the plate. The assay was initiated by adding 10 μl of a solution containing biotinylated peptide substrate EQEDEPEGDYFEWLE (SEQ ID NO:1) and ATP (final concentrations 500 nM and 140 µM respectively) in assay buffer. The plate was incubated at 25 °C for 1 hour. The reactions were terminated by adding 10 μl / well of quenching solution (50 mM Tris, 150 mM NaCl, 0.5 mg / ml BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-streptavidin). Tablet were allowed to equilibrate for ~1 hour before scanning the wells on a PheraStar plate reader (BMG Labtech). FGFR1 and FGFR2 were measured under equivalent conditions with subsequent changes in enzyme and ATP concentrations: FGFR1, 0.02 nM and 210 μM, respectively, and FGFR2, 0.01 nM and 100 μM, respectively. Enzymes were purchased from Millipore or Invitrogen. GraphPad prism3 was used for data analysis. IC50 values were obtained by fitting the data to the sigmoidal dose-response equation with variable slope. Y = Bottom + (Top-Bottom) / (1 + 10 ^ ((LogIC50-X) * HillSlope)), where X is the logarithm of the concentration and Y is the response. Compounds with an IC50 of 1 μM or less are considered active. Compound 1 of the invention has been found to be inhibitors of one or more of FGFR1, FGFR2 and FGFR3 according to the above analysis. IC50 data are given below in Table 1. The symbol “+” indicates an IC50 less than 100 nM, and the symbol “++” indicates an IC50 of 100 to 500 nM. Table 42 FGFR1 IC50 (nM) FGFR2 IC50 (nM) FGFR3 IC50 (nM) Compound 1 + + + Example B FGFR cell proliferation / survival assays The ability of exemplary compounds to inhibit the growth of cells that depend on FGFR signaling for survival, measured using viability assays. A recombinant cell line overexpressing human FGFR3, was developed by stable transfection of murine pro-B Ba / F3 cells (obtained from Deutsche Collection of Microorganisms and Cell Cultures) plasmid encoding full-length human FGFR3. Cells were sequentially selected for resistance to puromycin and proliferation in the presence of heparin and FGF1. A single clone cells was isolated and characterized for functional expression of FGFR3. This clone Ba / F3-FGFR3 used in cell proliferation assays, and compounds are tested for their ability to inhibit cell proliferation / survival. Ba / F3-FGFR3 cells are plated in 96-well plates for culture black cells at a rate of 3500 cells / well in RPMI1640 medium containing 2% FBS, 20 μg / ml heparin and 5 ng / ml FGF1. Cells were treated with 10 μl of 10X concentrations of serially diluted compounds (diluted with medium serum-free with 5 mM DSMO dots) to a final volume of 100 μl / well. After 72 hours incubation in each well add 100 μl of Cell Titer Glo® reagent (Promega Corporation), which measures cellular ATP levels. After 20- After a minute of incubation with shaking, the luminescence is read on a plate reader. Luminescent readings converted into percent inhibition relative to DMSO-treated control wells and IC50 values calculated using GraphPad Prism software by fitting the data to the equation for a sigmoidal dose response with a variable slope. Compounds with an IC50 of 10 μM or less are considered active. Cell lines representing various tumor types, including KMS-11 (multiple myeloma, FGFR3 translocation), RT112 (bladder cancer, FGFR3 overexpression), KatoIII (gastric cancer, gene amplification FGFR2) and H-1581 (lung, FGFR1 gene amplification) are used in similar proliferation assays. In In some experiments, MTS reagent, Cell Titer 96® AQueous One Solution reagent (Promega Corporation) is added to a final concentration of 333 µg / ml per Cell Titer Glo spot and read at 490 / 650 nm on the reader for tablets. Compounds with an IC50 of 5 μM or less are considered active. Example C Cellular assays of FGFR phosphorylation The inhibitory effect of the compounds on FGFR phosphorylation in the corresponding cell lines (Ba / F3-FGFR3, KMS-11, RT112, KatoIII, H-1581 cancer cell line and HUVEC cell line) can be assessed using immunoassays specific for FGFR phosphorylation. Cells are placed in a medium containing reduced serum (0.5%) and where absent FGF1 for 4-18 hours depending on cell line, then treated with various concentrations individual inhibitors for 1-4 hours. For some cell lines, such as Ba / F3-FGFR3 and KMS-11, cells stimulated with heparin (20 μg / ml) and FGF1 (10 ng / ml) for 10 min. Whole cell protein extracts obtained by incubation in lysis buffer with protease and phosphatase inhibitors [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, aprotinin (2 μg / ml), leupeptin (2 μg / ml), pepstatin A (2 μg / ml) and phenylmethylsulfonyl fluoride (1 mM)] at 4 °C. Protein extracts are cleared of cellular debris by centrifugation at 14,000 xg for 10 minutes and quantified using BCA (bicinchoninic acid) microplate assay reagent (Thermo Scientific). Phosphorylation of the FGFR receptor in protein extracts was determined using immunoassays, including western blot, enzyme-linked immunosorbent assay (ELISA), or bead-based immunoassay (Luminex). For detection phosphorylated FGFR2, a commercial ELISA kit can be used to analyze DuoSet IC Human Phospho-FGF R2α (R&D Systems, Minneapolis, MN). For KatoIII assay, cells are plated in 0.2% medium Iscove supplemented FBS (50,000 cells / well / per 100 μl) in 96-well flat-bottomed plates treated for tissue culture media (Corning, Corning, NY), in the presence or absence of a range of concentrations of the tested compounds and incubated for 4 hours at 37 °C, 5% CO2. The assay is stopped by adding 200 μL of cold PBS and by centrifugation. Washed cells are lysed in cell lysis buffer (Cell Signaling, # 9803) with inhibitor protease (Calbiochem, # 535140) and PMSF (Sigma, # P7626) for 30 min on ice. Cell lysates frozen at -80 °C before testing aliquots using the DuoSet IC Human ELISA kit Phospho-FGF R2α. GraphPad prism3 was used for data analysis. IC50 values were obtained by fitting the data to a sigmoidal dose-response equation with a variable slope. A bead-based immunoassay was developed to detect phosphorylated FGFR3. Mouse mAb against Human FGFR3 (R&D Systems, catalog number MAB7661) was conjugated to Luminex MAGplex microspheres, area of 20 beads and used as capture antibodies. RT-112 cells were plated in multiwell tissue culture plates and cultured to 70% confluence. Cells were washed with PBS and depleted in RPMI + 0.5% FBS for 18 hours. Cells were treated with 10 μl of 10X concentrations of serially diluted compounds for 1 hours at 37 °C, 5% CO2 before stimulation with 10 ng / ml human FGF1 and 20 μg / ml heparin for 10 min. Cells were washed with cold PBS, lysed with cell extraction buffer (Invitrogen), and centrifuged. Clarified supernatants were frozen at −80 °C until analysis. For analysis, cell lysates were diluted 1:10 in dilution buffer and incubated with beads bound to immobilized antibodies, in a 96-well filter plate for 2 hours at room temperature temperature on a plate shaker. The plates were washed three times using a vacuum collector and incubated with rabbit polyclonal antibodies anti-phospho-FGF R1-4 (Y653 / Y654) (R&D Systems, cat. no. AF3285) for 1 hour at room temperature with shaking. The plates were washed three times. Added diluted reporter antibody, goat antibody conjugated to rabbit RPE (Invitrogen cat. no. LHB0002), and incubated for 30 minutes with shaking. The plates were washed three times. The pellets were suspended in in washing buffer while shaking at room temperature for 5 minutes, and then read on Luminex 200 instrument set to count 50 events per sample, gating settings 7500-13500. Data expressed as mean fluorescence intensity (MFI). The MFI from the compound-treated samples is divided by the value MFI from DMSO controls to determine percent inhibition, and IC50 values are calculated using GraphPad Prism software. Compounds with an IC50 of 1 μM or less are considered active. Example D Cell-based FGFR signaling analysis Activation of FGFR leads to phosphorylation of Erk proteins. Detection of pErk is monitored using a test Cellu'Erk HTRF (homogeneous time-resolved fluorescence) (CisBio) according to the manufacturer's protocol. KMS-11 cells are seeded in 96-well plates at a rate of 40,000 cells / well in RPMI medium with 0.25% FBS and depleted for 2 days. Aspirate medium, cells treated with 30 μl of 1X concentrations serially diluted compounds (diluted with serum-free medium from 5 mM DSMO points) to a final volume of 30 µl / well and incubated for 45 min at room temperature. Cells are stimulated by adding 10 µl of heparin (100 μg / ml) and FGF1 (50 ng / ml) were added to each well and incubated for 10 min at room temperature. After lysis an aliquot of cell extract is transferred to 384-well low-volume plates and 4 μl of reagents is added for detection followed by incubation for 3 hours at room temperature. The plates are read on on the PheraStar instrument with HTRF settings. Normalized fluorescence readings are converted to percentage inhibition relative to control wells treated with DSMO and IC50 values are calculated using GraphPad Prism software. Compounds with an IC50 of 1 μM or less are considered active. Example E VEGFR2 kinase assay 40 μl enzyme reactions are carried out in black 384-well polystyrene plates for 1 hour at 25 °C. 0.8 μl of test compound in DMSO is added to the wells. The assay buffer contains 50 mM Tris, pH 7.5, 0.01% Tween-20, 10 mmol MgCl2, 1 mmol EGTA, 5 mmol DTT, 0.5 μM biotin-labeled peptide substrate EQEDEPEGDYFEWLE (SEQ ID NO: 1), 1 mmol ATP, and 0.1 nmol enzyme (Millipore catalog number 14-630). The reactions are stopped by adding 20 μl of stop buffer (50 mM Tris, pH = 7.8, 150 mmol NaCl, 0.5 mg / ml BSA, 45 mmol EDTA) with 225 nmol LANCE Streptavidin Surelight® APC (PerkinElmer catalog number CR130-100) and 4.5 nmol of LANCE Eu-W1024 anti-phosphotyrosine (PY20) antibody (PerkinElmer catalog number AD0067). After After 20 minutes of incubation at room temperature, luminescence was read using a plate reader. Pherastar (BMG Labtech). IC50 values can be calculated using GraphPad Prism by fitting the data to a sigmoidal dose-response equation with a variable slope. Compounds with an IC50 of 1 μM or less are considered active. Example F. Clinical trial evaluation of Compound 1 in the treatment of patients with advanced / metastatic or surgically inoperable cholangiocarcinoma This example describes an ongoing Phase 2 clinical trial to evaluate the efficacy of Compound 1 in subjects with advanced / metastatic or surgically unresectable cholangiocarcinoma with translocation FGFR 2 who have failed at least one prior treatment. The study additionally evaluates Efficacy of Compound 1 in subjects with advanced / metastatic or surgically inoperable cholangiocarcinoma with different molecular subgroups. The study also evaluates the safety of Compound 1 in subjects with advanced / metastatic or surgically unresectable cholangiocarcinoma. Additional objective is to identify and evaluate covariates that may affect the pharmacokinetics of Compound 1 in this population of subjects, using population pharmacokinetic analysis. The study also impact-response analyses on key efficacy and safety parameters are considered. In this study further investigation of the pharmacodynamics and potential biomarkers of Compound 1 in subjects with advanced / metastatic or surgically inoperable cholangiocarcinoma, and the impact is also being assessed Compound 1 on the quality of life of these subjects. The study is an open-label monotherapy study of Compound 1 in subjects with advanced / metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocations, with other FGF / FGFR alterations or with negative FGF / FGFR alterations. The study involves about 100 subjects in Group A (FGFR2 translocations), 20 subjects in Group B (other FGF / FGFR alterations) and 20 subjects in Group C (US only, negative for FGF / FGFR changes). Subjects received a once daily (QD) dose of Compound 1 at a dose of 13.5 mg for a 2-week course of therapy and a 1-week break in therapy. Treatment begins on Day 1. Subjects undergo regular safety assessments during treatment, as well as regular efficacy assessments. Subjects it is allowed to continue administration in a 21-day cycle until it is reported documented disease progression or unacceptable toxicity. Compounds 1 are administered alone as an oral QD preparation for 2 weeks of therapy and 1 week breaks in therapy. Each dose of Compound 1 is taken immediately upon awakening or after a 2-hour fasting; subjects fast for an additional 1 hour after taking Compound 1. Tablets are available with 2 mg and 4.5 mg dosages. Starting dose - 13.5 mg. One cycle is defined as 21 days. In addition to Compound 1 Each tablet contains microcrystalline cellulose, sodium starch glycolate and magnesium stearate. The subjects of the study are patients with advanced / metastatic or surgically inoperable cholangiocarcinoma with FGFR2 translocations, with other FGF / FGFR alterations, or with negative alterations FGF / FGFR who have failed at least 1 prior treatment. Key inclusion criteria include males and females aged 18 years and older. Subjects have histologically or cytologically confirmed advanced / metastatic or surgically unresectable cholangiocarcinoma. Subjects in Group A have FGFR2 translocations with a registered fusion partner in the central laboratory report. Subjects in Group B have other FGF / FGFR alterations. Subjects in Group C (US only) are negative for FGF / FGFR alterations. Additional key inclusion criteria include radiologically measurable disease according to RECIST v. 1.1; documented FGF / FGFR gene alteration status; documented disease progression after at least 1 course of prior systemic therapy; ECOG performance status 0 to 2; life expectancy not less than 12 weeks; adequate liver function; adequate kidney function; serum phosphate ≤ steady state ULN; and serum calcium level within normal limits. Key exclusion criteria include the following: prior receipt of a selective FGFR inhibitor; history and / or current evidence of ectopic mineralization of calcification, including, but not limited to, soft tissue, kidney, intestine, myocardium, or lungs, except for calcified lymph nodes and asymptomatic calcifications arteries or cartilage / tendon; current evidence of clinically significant corneal or retinal disease, confirmed ophthalmological examination; and use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug drug (topical use of ketoconazole is allowed). The study schedule and procedures include regularly scheduled visits to the clinical center as part of 21-day cycle. The visits provided by the study begin with a preliminary screening to obtain FGF / FGFR status if unknown (results within approximately 2 years of screening are valid). Screening is performed from day 28 to -1. Cycle 1 occurs on days 1, 8, and 15. Cycles 2+ begin on day 1. Further Safety follow-up is performed 30 days (+5 days) from the date of the last dose. Further Disease status monitoring is performed every 9 weeks for subjects who have discontinued treatment with reasons not related to disease progression. Every 12 weeks after stopping treatment is performed follow-up to assess survival. Up to 28 days are allowed for screening followed by continuous treatment in consecutive 21-day cycles until subjects benefit and do not respond no exclusion criteria from the study, and 30 days (+5 days) for follow-up to assess safety of the last dose of study drug. Study visits include collection of samples for hematology, chemistry, coagulation, endocrine monitoring, lipids, and urinalysis. In addition, screening is performed HIV screening (required for subjects outside the US) and hepatitis screening (serology). Pregnancy test also performed at screening, on day 1 of each cycle before dosing, and at the end of treatment. FGF / FGFR status can be determined on site. Tumor tissue is evaluated in a central laboratory to confirm FGF / FGFR alteration status. Samples blood for population pharmacokinetic analysis, whole blood pharmacodynamics and correlation studies collected at various points in time during the study and analyzed in a central laboratory or authorized person. The research center evaluates adverse events, vital signs, electrocardiograms, physical examination, comprehensive ECOG vision screening, and tumor response assessment and disease. Screening involves an objective assessment of disease status. Over time, disease status, including assessment of radiological response by RECIST, assessed every 2 cycles for the first 4 cycles and every 3 cycles thereafter. The central radiology group ensures centralized reading of all assessments. The primary endpoint of the study is to determine the objective response rate (ORR) in subjects with FGFR2 translocations based on the results of central genomics laboratory studies. Frequency Objective response rate is defined as the proportion of subjects who achieved a complete response (CR; disappearance of all target lesions) or partial response (PR; reduction in the sum of the longest diameters of target lesions greater than or equal to 30%) based on RECIST version 1.1. Clinical response is determined by an independent review committee. Secondary endpoints include: ORR in subjects with FGF / FGFR alterations other than FGFR2 translocations (Group B); ORR in all subjects with FGF / FGFR alterations (Groups A and B); ORR in subjects negative for alterations FGF / FGFR (Group C [US only]); progression-free survival (first dose to progression) disease or death; all groups); duration of response (time from date of CR or PR to progression disease; all groups); level of disease control (CR + PR + stable disease; all groups); overall survival (first dose to death from any cause; all groups); and population pharmacokinetics (all groups). In addition, safety and tolerability are assessed by assessing the frequency, duration and severity of adverse events. phenomena; by analyzing the results of the physical examination, changes in vital signs and electrocardiogram, and also by analyzing blood and urine samples in clinical laboratories (all groups). Research endpoints include tumor profiling and blood samples to determine baseline characteristics and on-treatment characteristics related to response, resistance and safety, including studies of plasma markers and characteristics of tumors and blood cells. Additional research endpoints include comparing the results of local genomic testing with the results of central genomic testing testing. Finally, research endpoints include quality of life assessment (Quality of Life Questionnaire European Organization for Research and Treatment of Cancer [EORTC QLQ]-C30 and EORTC QLQ-BIL21). Primary analysis is performed on FGFR2-translocated subjects. Approximately 100 subjects with documentation about FGFR2 translocations from the central genomics laboratory are scheduled for final analysis of the primary ORR endpoint. With an expected intervention rate of 33%, a sample size of approximately 100 subjects will provide > 95% probability of having a 95% confidence interval with a lower bound of > 15%, assuming that 10% lost to follow-up. Up to 20 subjects will be included in Groups B and C (US only), respectively, which will provide a >80% probability of observing at least 4 responders in each group if the baseline ORR is 30%. Safety analyses are performed on all patients enrolled in the study who received at least 1 dose of the study drug; Efficacy analyses are performed on all patients included in the study who received at least 1 dose of study drug and who have a known FGF / FGFR alteration or who have a negative FGF / FGFR change according to the central genomics laboratory. The proportion of subjects with ORR and DCR will be estimated with a 95% confidence interval. PFS, DOR and OS will be analyzed by the Kaplan-Meier method. For Group A (FGFR2 translocation), a futility analysis will be performed when approximately 25 subjects are enrolled. group and will have at least 1 tumor grade or permanently discontinue study treatment. Group A may be stopped due to futility if 2 or fewer respondents are observed for whom the probability of ORR > 15% is less than 10% based on a group of 60 subjects. Groups B (other FGF / FGFR alterations) and C (US only; negative for FGF / FGFR alterations) may be stopped if The first 10 subjects that have at least 2 data cycles have 1 or fewer respondents. Previous data The following preliminary data were obtained from 91 patients in Group A, 22 patients in Group B, and 18 patients in Group C. The analysis of Group A data focused on the first 47 patients enrolled in Group A, who were followed for 8 months or more. The median number of treatment cycles in Group A was 11 (range: 1-23); the median duration of treatment was 217 days (range: 14-489 days). The median number of cycles in Group B was 2.5 (1-14); and the median The median duration of treatment was 47.5 days (range: 7-287 days). The median number of cycles in Group C was 2.0 (1- 7); and the median duration of treatment was 39 days (range: 7-142 days). The distribution of patients by group is summarized in Table 43 below. Table 43 Group A (translocations FGFR2; N = 47) Group B (other genetic changes FGF / FGFR; N = 22) Group C (without genetic changes) FGF / FGFR; N = 18) Treatment discontinued: n = 28 PD: n = 20 AE: n = 2 Death: n = 1 Doctor's decision: n = 2 Subject sampling: n = 2 Other: n = 1 Treatment discontinued: n = 20 PD: n = 14 AE: n = 2 Death: n = 1 Doctor's decision: n = 1 Subject sampling: n = 2 Treatment discontinued: n = 18 PD: n = 11 AE: n = 2 Number lost for observations: n = 1 Subject sampling: n = 2 Other: n = 2 Treatment ongoing: n = 19 Treatment ongoing: n = 2 Treatment ongoing: n = 0 Baseline data and disease characteristics presented for all groups are shown in Table 44. In group A The median age of patients was 55 years (range: 26-76), 53.2% were female, and 98% had iCCA. In addition: - 98% of patients had PS ≤ 1 on the ECOG scale - 49% of patients received ≥ 2 courses of treatment - 94% of patients were from regions other than Asia. - 66% of patients had stage 4 disease at enrollment. - 1 patient had a history of chronic hepatitis B or hepatitis C. Table 44 Baseline data and disease characteristics Group A (n = 47) Group B (n = 22) Group C (n = 18) Age, mean (range), years 55 (26-76) 63 (28-78) 65 (31-78) Gender, n (%) Man Woman 22 (46.8) 25 (53.2) 11 (50.0) 11 (50.0) 10 (55.6) 8 (44.4) Region, n (%) Asia Outside Asia 3 (6.4) 44 (93.6) 11 (50.0) 11 (50.0) 0 (0.0) 18 (100.0) General condition indicator for ECOG score, n (%) 0 1 2 15 (31.9) 31 (66.0) 1 (2.1) 7 (31.8) 12 (54.5) 3 (13.6) 7 (38.9) 8 (44.4) 3 (16.7) Number of previous system therapies, n (%) 1 2 ≥3 24 (51.1) 15 (31.9) 8 (17.0) 13 (59.1) 5 (22.7) 4 (18.2) 11 (61.1) 3 (16.7) 4 (22.2) Previous surgery, n (%) 16 (34.0) 7 (31.8) 6 (33.3) Previous radiation, n (%) 9 (19.1) 4 (18.2) 5 (27.8) Stage at initial diagnosis, n (%) 1 2 3 4 Missing. 5 (10.6) 6 (12.8) 3 (6.4) 31 (66.0) 2 (4.3) 1 (4.5) 1(4,5) 3 (13.6) 17 (77.3) 0 (0.0) 1 (5.6) 1 (5.6) 1 (5.6) 12 (66.7) 3 (16.7) Tumor location, n (%) Intrahepatic Extrahepatic Others Unknown 46 (97.9) 0 (0.0) 0 (0.0) 1 (2.1) 15 (68.2) 3 (13.6) 4 (18.2) 0 (0.0) 11 (61.1) 7 (38.9) 0 (0.0) 0 (0.0) History of hepatitis, n (%) Chronic hepatitis B Hepatitis C 1 (2.1) 1 (2.1) 1 (4.5) 1 (4.5) 0 (0.0) 0 (0.0) The FGFR translocations of the patients are shown in Table 45. The most common FGFR2 translocation was FGFR2- BICC1 (29.8%), followed by FGFR2-AHCYL1 (4.3%), FGFR2-MACF1 (4.3%) and intron 17 rearrangement FGFR2 (4.3%). Table 45 FGFR2 translocations in group A FGFR2 translocation, n (%) Group A (n = 47) FGFR2-BICC1 14 (29.8) FGFR2-AHCYL1 2 (4.3) FGFR2-MACF1 2 (4.3) FGFR2 intron 17 rearrangement 2 (4.3) FGFR-NEDD4L 1 (2.1) FGFR2-SOGA1 1 (2.1) FGFR2-POC1B 1 (2.1) FGFR2-NOL4 1 (2.1) FGFR2-ACLY 1 (2.1) FGFR2-SLMAP 1 (2.1) FGFR2-FILIP1 1 (2.1) FGFR2-SPICE1 1 (2.1) FGFR2-KIAA1217 / FGFR2 exon 1-17 1 (2,1) FGFR2-KIAA1217 1 (2.1) FGFR2-TTC28 1 (2.1) FGFR2-CCDC158 1 (2.1) FGFR2-AFR 1 (2.1) FGFR2-SHROOM 1 (2.1) FGFR2-NRAP 1 (2.1) FGFR2-COL16A1 1 (2.1) FGFR2-GOPC 1 (2.1) FGFR2-NOL4 1 (2.1) FGFR2 amp / FGFR2-RABPGAP1L and FGFR2-LAMC1 1 (2,1) FGFR2-ARH GAP24 1 (2.1) FGFR2-PAWR 1 (2.1) FGFR2-GAB2 1 (2.1) FGFR2-RASSF4 1 (2.1) FGFR2-ARHGAP24 1 (2.1) FGFR2-TACC1 1 (2.1) FGFR2-STRN4 1 (2.1) FGFR2-ATF2 1 (2.1) Preliminary efficacy data are presented in Table 46 below. Table 46 Primary and secondary endpoints by patient group (independent reviewer assessment) Variable Group A (n = 47) Group B (n = 22) Group C (n = 18) ORR, % (95% CI) 40.4 (26.4-55.7) 0 (0.0-15.4) 0 (0.0-18.5) Best OR, n (%) CR PR SD PD NE 0 (0.0) 19 (40.4) 21 (44.7) 5 (10.6) 2 (4.3) 0 (0.0) 0 (0.0) 10 (45.5) 7 (31.8) 5 (22.7) 0 (0.0) 0 (0.0) 4 (22.2) 10 (55.6) 4 (22.2) Median DOR, months (95% CI) NE (6.93-NE) NE (NE-NE) NE (NE-NE) DCR, % (95% CI) 85.1 (71.7-93.8) 45.5 (24.4-67.8) 22.2 (6.4-47.6) NE = not evaluable, upper limit not reached. Table 46 shows preliminary results for the primary endpoints. The ORR in group A was 40.4%. In 19 patients (40.4%) had confirmed PR. In 21 patients (44.7%), the best response was stable disease. For secondary endpoints, median duration of response (DOR) in group A was not reached; probability The maintenance of response for six months or more was 86.2%. Disease Control Rate (DCR) was 85.1% in group A. DCR in groups B and C was 45.5% and 22.2%, respectively. Figure 79 shows the best percent change in target lesion size from baseline in patients with CCA and FGFR2 translocations (group A) according to independent analysis. Figure 80 shows duration of treatment and confirmed response in patients with CCA and FGFR2 translocations (group A) according to independent analysis. Figure 81 shows progression-free survival (PFS; independent analysis) estimates. Kaplan-Meier in groups A, B and C. PFS is defined as the time from the start of study drug drug (Day 1) to earlier death or disease progression by RECIST as assessed by an independent Centralized Radiological Supervisory Committee. Censorship for PFS follows, for example, in the following situations: lack of baseline tumor assessment, lack of adequate response assessment after baseline, lack of progression, study discontinuation due to undocumented progression, initiation of a new anticancer treatment and death or progression after several missed assessments. As shown in Table 47 below, the median The PFS was 9.2 months in Group A. The median PFS in Groups B and C was 2.1 and 1.7 months, respectively. The median OS was 15.8 months in Group A. Median OS in Groups B and C was 6.8 and 4.0 months, respectively. Table 47 Group A Group B Group C Patients evaluated, n 47 22 18 Events, n (%) 22 (46.8%) 17 (77.3%) 16 (88.9%) Censorship, n (%) 25 (53.2%) 5 (22.7%) 3 (11.1%) Median time to event (95% CI), months 9.20 (6.44-NE) 2.10 (1.18-6.80) 1.68 (1.38-1.84) Table 48 Number of patients at risk Time to event (months) Number of patients at risk Group A Group B Group C 0 47 22 18 1 46 20 15 2 40 11 3 3 36 8 2 4 34 8 1 5 30 6 1 6 30 6 1 7 23 3 0 8 23 1 0 9 17 1 0 10 10 0 0 11 9 0 0 12 5 0 0 13 3 0 0 14 3 0 0 15 1 0 0 16 0 0 0 Safety and tolerability The most common treatment-emergent adverse events (TEAEs) in all patients were hyperphosphatemia (60.7%), alopecia (41.6%), diarrhea (39.3%), decreased appetite (37.1%), fatigue (36.0%), and dysgeusia (36.0%). Hyperphosphatemia was treated with diet, phosphate binders, or dose modification. TEAE 3 Grade 3 or higher in more than 5% of all patients include hypophosphatemia (13.5%), hyponatremia (7.9%), pain abdominal pain (6.7%) and arthralgia (6.7%). Five patients experienced fatal TEAEs, none of which were was related to the study treatment: in Group A 1 patient died due to failure to thrive; in Group B 3 patients died due to abdominal distension, sepsis, progression of malignant neoplasms, dyspnea, and pleural effusion. effusion; in Group C 1 patient died of cholangitis. The most common TEAEs and TRAEs are shown below in Table 49. Table 49 Most common TEAEs and TRAEs occurring in ≥ 20%a of patients with CSA TEAE- All Groups (N = 89)b TRAE - All Groups (N = 89)b Adverse event, n (%) All classes Class 3 / 4 All classes Class 3 / 4 Hyperphosphatemia 54 (60.7) 0 (0.0) 49 (55.1) 0 (0.0) Alopecia 37 (41.6) 0 (0.0) 33 (37.1) 0 (0.0) Diarrhea 35 (39.3) 2 (2.2) 26 (29.2) 2 (2.2) Decreased appetite 33 (37.1) 2 (2.2) 22 (24.7) 1 (1.1) Fatigue 32 (36.0) 4 (4.5) 21 (23.6) 1 (1.1) Dysgeusia 32 (36.0) 0 (0.0) 31 (34.8) 0 (0.0) Constipation 27 (30.3) 0 (0.0) 10 (11.2) 0 (0.0) Stomatitis 27 (30.3) 3 (3.4) 24 (27.0) 3 (3.4) Dry mouth 26 (29.2) 0 (0.0) 21 (23.6) 0 (0.0) Nausea 26 (29.2) 0 (0.0) 14 (15.7) 0 (0.0) Hypophosphatemia 23 (25.8) 12 (13.5) 9 (10.1) 5 (5.6) Arthralgia 21 (23.6) 6 (6.7) 10 (11.2) 4 (4.5) Peripheral edema 20 (22.5) 1 (1.1) 3 (3.4) 0 (0.0) Dry eye 18 (20.2) 1 (1.1) 12 (13.5) 1 (1.1) TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event. A Patients were counted once for each preferred term from the Medical Dictionary regulatory activities (MedDRA). bTwo patients were classified as “other” due to lack of FGF / FGFR alterations confirmed by central laboratory, therefore, group allocation was not carried out. Conclusion In this interim analysis of patients from the Group with a follow-up of at least 8 months, Compound 1 was generally well tolerated and demonstrated preliminary efficacy in previously treated patients with CCA carrying FGFR2 translocations. ORR was 40.4%. The most common TEAEs included hyperphosphatemia, alopecia and diarrhea. These results support the continued development of Compound 1 for the treatment of patients with CCA, carrying FGFR2 translocations. Example G. Clinical Study Evaluating Compound 1 in the Treatment of Patients with Myeloid / Lymphoid neoplasms with FGFR1 rearrangement. This example describes an ongoing Phase 2 clinical trial to evaluate the efficacy of Compound 1 in subjects with myeloid / lymphoid neoplasms with FGFR1 rearrangement. The study additionally The safety of Compound 1 is being evaluated in subjects with myeloid / lymphoid neoplasms with FGFR1 rearrangement. Additional research objectives are to assess pharmacokinetics, biomarkers, and quality of life of subjects with myeloid / lymphoid neoplasms with FGFR1 rearrangement treated with Compound 1. This study is an open-label study of Compound 1 monotherapy in subjects with myeloid / lymphoid neoplasms with FGFR1 rearrangement. Subjects received a once daily (QD) dose of Compound 1 at a dose of 13.5 mg during a 2-week course of therapy and a 1-week break in therapy. In addition, the administration was adjusted so that newly enrolled subjects received Compound 1 at a dose of 13.5 mg continuous administration (without maintaining the planned dose). Subjects who received treatment according to previous versions, may be switched to continuous administration after completion of at least 3 cycles, if there is no ongoing TEAEs of grade 2 or higher. All potential subjects must have the 8p11 translocation, which is known to activate FGFR1, documented confirmed by the cytogenetic laboratory of the research center. After providing the documentation, the subject is checked for compliance with other inclusion / exclusion criteria. After the subject has completed screening and enrolled in the study, treatment begins on the first day of cycle 1. Subjects undergo regular safety assessment during treatment, as well as regular evaluation of efficacy. Subjects are allowed to continue administration in a 21-day cycle until reported. loss of benefit from therapy or unacceptable toxicity. Compound 1 is administered alone as an oral QD formulation on a 2-week dosing schedule and treatment regimen for 1 week or continuous administration (without withholding the scheduled dose). Each dose Compounds 1 are taken immediately upon awakening or after a 2-hour fast; after taking of the study drug, subjects fast for another 1 hour. The tablets are available in 2 mg and 4.5 mg strengths. The starting dose is 13.5 mg. One cycle is defined as 21 days of treatment. In addition to Compound 1, each tablet contains microcrystalline cellulose, sodium starch glycolate and magnesium stearate. The study population is patients with myeloid / lymphoid neoplasms with FGFR1 rearrangement. Key inclusion criteria include: men and women aged 18 years and older; documented lymphoid or myeloid neoplasm with 8p11 rearrangement, which is known to result in FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed on site, prior to signing informed consent for this study; life expectancy of at least 12 weeks; ECOG performance status of 0 to 2. In addition, only subjects who are not candidates for stem cell transplantation or who have relapsed after stem cell transplantation and delayed lymphocyte infusion, and who have progressed and are not candidates for other modified methods of treating the disease, are eligible for study. All patients with relapsed / refractory must have evidence of cytogenetic or hematological disease and have no evidence of residual toxicity (e.g. graft-versus-host disease requiring treatment). Key exclusion criteria include prior receipt of a selective FGFR inhibitor; History of calcium and phosphate hemostasis or systemic mineral imbalance with ectopic calcification soft tissue (exception: calcifications commonly seen in soft tissues such as skin, kidneys, tendons or vessels, due to trauma, disease and aging, in the absenc...
Claims
1. A method of treating cholangiocarcinoma in a patient in need thereof, comprising administering to a patient a therapeutically effective amount of Compound 1, having the formula: NN H N About NN About About About F F Compound 1.
2. The method according to claim 1, characterized in that the cholangiocarcinoma is a common or metastatic cholangiocarcinoma.
3. The method according to claim 1, characterized in that the cholangiocarcinoma is inoperable.
4. The method according to claim 1, characterized in that the cholangiocarcinoma is intrahepatic.
5. The method according to claim 1, characterized in that the cholangiocarcinoma is extrahepatic.
6. The method of claim 1, wherein the cholangiocarcinoma is hilar or perihilar.
7. The method of claim 1, wherein the cholangiocarcinoma is distal. extrahepatic.
8. The method according to any one of claims 1-7, characterized in that the cholangiocarcinoma characterized by tumors genetically altered by FGF / FGFR.
9. The method of claim 8, wherein the tumor exhibits FGFR2 gene translocations.
10. The method according to claim 9, characterized in that the FGFR2 gene translocation is selected from the group consisting of consists of FGFR2-BICC1, FGFR2-AHCYL1, FGFR2-MACF1, FGFR2 intron rearrangement 17.
11. The method of claim 8, wherein the tumor exhibits FGF / FGFR alterations, distinct from FGFR2 translocations.
12. The method according to any one of claims 1-7, characterized in that the cholangiocarcinoma is not demonstrates tumors with genetically altered FGF / FGFRs.
13. The method according to any one of claims 1-12, characterized in that at least one of the preceding The treatment was ineffective for the patient.
14. The method according to claim 13, characterized in that the preliminary treatment is surgical. intervention or radiation therapy.
15. The method according to any one of claims 1-14, characterized in that the patient has a history of hepatitis.
16. The method according to claim 15, characterized in that the hepatitis is chronic hepatitis B or hepatitis C.
17. The method according to any one of claims 1-16, characterized in that Compound 1 is administered orally.
18. The method according to any one of claims 1-17, characterized in that Compound 1 is administered once per day.
19. The method according to any one of claims 1-17, characterized in that Compound 1 is administered daily at a dose of about 5 to about 20 mg.
20. The method according to any one of claims 1-17, characterized in that Compound 1 is administered daily a dose of about 10 to about 15 mg.
21. The method according to any one of claims 1-17, characterized in that Compound 1 is administered daily dose of about 13.5 mg.
22. The method according to any one of claims 1-17, characterized in that Compound 1 is administered daily dose of about 13.5 mg.
23. The method according to any one of claims 1-22, characterized in that Compound 1 is administered in the form of pills.
24. The method of claim 23, wherein the tablet contains from about 1 to about 10 mg of Compound 1.
25. The method of claim 23, wherein the tablet contains from about 1 to about 5 mg of Compound 1.
26. The method of claim 23, wherein the tablet contains from about 2 to about 4.5 mg of Compound 1.
27. The method of claim 23, wherein the tablet contains about 4.5 mg of Compound 1.
28. The method of claim 23, wherein the tablet contains about 9 mg of Compound 1.
29. A method of increasing survival or progression-free survival in a patient with cholangiocarcinoma, in which the cholangiocarcinoma is characterized by a FGFR2 fusion, which comprises administering to a patient a therapeutically effective amount of Compound 1 having the formula: NN H N About NN About About About F F Compound 1.
30. The method according to any one of claims 1-17 and 19-28, characterized in that Compound 1 is introduced into 21-day dosing regimen, where the 21-day dosing regimen includes: (a) a first period in which Compound 1 is administered once daily for 14 days; and (b) a second period where Compound 1 is not administered for 7 days.
Citation Information
Patent Citations
Compounds and compositions as protein kinase inhibitors
WO2007134259A2
Substituted tricyclic compounds as FGFR inhibitors
WO2014007951A2
